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Abstract
Hybrid diffuse optics for
monitoring of tissue hemodynamics
with applications in oncology
Parisa Farzam
Noninvasive measurement of hemodynamics at the microvascular
level may have a great impact on oncology in clinics for diagnosis, ther-
apy planning and monitoring, and, in preclinical studies. To this end,
diffuse optics is a strong candidate for noninvasive, repeated, deep tissue
monitoring.
In this multi-disciplinary, translational work, I have constructed and
deployed hybrid devices which are the combination of two qualitatively
different methods, near infrared diffuse optical spectroscopy (NIRS) and
diffuse correlation spectroscopy (DCS), for simultaneous measurement
of microvascular total hemoglobin concentration, blood oxygen satura-
tion and blood flow.
In a preclinical study, I applied the hybrid device to monitor the
response of renal cell carcinoma in mice to antiangiogenic therapy. The
results suggest that we can predict the output of therapy from early
hemodynamic changes, which provide us with valuable information for
better understanding of the tumor resistance mechanism to antiangio-
genic therapies.
xIn two in vivo studies in human volunteers, I have developed pro-
tocols and probes to demonstrate the feasibility of noninvasive diffuse
optical spectroscopy to investigate the pathophysiology of bone. First
study was study on the physiology of the patella microvasculature, the
other introduced the manubrium as a site that is rich in red bone mar-
row and accessible to diffuse optics as a potential window to monitor
the progression of hematological malignancies.
Overall, during my Ph.D., I have developed instrumentation, algo-
rithms and protocols and, then, applied this technique for preclinical
and clinical investigations. My research is a link between preclinical
and clinical studies and it opens new areas of applications in oncology.
Resumen
Óptica difusa híbrida para la
monitorización de la hemodinámica de los
tejidos con aplicaciones en oncología
Parisa Farzam
La medición no invasiva de la hemodinámica a nivel microvascular
puede alcanzar un gran impacto en oncología: en las clínicas para el di-
agnóstico, la planeación y monitorización de las terapias, y en estudios
preclínicos. La óptica difusa es una fuerte candidata para la monitor-
ización no invasiva y repetida del tejido profundo.
En este trabajo multidisciplinario y traslacional, construí e imple-
menté dispositivos híbridos que son la combinación de dos métodos
cualitativamente diferentes: espectroscopía infrarroja de óptica difusa
-near infrared diffuse optical spectroscopy (NIRS)- y espectroscopía de
correlación de luz difusa -diffuse correlation spectroscopy (DCS)-. Es-
tos híbridos permiten la medición simultánea de la concentración de
hemoglobina total en sangre, la saturación de oxígeno y el flujo sanguí-
neo.
En un estudio preclínico, apliqué el dispositivo híbrido para moni-
torizar la respuesta de carcinomas de células renales, implantados en ra-
tones, a terapias antiangiogénicas. Los resultados sugieren que podemos
predecir la evolución de la terapia con base en cambios hemodinámicos
xii
tempranos, lo cual proporciona información valiosa para un mejor en-
tendimiento del mecanismo de resistencia de los tumores a las terapias
antiangiogénicas.
En dos estudios in vivo realizados en pacientes voluntarios, desarrollé
protocolos y sondas para demostrar la viabilidad de la espectroscopía
de óptica difusa no invasiva en el estudio de la patofisiología ósea. El
primer estudio se concentró en la fisiología microvascular de la rótula
y en el otro se muestra que el manubrio, hueso rico en médula ósea
roja, es un sitio accesible para la óptica difusa, y se presenta como una
ventana para monitorizar la progresión de enfermedades hematológicas
malignas.
En resumen, durante mi trabajo doctoral, desarrollé instrumentación,
algoritmos y protocolos que posteriormente apliqué en estudios preclíni-
cos y clínicos. Mi trabajo de investigación constituye así un enlace entre
estos estudios y abre nuevas áreas de aplicación en oncología.
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Chapter 1
Introduction
In many languages feelings and emotions are described by colors – “It
was embarrassing, she blushed.”. One can learn a lot by looking at the
color changes in a person’s face. If we can see deeper than skin we will
observe how diseases alter the tissue colors. Sounds exciting? It is what
my dissertation is about – diffuse optics.
Diffuse optical spectroscopy, often denoted as near infrared spec-
troscopy (NIRS), has recently found many applications in biomedicine
due to advances in the physical modeling of photon propagation through
tissues, improvements in analysis algorithms, detector and source (laser,
lamp etc) technologies as well as better understanding of its capabilities
in relation to the physiological/clinical problems [1, 2].
The technique relies on the “physiological window” (650-950 nm)
(figure 1.1) where the photon propagation in the tissue is dominated by
scattering rather than absorption [3]. In this part of the spectrum , as
it is shown in figure 1.2, light experiences many scattering events and
can penetrate several centimeters (>5 cm) into the tissue due to the low
absorption. As a rule of thumb, the mean light penetration depth in
the reflection geometry is about half of source-detector separation. The
sampled volumes in the reflection geometry, the map of the visitation
2 Introduction
probabilities of the detected photons from a particular source , has the
so-called “banana shape” (figure 1.2).
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Fig. 1.1 Absorption (µa) spectra of water, deoxy- and oxy-hemoglobin in
part of visible and near infrared range. The inset shows the “physiolog-
ical window” where the absorption is relatively low and photon propa-
gation is dominant by scattering events and photons can penetrate deep
in the tissue.
Furthermore, in the “physiological window” there are clear features
in the absorption spectra which enables us to estimate the chromophores
concentrations (such as oxy- and deoxy-hemoglobin concentrations) and
related them to total hemoglobin concentration (blood volume), blood
oxygen saturation and oxygen consumption [4–7].
The main chromophores in this window are oxyhemoglobin (Hbo2),
deoxyhemoglobin (Hb), water (H2O) and lipids. For typical concen-
trations their spectrum is shown in figure 1.1. This is all done in the
3Fig. 1.2 The photons undergo multiple scattering events while propa-
gating in a turbid media (such as tissue). These repeated scatterings
change the direction of the photon path (random walk). The shadow of
“banana shape” showing the sampled volumes in the reflection geometry
which is the most probable path of photons for a given source-detector
pair.
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microvasculature which makes the technology particularly unique as a
noninvasive monitoring and imaging tool. Knowing the concentration
of oxygenated and deoxygenated hemoglobin provided us with informa-
tion about the blood oxygen saturation which is an vital parameter and
noninvasive measurement of it can provide valuable information over
a wide range of medical conditions. For instance cerebral oxygenation
monitoring has a great importance in minimizing secondary hypoxic and
ischemic brain damage following severe head injury [8–11] or tumor hy-
poxia is an crucial parameter in oncology [12–15] therefore knowledge
about oxygen level has a high impact on cancer therapies [16, 17]. For
instance figure 1.3 shows the difference in the reflected spectrum (mea-
sured by the system described in the next chapters) of healthy tissue
and tumor due to the hypoxia in the tumor. In hypoxic tissue (tumor)
there is an absorption peak at ∼760 nm, which is the absorption peak
of deoxyhemoglobin.
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Fig. 1.3 The difference in the reflected spectrum of healthy tissue and
tumor due to the hypoxia in the tumor. In hypoxic tissue (tumor) there
is an absorption peak at ∼760 nm, which is the absorption peak of
deoxyhemoglobin.
Deploying multiple wavelengths enables us to measure Oxy- and
5deoxy-hemoglobin concentration as well as water, lipid, bone miner-
als and other desired tissue chromophores as the endogenous contrast
species [18]. The sensitivity of measurement can be increased by the
measurement of the concentration and lifetime of exogenous for exam-
ple in the tumors [19–23]. Furthermore, from the speckle patterns of
the multiply scattered light more information about dynamic proper-
ties of tissue (blood flow) can be obtained by a relatively new NIR
technique, called diffuse correlation spectroscopy (DCS) or diffuse wave
spectroscopy (DWS) [24–31]. DCS has been validated against perfusion
magnetic resonance imaging (MRI) [32–36], power Doppler ultrasound
[37, 38], Doppler ultrasound [39–42], laser Doppler [43, 44], Fluorescent
microspheres [45], and xenon-enhanced computed tomography [46].
Hybrid devices, combination of traditional NIRS devices and DCS,
contain information from both static (total hemoglobin concentration
and oxygen saturation) and dynamic (blood flow) properties of tissue
which can provide us with information about metabolism of the tissue,
which is an important clinical parameter.
Although diffuse optics is limited by its resolution, due to its ability
to noninvasively measure vital physiological parameters, it has found a
wide range of applications specially in neurology and oncology [47–55].
In neurology it has been applied mostly in brain functional spectroscopy
and imaging [56–66], brain studies in animal models [35, 44, 45, 67–
77], stroke and brain damage investigation in adults and neonates [34,
40, 41, 78–87]. Wide range of neurological studies suggest that diffuse
optics can play an important role not only as a complex research tool
at the laboratory stage, but also as a powerful instrument for clinical
applications.
Optical mammography mostly focuses in classifying women with
high risk of breast cancer, diagnosis, characterization of malignant tu-
mors, and monitoring the therapy efficiency [88–104]. All these studies
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demonstrated the feasibility of employing diffuse optics for detecting,
imaging, characterizing and monitoring the hemodynamic changes in
cancer.
Diffuse optics has been applied in experimental oncology to study
tumors in animal samples for better understanding of cancer mecha-
nisms and drug development [37, 38, 105–110]. Murine models are the
most popular in vivo models in oncology study since they an approx-
imation of reality. Due to their similarity to the human in terms of
genetics, anatomy and physiology, and ease of manipulation [111], they
have been proven to be useful for novel cancer therapeutic strategies
[112, 113].
My PhD is motivated mainly by application of diffuse optics for
cancer studies to enhance the efficiency of new therapies and drugs.
For this goal, I have applied hybrid diffuse optical devices to measure
oxygen saturation, total hemoglobin concentration (blood volume), and
blood flow which are important biomarkers of angiogenesis. Angiogen-
esis, formation of new vessels, is a necessary process for tumor growth
and metastasis. One of the new class of cancer drugs are angiogenesis
inhibitors. These type of therapy does not follow the general rules of
conventional chemotherapy. The successful translation of angiogenesis
inhibitors to clinical application depends on better understanding of an-
giogenesis in the tumor and the mechanisms of antiangiogenic therapies.
As described, murine models are the good options for these investiga-
tions. In order to study murine tumors, we have combined broadband
near infrared spectroscopy (NIRS) and diffuse correlation spectroscopy
(DCS) in a single hand-held self-calibrating probe for noninvasive, re-
peated hemodynamic monitoring of murine tumors. The details of each
device specification, probe design and validation tests are described in
chapter 3.
After successful validation of device, we moved it to the animal fa-
7cility of IDIBELL (Bellvitge Biomedical Research Institute, Barcelona,
Spain) for a multidisciplinary collaboration with Dr. Oriol Casanovas.
We have monitored the hemodynamics of the murine tumors during
antiangiogenic therapy for better understanding of tumors mechanisms
again antiangiogenic therapies. The details of measurements and results
are described in chapter 4.
To continue the cancer studies in clinical stage, we initiated a collab-
oration with Dr. Alvaro Urbano at Hematology Department of Hospital
Clínic de Barcelona in order to investigate the feasibility of applying
diffuse optics in hematological malignancies. Most of the hematological
malignancies originate in the bone marrow and alter its hemodynamics.
Therefore, noninvasive methods that measure changes in hemodynamics
induced by angiogenesis in the bone marrow have a potential impact on
the earlier diagnosis, more accurate prognosis and in treatment moni-
toring. To this end we have applied hybrid diffuse optical spectroscopy
methods, time resolved spectroscopy (TRS) and DCS, to evaluate the
feasibility of the noninvasive hemodynamics measurement in the healthy
manubrium as a site of bone marrow. The measurement protocol and
the details of the measured optical and physiology properties can be
found in chapter 5.
My interest in bone marrow led me to review the literature of bone
optical properties. Despite skeletal muscle which is a well studied tissue
[33, 114–119], the research on bone optical properties was very lim-
ited. Noninvasive, quantitative and practical measurements of local
microvascular hemodynamics of bones could improve our fundamental
understanding of bone function with potential applications in diagno-
sis and treatment of bone diseases [120–122]. This motivated me to
apply optics to answer some physiological questions about bone hemo-
dynamics. Having this goal in mind, we have started a collaboration
with Dr. Tiziano Binzoni from University of Geneva, who is one the
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pioneers of optical studies of bone. In this collaborative work we inves-
tigate the cardiac cycle related pulsatile behavior of the absorption and
scattering coefficients of diffuse light and the corresponding alterations
in hemoglobin concentrations in the human patella. The physiological
origin of the observed signals was confirmed by applying a thigh cuff.
Moreover, we have investigated the optical and physiological proper-
ties of the patella bone and their changes in response to arterial cuff
occlusion. The details of this study is presented in chapter 6.
As it is described, I have performed optical measurements on hu-
man and animal by hybrid (NIRS-DCS) devices. Can we utilize the full
set of information available from multi-distance DCS measurements for
better absolute quantification instead of hybrid devices? This question
led me to develop a new algorithm using multi-distance DCS for simul-
taneous measurement of absorption and scattering coefficient as well as
blood flow index. The fitting is validated against numerical data, tissue
simulating phantoms, and in-vivo measurements. The multi-distance
DCS fitting is proposed as an alternative to hybrid NIRS-DCS devices
for some applications. The fitting algorithm and validation data are
presented in chapter 7.
Chapter 2
Theoretical background
2.1 Light propagation in tissues
The propagation of the photons in tissues is mainly affected by scatter-
ing rather than absorption. In this highly scattering medium few length
scales are important: “scattering length” which corresponds to the typ-
ical distance traveled by photons before they scatter and its reciprocal
is named scattering coefficient (µs). The longer distance, “transport
mean-free path”, ltr, is the typical distance traveled by photons before
their direction is randomized. The reciprocal of the photon transport
mean-free path is called the reduced scattering coefficient µs′ = 1/ltr.
The absorption length in tissue corresponds to the typical distance
traveled by a photon before it is absorbed; its reciprocal, the absorp-
tion coefficient, is denoted by µa. All three of these length scales are
wavelength-dependent [2].
Through this manuscript the light propagation in tissue is described
by “diffusion equation” where the photon fluence rate, Φ(ρ, t) (photons/[cm2s]),
obeys the diffusion equation [123–125]:
∇ · (D(ρ)∇Φ(ρ, t))− νµa(ρ)Φ(ρ, t)− ∂Φ(ρ, t)
∂t
= −νS(ρ, t). (2.1)
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This photon diffusion equation is valid when the radiance is nearly
isotropic. This isotropy is achieved when µs′ ≫ µa and and when pho-
ton propagation distances within the medium are large relative to ltr
that needs optode distance (ρ = |ρ|) to be more than 3ltr. In addi-
tion, the assumptions of isotropic source, slow temporal flux variations,
and rotational symmetry should be valid [126]. Here, ν is the speed of
light in the medium (cm/s) and D = ν3(µa+µs′) is the photon diffusion
coefficient. To apply the photon diffusion equation the diffused light is
detected at a known distance from the source.
2.2 Source types
One can categorize near infrared spectroscopy (NIRS) methods based
on the source type. Three types of light sources are used in diffuse optics
as it is shown in figure 2.1: continuous wave, intensity modulated and
time pulsed.
The simplest source type is CW, where the intensity remains con-
stant over time [37, 38, 43, 44, 50, 58, 68–70, 74, 80, 91, 92, 95, 97, 105–
109, 127–137]. CW measurements are simple and fast but they contain
low amount of information. By single continuous wave (CW) measure-
ment one can measure effective attenuation of medium but contribution
of µa and µs′ cannot readily be decoupled.
Intensity modulated sources are more complex but also provide more
information about the medium [35, 41, 45, 77, 85, 89, 116, 117, 119,
130, 132, 138–144]. In frequency domain (FD) measurements light in-
tensity of the source is modulated with a frequency in order of 100 MHz
or larger, up to ∼1 GHz, producing a diffusive wave in the medium
oscillating at the same frequency. At a given source-detector sepa-
ration, both the amplitude and phase of the diffusing wave are mea-
sured. The increase of phase shift and intensity decrease over several
2.3 Diffuse photon density waves (DPDW) 11
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Fig. 2.1 Three types of sources that are deployed to measure optical
properties of medium. [Left] continuous wave (CW) is the simplest
method that measures the intensity drop at a specific distance from the
source. P0 is the intensity of the incident light and P(r) is detected
intensity at distance r from the source. [Middle] Frequency domain
that delivers intensity modulated light to the medium and measures the
phase shift (θ) and intensity drop of the detected light. [Right] Time
resolved spectroscopy (TRS) that shoots a narrow pulse to the medium
and measures the broadening of the pulse.
source-detector separations provide simultaneous determination of µa
and µs′. Time-domain technique (time resolved spectroscopy, TRS) is
Fourier transform of frequency modulated measurement and it contains
the same information content as FD measurement which is scanned
over the wide range of modulation frequencies present in the pulse
[51, 75, 90, 114, 145–157]. Due to multiple scattering in tissues the
pulse temporally broadens. The information about optical properties of
tissue can be extracted from the broadening of the detected light.
2.3 Diffuse photon density waves (DPDW)
The following theoretical discussion will be given in the frequency do-
main (assumption of ω = 0 will be CW formulation), with the time-
domain solution given for a common case. When the source of photons
12 Theoretical background
in a turbid medium is intensity modulated, with “ac” and “dc” com-
ponents (Sac and Sdc), the photon fluence will oscillate at the same
frequency. This small but measurable traveling wave disturbance of the
light energy density is referred to as a diffuse photon density wave that
oscillate at the same angular frequency as the source. [138, 158, 159].
The source term can be written as S(ρ, t) = Sdc(ρ) + Sac(ρ)e−iwt.
These ac solutions that oscillate at the same angular frequency as
the source will have the following general form:
Φac(ρ, t) = U(ρ)e−iwt. (2.2)
By substituting equation 2.2 to diffusion equation (equation 2.1) we
have:
∇ · (D(ρ)∇U(ρ))− (νµa(ρ)− iω)U(ρ) = −νS(ρ, t)),
which for the homogeneous medium will be simplified to:
(∇2 − k2)U(ρ) = − ν
D
Sac(ρ).
The fluence rate of DPDW [2] in infinite geometry is:
U(ρ) = νSac4πDρexp(−kρ). (2.3)
In equation 2.3, k is a complex wavevector k = kr + iki:
kr = (
νµa
2D )
1/2
[(1 + [ ω
νµa
]2)
1/2
+ 1]1/2, (2.4)
ki = −(νµa2D )
1/2
[(1 + [ ω
νµa
]2)
1/2 − 1]1/2. (2.5)
The real and imaginary parts of wavevector (kr, ki) are both function
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of modulation frequency. The higher modulation frequency the larger
wavevector. The dependency of kr and ki on modulation frequency is il-
lustrated in figure 2.2. Writing the fluence rate in the form U(r) = Aeiθ,
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Fig. 2.2 The dependency of real and imaginary parts of diffuse wave
density wavevector (kr, ki) on modulation frequency (ω).
the determination of the change in wave amplitude, A, and wave phase,
θ, with distance from the source enables experimenters to extract µa
and µs′ of the turbid medium.
DPDWs have been demonstrated to exhibit several familiar wave-like
properties including diffraction, refraction, interference and dispersion
[159–162]. Figure 2.4 shows the dependency of DPDW’s wavelength on
optical properties of the medium as well as its intensity modulation.
While its wavelength, λDPDW , has direct relation with the absorption
coefficient (µa) of the medium, it has inverse relation with reduced scat-
tering coefficient (µs′), ratio of index of refraction to the outside (n) and
modulation frequency (ω).
While the DPDW propagates in the medium by getting further from
the source its amplitude decreases. The amplitude of DPDW and its
decline over distance depends on optical properties of the medium. Fig-
ure 2.5 demonstrates the dependency of amplitude of different source-
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Fig. 2.3 The phase shift,(green dashed line), and ln(Aρ), (blue solid
line), are plotted as the function of distance from the source in an in-
finite turbid medium. The slopes reveal −ki and −kr (effective attenu-
ation coefficient, µeff ), from which µa and µs′ can be calculated using
equations 2.4 and 2.5.
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Fig. 2.4 The dependency of DPDW wavelength (λDPDW ) on optical
properties of the medium and modulation frequency. [A] The reverse
relation of DPDW’s wavelength and reduced scattering coefficient (µs′)
of the medium. [B] In the medium with higher absorption (µa), the
wavelength of DPDW is larger. [C] In the medium with higher index
of refraction, the wavelength of DPDW smaller. [D] The wavelength of
DPDW has reverse relation with the modulation frequency.
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detector separations on the optical properties of tissue. In figure 2.5-A
the relation between amplitude and µs′ is presented. In small values
of µs′ and small source-detector separations increase of µs′ lead to rise
in amplitude. While in larger µs′ and larger source-detector separations
higher µs′ results to lower amplitude. Figure 2.5-B shows the reverse re-
lation between absorption in the medium and the amplitude of DPDW.
Similarly, Figure 2.5-c shows increase in ratio of index of refraction lead
to decrease in intensity. Finally, the amplitude The amplitude decreases
with increase of modulation frequency. (figure 2.5-D).
Due to multiple scattering in tissues by getting further from the
source the phase increases. The dependency of phase on the medium
optical properties as well as source modulation frequency over different
source-detector separations is demonstrated in figure 2.6. While phase
has reverse relation with the absorption coefficient (µa) of the medium,
it has direct relation with reduced scattering coefficient (µs′), index of
refraction (n) and modulation frequency (ω).
2.4 Green’s function solution to diffusion
equation for semi-infinite boundary con-
ditions
In NIRS, the most commonly used model approximate tissue as a ho-
mogeneous semi-infinite medium. In order to find the diffusion equation
Green’s function we have used method of images (figure 2.7). The ex-
trapolated zero boundary condition is satisfied by introducing a negative
image point source at zs = −(2zb + ltr). The fluence rate curve is ap-
proximated by its tangent line at z = 0, and the Φ= 0 intercept of this
curve is found to occur z = -zb. Equation 2.6 is the Green’s function
2.4 Green’s function solution 17
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Fig. 2.5 The dependency of amplitude of different source-detector sep-
arations on the optical properties of tissue. [A] The relation between
amplitude and µs′: in small values of µs′ and small source-detector sep-
arations increase of µs′ lead to rise in amplitude. While in larger µs′ and
larger source-detector separations higher µs′ results to lower amplitude.
Figure [B] The inverse relation between absorption in the medium and
the amplitude of DPDW in all source-detector separations. [C] The in-
crease of ratio of refraction of the medium to the outside lead to decrease
intensity. [D] The amplitude decreases with increase of modulation fre-
quency.
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Fig. 2.6 The dependency of phase on the medium optical properties and
source modulation frequency over different source-detector separations.
[A] Phase has direct relation with the reduced scattering coefficient (µs′)
of the medium. [B] There is a reverse relation between phase and the
absorption coefficient of the medium. [C] Medium with higher index of
refraction causes larger phase values. [D] DPDWs with higher source
modulation frequency have larger phase values.
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solution to diffusion equation for semi-infinite boundary conditions[2].
G(ρ) = 14π [
exp(−kr1)
r1
− exp(−krb)
rb
] (2.6)
where:
r1 =
√
ρ2 − ltr2
rb =
√
ρ2 + (ltr + 2zb)2
ltr =
1
µs′
zb = 2ltr
1 +Reff
1−Reff
k =
√
(µav − iw)
D
D = ν(µa + µs′)
Air Tissue
-zb-(2zb+ ltr) ltr
Image (–) Source (+)
Extrapolated
Boundary
Fluence Rate Φ 
z
Fig. 2.7 The extrapolated zero boundary condition is satisfied by intro-
ducing a negative image point source at zs = −(2zb + ltr). The fluence
rate curve is approximated by its tangent line at z = 0, and the Φ= 0
intercept of this curve is found to occur z = -zb.
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Here ρ is distance between source and detector, w is the intensity
modulation frequency. ltr is the mean distance that photon propagation
direction becomes randomize. zb is the extrapolated zero boundary and
D is the photon diffusion coefficient. Reff is the effective reflection
coefficient to account for the index mismatch between tissue and air.
The absolute value of photon fluence is corresponding to amplitude
and angle part is the detected phase. Equation 2.6 can be fit exactly,
but in the approximation of ρ ≫ (ltr + 2zb). In this case the solution
simplifies to:
U(ρ) = A(ρ)eiθ(ρ),
ln(ρ2A(ρ)) = −krρ+ lnA0, (2.7)
θ(ρ) = −kiρ+ θ0. (2.8)
The equations 2.7 and 2.8 makes it possible to fit exactly for ki and kr
and calculate µa and µs′. Figure 2.8 shows that the slope of ln(A(ρ)ρ2)
versus ρ in semi-infinite boundary conditions is kr. Similarly, the slope
of phase versus ρ is kr. In CW measurements where we do not have
information about the phase by exact fitting for kr one can have infor-
mation about effective attenuation coefficient (µeff ).
Patterson et al. [147] described the analytical solution of the diffusion
equation (equation 2.1 for TRS. They have shown that the reflectance
in a semi-infinite homogeneous medium for the time domain is described
by:
R(t, ρ) = (4 πD ν)− 32 µs′−1 t−
5
2 exp [−µa ν t] exp
[
−ρ
2 + µs′−2
4Dν t
]
. (2.9)
Photon penetration depth In experiments the detection of light can
be in transmission or reflection geometry. In all of my studies reported
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Fig. 2.8 The phase (green dashed line) and ln(A(ρ)ρ2) (blue solid line)
are plotted as the function of distance from the source in semi-infinite
boundary condition. The slopes reveal −ki and −kr (effective attenu-
ation coefficient, µeff ), from which µa and µs′ can be calculated using
equations 2.4 and 2.5.
22 Theoretical background
through this manuscript, reflection geometry has been deployed. In the
reflection geometry the probed medium has a “banana” shape which is
demonstrated in figure 2.9. The simulated medium has µa = 0.1 cm−1,
µs
′ = 10 cm−1 and ρ = 2.5 cm. As a rule of thumb, the mean light
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Fig. 2.9 The “banana patterns” showing the sampled volumes in the
reflection geometry. As a rule of thumb, the mean light penetration
depth in the reflection geometry is in the order of half of source-detector
separation (ρ/2). The simulated medium has µa = 0.1 cm−1, µs′ = 10
cm−1 and ρ = 2.5 cm.
penetration depth in the reflection geometry is in the order of half of
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source-detector separation (ρ/2). In other words, the larger the source-
detector separation, the deeper volume is probed [163]. In figure 2.10,
the probability of detecting photons below certain depths is shown. The
absorption coefficient (µa) of the simulated medium is 0.1 (cm−1), and
reduced scattering coefficient (µs′) is 10 (cm−1). It illustrates that larger
optode distances have higher probability of photon detection in deeper
volumes. For instance, in optode distance of 0.5 cm, just less than 2%
of detected photons traveled deeper than 1 cm, in optode distances of 5
cm this quantity is 40%.
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Fig. 2.10 The probability of detecting photons below certain depths.
The probability function is presented for optode distances from 0.5-5
cm.
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2.5 Multi-wavelength spectroscopy for de-
termination of tissue chromophore con-
centrations
The tissue absorption depends linearly on the concentrations of tissue
chromophores. In particular, the wavelength-dependent absorption co-
efficient is given by equation 2.10.
µa(λ) =
nc∑
i
ϵi(λ)ci (2.10)
The sum is over the different tissue chromophores. and nc is the
number of chromophores assumed. ϵi(λ) is the wavelength-dependent
extinction coefficient of the ith chromophore obtained from the literature
[164], and ci is the concentration of the ith chromophore. By equation
2.10 one can calculate concentration of oxygenated hemoglobin and de-
oxygenated hemoglobin (cHbO2 and cHb). The total hemoglobin concen-
tration (THC) is the sum of oxygenated and deoxygenated hemoglobin,
i.e:
THC = cHbO2 + cHb. (2.11)
The blood oxygen saturation can be determined by:
SO2 =
cHbO2
THC
× 100. (2.12)
Oxygen saturation and hemoglobin concentration are important bior-
makers in oncology, brain studies, etc. [165].
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2.6 Diffuse correlation spectroscopy (DCS)
DCS measures the temporal speckle fluctuations of the scattered light,
that is sensitive to the motions of scatterers such as red blood cells
(RBCs) which in turn could be used to estimate microvascular blood
flow [24, 25, 29, 166–168]. [2, 26–28]. The motional dynamics of the
medium can be determined by measurement of intensity autocorrela-
tion from which the electric field autocorrelation function (G1) can be
derived. The fluctuations of the speckles are primarily due to move-
ment of scatterers. Therefore, faster motion of the scatterers can be
indicated by faster fluctuations (i.e., more rapid decay of the intensity
temporal autocorrelation function). The Green’s function solution of
the correlation diffusion equation for semi-infinite boundary conditions
is [2]:
G1(ρ, τ) =
3µs′
4π [
exp(−K(τ)r1)
r1
− exp(−K(τ)rb)
rb
] (2.13)
Where τ is delay time, r1 and rb are described in section 2.4 and K(τ)
is:
K(τ) =
√
3µaµs′ + 6µs′2κ2αDbτ . (2.14)
α represents the fraction of photon scattering events that occur from
moving particles in the medium, κ is the wave-number of light in the
medium: 2π/λ. DCS instrumentation measures the intensity temporal
autocorrelation function, while the correlation diffusion equation applies
to the electric field temporal autocorrelation function. To compare the-
ory with experiment, the normalized intensity autocorrelation function
(g2) must be related to the normalized electric field temporal autocorre-
lation (g1). This connection is through Siegert relation (equation 2.15).
g1(τ) =
√
g2(τ)− 1
β
(2.15)
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β is a constant determined primarily by the collection optics of the
experiment. β is approximately equal to 1
N
where N is the number of
detected speckles/ modes. In most of DCS studies non-polarized sources
(vertical and horizontal modes) and single mode fibers are used to collect
the diffused light and in this case β ∼ 0.5 [169]. In experimental data β
can be measured from the g2 when τ is near to zero. Thus, g1 is derived
from the experimentally measured g2 , and K2 is determined by fitting
to the temporal decay of g1 (for a given source-detector separation).
This information in addition to optical property information (µa, µs′,
n) provide us with determination about mean square displacement of
scatterers (< △r2(τ) >). The brackets represent time-averages (for ex-
periments) or ensemble averages (for calculations). Thus by measuring
the temporal fluctuations of scattered light, one obtains quantitative in-
formation about the particle motions. For the case of Brownian motion,
< △r2(τ) >= 6Dbτ and for random flow, < △r2(τ) >=< △V 2 > τ 2 .
Here, Db is the particle diffusion coefficient and < △V 2 > is the second
moment of the particle speed distribution. In the study of blood flow
in the microvasculature the random flow model seems the trivial choice
for the dynamics of RBCs. In practice, it has been found [32–38, 46]
that the Brownian model,< △r2(τ) >= 6Dbτ , fits the observed correla-
tion decay curves better over a wide range of tissue types. It has been
demonstrated in several DCS measurements that the fitted parameter
αDb (from the Brownian model) correlates well with blood flow values
measured by other modalities [32–45]. Therefore we have defined αDb
as the blood flow index (BFI).
Figure 2.11 demonstrates the effect of different parameters on the
shape of autocorrelation curves. This plot suggest that error in assump-
tion of tissue µa or µs′ will introduce error in fitted BFI [170].
Noise model for DCS: In the following chapters we have simulated
DCS measurements. For numerical simulations we have added noise to
2.6 Diffuse correlation spectroscopy (DCS) 27
10−6 10−5 10−4 10−3 10−2 10−1
0
0.2
0.4
0.6
0.8
1
g 1
 
 
0.3 x 10−8
0.4 x 10−8
0.6 x 10−8
0.8 x 10−8
1.0 x 1.0−8
 cm2/sec
10−6 10−5 10−4 10−3 10−2 10−1
0
0.2
0.4
0.6
0.8
1
g 1
 
 
0.5 cm
0.7 cm
1.0 cm
1.2 cm
1.5 cm
10−6 10−5 10−4 10−3 10−2 10−1
0
0.2
0.4
0.6
0.8
1
g 1
Delay time (sec)
 
 
0.001
0.040
0.100
0.500
1.000
 cm−1
10−6 10−5 10−4 10−3 10−2 10−1
0
0.2
0.4
0.6
0.8
1
Delay time (sec)
g 1
 
 
05 cm−1
07 cm−1
10 cm−1
12 cm−1
15 cm−1
lower BFI lower ρ 
higher µ
a
 lower µ
s
’ 
Fig. 2.11 Effect of different parameters on the shape of field autocorrela-
tion curve. Decrease in blood flow index (BFI), source-detector separa-
tion (ρ) and scattering coefficient (µs′) as well as increase in absorption
coefficient (µa) will cause higher correlation therefore later drop of AC
curve.
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theoretical intensity autocorrelation. The noise model for DCS measure-
ments is developed by Zhou et al. [76]. It has adapted the noise model
for fluorescence correlation spectroscopy developed by Koppel [171]. In
a DCS experiment, the normalized field autocorrelation function decays
exponentially ( g1(τ) = e−Γτ ). The optical/mechanical properties of
medium and experimental conditions define the value of Γ . The stan-
dard deviation (σ(τ), noise) of the measured intensity AC, g2(τ), at each
delay time (τ) is estimated to be:
σ(τ) =
√
T/t
[
β2
(1 + e−2ΓT )(1 + e−2Γτ ) + 2m(1− e−2ΓT )e−2Γτ
1− e−2ΓT
] 1
2
+
[
2 < n >−1 β(1 + e−2Γτ )+ < n >−2 (1 + βe−Γτ )
] 1
2 . (2.16)
In equation 2.16, T is the correlator bin time interval, m is the bin
index corresponding to the delay time τ . In our correlator the bin time
interval is T = 200 ns for the first 16 channels and is doubled every 8
channels afterwards. The average number of photons < n > within bin
time T (i.e. < n >= IT , where I is the detected photon count rate), t
is the total averaging time.
Chapter 3
Hybrid broadband
NIRS-DCS instrumentation
for experimental oncology
3.1 Introduction
Murine models are the most popular in vivo models in oncology study
and by definition, are an approximation of reality. The major reason
that mice are used is the similarity of mouse and human genetic and
this greatly increased the value of animal models for research on human
disorders specially cancer [111].
Genetically engineered mouse models have significantly contributed
to the understanding of cancer biology. They have proven to be useful
in clinical models in which novel therapeutic strategies are tested [112,
113].
Cancer is abnormal, uncontrolled production of cells in a part of
body. The high proliferating activity of malignant tissue demands more
oxygen and nutrition. To fulfill this demand, cancerous tissue develops
angiogenesis. Angiogenesis is the proliferation of a network of blood
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vessels that penetrates into cancerous regions, supplying nutrients and
oxygen and removing waste products [172–174]. The high metabolism
and vascular supply make a contrast between cancerous and normal
tissue hemodynamics.
By taking advantage of near infrared spectroscopy (NIRS) ability to
map oxygen saturation and blood volume as well as diffuse correlation
spectroscopy (DCS) for blood flow measurements, (look at section 2.5),
we can study microvascular physiology noninvasively as opposed to the
most common imaging modalities that allow probing of tumor morphol-
ogy [6]. For example, metastatic cancers (when a cancer spreads from
its original site to another area of the body, it is termed metastatic can-
cer), in general, have higher metabolism and higher blood volume and by
NIRS and DCS techniques we can find tissues with higher metabolism
and distinguish metastatic tumors from benign ones.
Furthermore, monitoring the hemodynamics changes induced by ther-
apies can provide valuable information about the outcome of therapy.
This information can be used to personalize the therapeutic plan for
each patient. Many techniques have aimed to monitor the cancer ther-
apies [175–178]. This aspect of my research focuses on monitoring of
cancer therapies where we postulate that physiological changes could
be observed prior to morphological changes.
3.1.1 Cancer therapies and optimizing their effi-
ciency
The type of cancer therapy depends on the type, stage, and location
of cancer as well as several other parameters. Considering condition of
patient and cancer usually a combination of therapies will be applied. In
cancer treatment the complete removal of the cancer without damage
to the rest of the body is the goal of treatment. Sometimes this can
be accomplished by surgery, but the propensity of cancers to invade
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adjacent tissue or to spread to distant sites by microscopic metastasis
often limits its effectiveness; chemotherapy, radiotherapy, phtodynamic
therapy are prominent treatments.
Chemotherapy: It uses drugs to stop or slow the growth of cancer
cells to shrink the tumors. It is often applied before surgery (neoadju-
vant) or after radiation therapy or surgery to destroy remaining cancer
cells from radiation therapy or surgery [179–181]. Chemotherapy may
have serious side effects such as: anemia (low red blood cell count) [182]
which causes lack of oxygen circulating in the body, thrombocytope-
nia (low platelet count) that may reason bruising or excessive bleeding,
neutrogena (low white blood cell count) hair losses, eating and skin
problems, etc. While certain cytotoxic side effects can be even life-
threatening [183], under-dosing of patients, which may compromise the
probability of cure for cancers that are curable with chemotherapy, is not
acceptable. Because of the enormous consequences to cancer patients,
maximizing the efficacy of chemotherapy is of prime importance.
Radiation therapy: It uses high energy radiation: X–ray, gamma,
neutrons, protons, etc. to kill cancer cells and shrink tumors [184, 185].
It has two kinds:
1. internal: it has internal source of radiation like radioactive mate-
rial.
2. external: it has external source of radiation like X-ray.
Unfortunately, early and late toxicity limits the deliverable intensity
of radiotherapy, and might affect the long-term health related quality of
life of the patient and also side effect such as: diarrhea, hair loss in the
treatment area, mouth problems, nausea and vomiting, sexual changes,
Swelling, trouble swallowing, urinary and bladder changes. All these
issues arise an importance to optimize the efficacy of therapy [186].
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Photodynamic therapy (PDT): Although this method is still mainly
experimental, it is of particular interest for a photonics research group
since it uses light activated drugs to destroy cells [187, 188]. In this
method photosensitizer is injected to the patient. The interaction be-
tween laser light and photosensitizer makes excited singlet oxygen which
can destroy cells. There are important key components that need to be
optimized, for example, the drug dose and the activating light dose.
It is generally a difficult problem to predict how much light would be
delivered into deep tissues.
Cancer therapy monitoring and enhancement Here I outline one
of our key goals which is to monitor cancer therapy to understand its
fundamental effects on different types of tumors and physiological condi-
tions as well as to suggest potential strategies that could then be tested
on humans to optimize the treatment. Let’s take PDT as an exam-
ple. The micro-vasculature is the primary mechanism to delivers the
treatment drug to the remote parts of the tissues of interest, but the
selectivity (in general, unless some targeting mechanism is used) is low
and the drug can kill cancer cells as well as the normal tissue and blood
vessels. In fact, the destruction of blood vessels to the cancerous regions
is often the goal but it has a side-effect that it may stop the delivery
of the drug to the cancer tissue prematurely, hence hindering the treat-
ment. Monitoring the blood flow during the therapy can assist us to
control this situation and we can “tune” the therapy so that the blood
flow is maintained long enough to ensure adequate delivery of drug to
the tumor. Monitoring of microvascular blood flow is possible by means
of diffuse correlation spectroscopy. In radiation therapy and PDT, oxy-
gen plays an important role in the therapy effect. Without oxygen, the
therapy is not effective and hence local, microvascular, monitoring of
the oxygen is important. We can continuously measure the HbO2 con-
centration by NIRS which is assumed to be an indicator of the available
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oxygen locally. In the work by Yu et al. [37], it has been shown that by
finding the optimum blood flow patterns during therapy and providing
a feed-back mechanism to alter the light fluence/duration, we may be
able to improve the efficiency of therapy. Since then similar effects have
been observed in other tumor models and even was suggested in human
trials of PDT [106, 109, 110, 131, 132, 142, 189].
3.2 Combination of broadband NIRS and
DCS in a single probe
The murine tumors are small in size (< 1 cm in diameter) (figure 3.1)
therefore to perform measurement on them the maximum distance be-
tween source and detector can not be more than few millimeters (5 mm).
Although time resolved spectroscopy (TRS) and frequency domain (FD)
contain higher amount of information (look at figure 2.1), in such small
source-detector separation the broadening of pulse in TRS and phase
shift in FD is small and is difficult to be detected by current instru-
mentation. Therefore, we have chosen multi-distance continuous wave
(CW).
In single wavelength CW measurement one can not decouple µa and
µs
′, and we can just measure effective attenuation coefficient (which is
called k, kr or µeff ). In order to decouple µa and µs′ we have used
broadband light source [37, 43, 58, 69, 70, 91, 92, 95, 97, 105–109, 127–
129, 131, 133–135, 137]. By broadband NIRS we can measure optical
properties of tissue (µa, µs′) as well as concentration of oxygenated
hemoglobin (cHbO2), deoxygenated hemoglobin (cHb), total hemoglobin
concentration (THC) and oxygen saturation (SO2) (for more details
look at section 2.5). Diffuse correlation spectroscopy measures blood
flow in microvasculature. Knowing blood flow changes as well as oxygen
saturation and THC, one can measure changes in metabolism which is
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Fig. 3.1 An anesthetized nude mouse with a renal tumor and the optical
probe on top of the tumor. The tumor is small in size (< 1 cm in
diameter) and the source-detector separation in the optical probe should
be less than 5 millimeters.
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an important parameter for in-vivo studies.
3.3 Broadband near infrared spectroscopy
In the last decades several groups have applied broadband NIRS for
experimental oncology in small animals.Weersink et al. [108] are one
of the first groups who have used self-calibrating probe for broadband
NIRS study. To increase the speed of measurements some groups have
taken advantage of two-dimensional CCD cameras for gathering simul-
taneous spectral and spatial information [105, 131]. The goal here was
to develop an instrument with high information content (i.e. high quan-
tification) while being easy to operate by a small probe that resembles a
“pen” (figure 3.7). It should be operated by biomedical researchers. It
takes advantage of white light and multi-track spectrometers for NIRS
to acquire a relatively complete spectrum from multiple separations
[37, 43, 58, 70, 92, 95, 97, 105–109, 127–129, 131, 133]. The goal is
to acquire multi-spectral, multi-distance measurements to be used in an
algorithm that uses both these aspects for both NIRS and DCS to re-
cover the optical properties and blood flow accurately. Figure 3.2 shows
that the light source is a broadband lamp. The light is delivered to the
tissue through multi-mode fibers and the diffuse light is collected in dif-
ferent distances from the source to a 2D spectrometer. The information
about intensity on each wavelength/distance is transformed a computer
for post-processing.
Light Source: We want to work in physiological window (650-1000
nm), and we need a source which does not have any narrows peak in
this range. For this purpose we have chosen Fused Silica Collimating
Quartz Tungsten Halogen (QTH) Lamp. The chosen light is a 250W
fiber illuminator from Oriel Instruments- Newport Corporation (CA,
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Fig. 3.2 The schematic of white-light device.The light source is a broad-
band lamp. The light is delivered to the tissue through multi-mode
fibers and the diffuse light is collected in different distances from the
source to a 2D spectrometer. The information about intensity on each
wavelength/distance is transformed to a computer for post-processing.
USA). It has an internal shutter which enables us to block white-light
when we want to work with the DCS laser.
Spectrometer and CCD: We planned to image eight fibers on to
the CCD (rows) and many wavelengths (columns). Therefore we need
a 2D CCD, i.e. spatial separation of fibers will be on one dimension of
CCD and spectral separation in the other. As the detected light from
point which are far from source is very weak we need to have high quan-
tum efficiency and sensitivity as well as adequate dynamic range. Back
illuminated CCDs allow incident photons to interact directly with the
photosensitive silicon substrate without having to penetrate an elec-
trode layer. This design results in increased sensitivity and quantum
efficiency. But, in NIR, back illuminated CCDs experience reflections
between their front and back surfaces leading to etaloning. A technique
to reduce the etaloning effect is named excelon. With excelon CCDs not
only the effect of etaloning will be reduced, but also the sensitivity and
quantum efficiency will increase. Therefore our final choice for CCD was
an excelon back illuminated CCD whose peak of quantum efficiency was
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95% at 700nm. (PIXIS: 400B-eXcelon , Princeton Instrument1). This
CCD is a 1340 × 400 imaging array, with 20 × 20 microns pixels. We
can improve the resolution of spectrometer by increasing the intensity
of grooves of grating. But grating with higher groove intensity can cover
narrower spectral range, so there is a compromise between range of cov-
ered spectra and resolution. Resolution also depends on size of entrance
slit. Smaller slits makes higher resolution but the light which can enter
is lower (lower level of signal). With bigger grating we can have better
spatial and spectral separation. However, the cross-talk between fibers
on CCD was also an important parameter for us. We need to have the
cross talk less than 1% for 8 fibers with 200µm cores. Considering all
these parameters our final choice was Acton InSight-EPF from Princeton
instruments with 150 g/mm grating which gives us a resolution about
5 nm covering 545-1055 nm.
3.4 Diffuse correlation spectroscopy
In this setup, DCS is employed for the measurement of blood flow. It
has a single longitudinal mode laser as source(DL785-120-SO, 120mW,
785nm from Crystalaser); the coherence length (>15 m) of the laser
is much longer than a typical photon path length. The laser light is
delivered to the tissue through a multimode fiber with a core diameter
of 200 µm (NA = 0.22). Due to necessity to detect single speckle, DCS
uses single mode fibers of 5.8 µm core diameters for collection. Photon
counting avalanche photodiodes (APDs) are used as detectors (SPCM-
AQRH-14-FC, Pacer Internal) whose output is fed to a digital correlator
(Correlator.com, NJ, USA) to obtain the autocorrelation functions. The
schematic of DCS device is shown in figure 3.3.
1Data is retrieved from Princeton Instrument website. Last access on
30/July/2014:
“http://www.princetoninstruments.com/products/speccam/pixis/”.
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Fig. 3.3 The schematic of DCS device. A high coherent laser light is de-
ployed as the source. The diffused light from the tissue will be delivered
to the detectors (avalanche photodiodes) through single mode fibers. A
correlator calculates the autocorrelation function of the detected light.
3.5 Design and construction of the hand-
held probe
The probe design is based on a rigorous computational simulation which
employs a physical model for semi-infinite media as its principal element.
The properties of a typical tissue are given as optical properties of media.
The desired probe is a semicircle (half a centimeter diameter). There
is a source in one end of diameter and also a self-calibration source in
the center. The detectors for NIRS are located on the circumference of
this semicircle. The simplest way is to distribute all detectors evenly.
but as much as we get far from the source, the changes in intensity is
smaller; therefore while the first consecutive detectors (nearest detec-
tors to the source) have a lot of difference in detected intensities, last
detectors have no measurable difference. Figure 3.4 shows the simulated
detected intensity of 8 uniformly distributed detectors whose intensities
are calculated by applying the diffusion equation. Using HbO2 , Hb and
water as chromophores.
The positions of the detectors are determined according to several
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Fig. 3.4 [Left] Simulated detected intensity of 8 uniformly distributed
detectors. [Right] The schematic of a probe with uniform distribution
of detector.
considerations:
• Photon diffusion equation should be applicable; the distance be-
tween source and the first detector should be more than 2ltr (ltr
is transport mean path).
• The detected intensities should cover the whole dynamic range of
the CCD uniformly where the lowest signal level that is allowed
should allow for an SNR > 10. For example, in a 16-bit CCD with
∼ 500 dark counts the signal from the furthest detector should be
more than 5000 counts. While the maximum count in a 16-bit
camera is ∼ 650000 counts. Therefore the detectors should cover
a range between 5000-65000 counts.
• In order to ensure that under all conditions we can separate the
changes in intensity due to changes in distance, we allow for 10%
deviation due to physiology and noise in time. Therefore, the dif-
ference between detected intensities from detectors with increased
separation should be more than 10%.
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• For practical reasons, we limit ourselves to eight detector positions
in order to ensure (with current commercially available hardware)
that the inter-fiber cross-talk is less than 1% for ∼200µm detector
fibers.
• The distance between following detectors cannot be less than 0.5
mm because of the size of the fibers.
Figure 3.5 illustrates the constraints for the position of detectors.
2
Fig. 3.5 The schematic of desired self-calibrating probe and the con-
straints on the detector positions.
We then simulate a large (thousands) of positions on a semi-circle
using the numerical model and apply the above constraints to find out
candidate positions. Their potential is tested by fitting for unknowns
from forward simulations including shot-noise, CCD noise, CCD quan-
tum efficiency, source spectrum and dark counts. The detailed descrip-
tion of implemented CCD noise, coupling errors, calibration and fitting
data is explained in the following sections. for a range of optical prop-
erties. Our simulations have let us that for 8 fibers with source-detector
separation 2.5 to 5 mm (2.5, 2.9, 3.2, 3.6, 3.9, 4.3, 4.6, 5.0 mm). The se-
lected detector position satisfying all the above constraints we will have
3.5 Design and construction of the hand-held probe 41
the detected intensity of ith detector is least 23% more than previous
one (i-1)th for average tissue properties. We note that this provides us
with a better quality data than simply distributing the detectors evenly
along the semi-circle since the diffusing photons are decaying exponen-
tially with distance. Figure 3.6 shows the simulated detected intensity
of 8 detector positions satisfying all the desired constraints.
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Fig. 3.6 [Left] Simulated detected intensity of 8 detector positions satis-
fying all the desired constraints. [Right] The schematic of a probe with
final distribution of NIRS detectors.
Since we want the DCS and NIRS provide information from the same
depth in the tissue, and source-detector separation is the indicator of
depth, we have chosen the DCS source-detector separation same as NIRS
ones.
As there are 4 APDs in the DCS setup and we need 8 source-detector
separations, we have considered two DCS source which shine light in
turn and two source positions with 4 detector positions results in 8
source-detector separations. All we need is finding a set of locations
for these fibers on the probe such that it retrieves eight source-detector
separations of NIRS probe to cover the same volume. Figure 3.7 demon-
strates the final design of probe the way it will be located on the tumor.
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Fig. 3.7 The schematic of hand-held NIRS/DCS probe and the way it
will be located on the tumor.
The designed probe was made by Fiberoptic Systems, Inc. (FSI,
Simi Valley, CA. USA). The drawing of manufactured probe with all
the details can be found in appendix A. Some spare single and multi-
mode fibers are implemented in the fabricated probe to be used in case
of fiber damage. The 8 NIRS detectors are connected to an 8 to 1 fiber
bundle, and the bundle is placed on the entrance of the spectrometer.
The bundle is also made by Fiberoptic Systems, Inc. The drawing of
manufactured bundle can also be found in appendix A.
Figure 3.8 is a picture of the probe tip. Since the illuminated light
to different fibers was not homogeneous they have different brightness.
The smaller dots correspond to single mode fibers (DCS detector fibers).
3.5.1 Noise in CCD
Dark noise: Dark current is the relatively small electric current that
flows when no photons are entering the device. Physically, dark cur-
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Fig. 3.8 A picture of the probe tip. Since the illuminated light to dif-
ferent fibers was not homogeneous they have different brightness. The
smaller dots correspond to single mode fibers (DCS detector fibers).
rent is due to the random generation of electrons and holes within the
depletion region of the CCD that are then swept by the high electric
field. Dark current can be reduced by cooling. The cooling temperature
in our CCD is -75o C. The typical dark current at this temperature is
0.005 (e−/pixel/sec).
Read out Noise: The readout noise of the system is due to the
readout electronics of the sensor and the analogue to digital converter.
Our CCD has 3 electrons readout noise at slow speeds (100 kHz) and
at speeds of 2 MHz; readout noise of 12 electrons is typical.
Shot noise: Shot noise is associated with incident photon statistics.
It is proportional to square root of number of photons. Shot noise is
the main source of noise in this CCD. We can increase the ratio of
signal to shot noise by increasing the signal. It is possible by increasing
the exposure time or intensity of the light source. Since the dominant
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noise in our system is the shot noise, we just consider shot noise in our
simulations.
Coupling errors: In the experiments, the inherent imperfections of
the fibers and deficiency of contacts between the fiber tips (sources and
detectors) and the tissue due to air gaps or surface moisture cause sig-
nificant errors which are known as “coupling errors” [190]. In this sim-
ulation in order to mimic experimental data, computational coupling
coefficients, F i,j(λ), are introduced as follow (i is detector number and
j is source number).
F i,j(λ) = F iD(λ)F
j
S(λ) (3.1)
Where F iD(λ) is detector fiber coupling coefficient and F
j
S(λ) is the
source fiber coupling coefficient. The simulated coupling coefficients
are obtained by:
F iD(λ) = F iD(λ)min + F iD(λ)error ×Rand. (3.2)
Where F iD(λ)min is the minimum coupling error and F iD(λ)error is the
difference between maximum and minimum coupling error. “Rand” is a
pseudo-random number between zero and one generated by “rand” func-
tion of Matlab (Mathworks Inc, Massachusetts, USA). F jS(λ) is defined
in the same way as F iD(λ).
Quantum efficiency: The quantum efficiency (QE) of a detector
represents its response to different wavelengths of light and is defined
as the percentage of photons hitting the photo-reactive surface that will
produce an electron–hole pair. In figure 3.9, solid green line shows the
quantum efficiency of the detectors (PIXIS: 400 B-eXcelon) which is
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used in the setup 2. In order to have more realistic data, thus, quantum
efficiency, as well as CCD noise and coupling errors, should be consid-
ered in the simulated intensity. To simulated the detected intensity from
each source-detector pair the Poisson noise is added to the theoretical
amplitude at a specific source-detector separation (rho) and wavelength
(λ). Then the quantum efficiency at λ and coupling coefficient are multi-
plied to the noise-added amplitude. Equation 3.3 illustrates the formula
for intensity simulation. I i,jm (λ) is related to detected intensity in ith de-
tector from jth source.
I i,jm (λ) = QE(λ)F i,j(λ) Poiss(G(ρ, λ)) (3.3)
In equation 3.3 G(ρ, λ) is the Green’s function solution for diffusion
equation in semi-infinite boundary condition (for more details at equa-
tion 2.6). Poiss is a random number from the Poisson distribution with
mean parameter G(ρ, λ). Poiss is produce by “poissrnd” function of
Matlab.
Self-calibrating probe Our probe is designed to be self-calibrated by
utilizing a center- mounted source for estimating the relative detector
coupling coefficients. We need to find the calibration coefficient for
detectorsDicalibration. For calibrating the detectors, we assume a detector
as base detector and calibrate the other detectors with respect to that
one. For calibrating with respect to the first detector, the first detector
calibration coefficient, D1calibration, can be assumed to be unity or kept as
an constant. The self calibrating probe is based on the fact that all the
detectors should represent the same intensity when calibrating source is
on since they all have the same distance (2.5 mm) from the calibrating
2The plots is retrieved from Princeton Instrument website. Last access on
30/July/2014:
“http://www.princetoninstruments.com/products/speccam/pixis/”.
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Fig. 3.9 The solid green line is quantum efficiency spectrum of the CCD
that we have used in our setup (B-eXcelon). The other colors corre-
sponds to other types of CCD cameras from Princeton Instrument.
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source (first source, j = 1). In other words intensities after calibration
(I i1c ) should be equal and all equal to the measured intensity of the first
detector (I11m ).
I11m = I i1c = I i1m ×Dicalibration
Dicalibration = I11m /I i1m (3.4)
Figure 3.10 demonstrates the effect of calibration on the measured
values. All values are normalized by the first detector to cancel out the
source term (I/Iref ). Red circles represent normalized intensities before
calibration over different source-detector separations. The red circles do
not follow the exponential decay. The blue triangles are the calibrate
normalized intensities and they have a good agreement with the theory
(fitted curve).
Figure 3.11 demonstrates how calibration improves the quality of
fitting over a wide range of wavelengths (600-1000 nm) for seven source-
detector separations. Similar to figure 3.10 all values are normalized by
the reference detector (I/Iref ) to cancel out the source term. On the
left the normalized intensities before calibration over wavelength do not
follow the theory while the right figure shows the calibration improves
the agreement of measurement and theory.
3.6 Data fitting for NIRS setup
The output of NIRS setup is the detected intensities over wavelength
and source-detector separation. We go through the following procedure
to obtain concentration of oxy- and deoxy- hemoglobin in in-vivo mea-
surements. The intensities in all detector fibers from the main source,
Imain were first calibrated using the calibration factors obtained from
calibration source (Look at equation 3.4). The calibrated intensities
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Fig. 3.10 The effect of calibration on the measured values. All values are
normalized by the reference detector (I/Iref) to cancel out the source
term. Red circles represent normalized intensities before calibration over
different source-detector separations. The red circles do not follow the
exponential decay. The blue triangles are the calibrate normalized in-
tensities and they have a good agreement with the theory (fitted curve).
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Fig. 3.11 The effect of calibration on the quality of fitting over a wide
range of wavelengths (600-1000 nm) for seven source-detector separa-
tions.. All values are normalized by the first detector to cancel out the
source term (I/Iref). [Left] The normalized intensities before calibra-
tion over wavelengths do not follow the theory. [Right] The calibration
improves the agreement of measurement and theory.
This adjusted light intensity, I(ρ, λ), at a distance ρ from the main
light source is proportional to the Green’s function solution for diffusion
equation in semi-infinite boundary condition (for more details look at
equation 2.6). It has been shown that the scattered spectrum can be fit-
ted to the effective particle size and number density, under the assump-
tion of Mie scattering model. Alternatively, the spectra is thought to fit
to a Mie-like spectra with some Rayleigh scatter influence [191, 192].
µs
′ = A1(λ)−b + A2(λ)−4 (3.5)
The absorption coefficient µa is assumed to be the sum of the absorp-
tion coefficients for oxygenated and deoxygenated hemoglobin (610–800
nm from [193], 800-1000 nm from [194]) and water (from [195]) times
their concentrations ci (more details are available in section 2.5). Nu-
merical fitting was done for A1, A2, b and ci in the wavelength range 610
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– 1000 nm for the ratio of the Green’s functions of two fibers at the same
time, G(A1, A2, b, ci, ρ0)/G(A1, A2, b, ci, ρ). The four short separations
(2.5, 2.9, 3.2, and 3.6 mm) were used for ρ0 and the four longest (3.9,
4.3, 4.6, and 5.0 mm) for ρ. The numerical fitting was done in Matlab
using a nonlinear least square method (LSQNONLIN with Levenberg-
Marqardt algorithm).
3.7 Test and validation by phantom and
in-vivo measurements
Test and validation by liquid phantom measurement: The func-
tion of the device and data analysis is validated by various tissue sim-
ulating phantom measurements. Figure 3.12 shows the results of a test
on liquid phantom. The phantom is consist of water (1.9 liters) of
lipofundin [196] (for the scattering) and dark green Ecoline ink (for ab-
sorption).
µa of diluted dark green Ecoline ink at 685 nm was measured by
absorption spectroscopy and its absorption is ∼ 5.3 cm−1. µa of water
at 685 nm is ∼ 0.0052 cm−1. By lipofunid titration we increased the
concentration of scatterers in the medium which is expected to have
direct relation with the µs′ of the phantom. The titration causes volume
increase which reduces the concentration of ink that lead to slightly
lower µa. We have measured changes µs′ as well as small changes in µa
very precisely. Figure 3.12 shows the agreement of measured µa and µs′
with the changes in ink and lipofundin concentrations.
Test and validation by in-vivo measurement: After successful
validation on phantoms, we moved the device to animal facility of IDI-
BELL (Instituto de Investigación Biomédica de Bellvitge) for the mea-
surement on the murine tumors. In the last step of validation we per-
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Fig. 3.12 The agreement of measured µa and µs′ with the changes in
ink and lipofundin concentrations in a liquid phantom. [Left] measured
µs
′ increases linearly by increase of lipofundin concentration. [Right] µa
decreases linearly by decrease in ink concentration. The measured value
of absolute µa is in agreement with the absorption spectroscopy value.
formed a thigh cuff occlusion on a mouse to monitor the hemodynamics
changes due to occlusion. Figure 3.13 shows the procedure of cuff and
the location of probe on the mouse’s thigh.
Preliminary Animal Study
Leg- cuff
Probe
Fig. 3.13 The procedure of arterial thigh cuff occlusion and the location
of probe on the mouse’s thigh.
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Figure 3.14 shows the hemodynamics respond to the arterial cuff
occlusion on a mouse thigh. On the left side, the changes in relative
blood flow is demonstrated. As expected by applying occlusion blood
flow has a sharp drop and afterwards it stays constant. As it has been
observed before [33, 119], there is an over shoot of blood flow caused
by the release of occlusion. Figure 3.14-right shows the response of
blood oxygen saturation to the cuff occlusion. After full occlusion (first
dotted red line). Oxygen saturation drops gradually as expected by ap-
plying occlusion since the blood flow in the tissue will be restricted and
tissue does not receive oxygenated hemoglobin. Tissue consumes the re-
mained oxygen and the ratio of oxygenate hemoglobin to deoxygenated
hemoglobin (oxygen saturation) decreases in time. Similar to previous
studies [33, 119], we have observed the hyperemia after the release of
occlusion
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Fig. 3.14 Hemodynamics changes induced by mouse thigh cuff occlusion.
Vertical lines indicate the beginning and end of the occlusion.[Left] Rela-
tive blood flow during arterial cuff occlusion. By applying the occlusion
blood flow decrease and the cuff release causes and over shoot in rela-
tive blood flow. [Right] Relative blood oxygen saturation during arterial
cuff occlusion on a mouse thigh. Deoxygenation during occlusion and
hyperemia after the release of occlusion is observed.
Chapter 4
Monitoring the effect of
antiangiogenic therapy on
murine renal cell carcinoma
4.1 Introduction
Angiogenesis, the formation of new blood vessels, plays an important
role in the growth and spread of cancer [172, 173, 197]. Tumors need
new blood vessels that provide them with oxygen and nutrients in order
to grow [198]. Access to the newly formed vessel network allows the
cancer cells to invade nearby tissue, and to move throughout the body
to form new colonies of cancer cells (metastases) [174, 199]. In order
to develop angiogenesis, tumors undergo complicated signaling process
by production of angiogenic agents such as vascular endothelial growth
factor (VEGF) [200]. Inhibition of angiogenesis is emerging as a new
therapeutic approach to control tumor progression [201, 202]. Several
clinical trials have provided evidence that antiangiogenic therapy, alone
or in combination with chemotherapy, is effective and may increase the
survival of patients [203, 204]. Followed by effective phase of antiangio-
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genic therapies, tumors adapt and begin regrowing via a process referred
to as “evasive resistance” [205–207]. In several studies the development
of nonresponsiveness to an initially efficacious anti-VEGFR therapeu-
tic regimen in a xenotransplant model is demonstrated [208–210]. The
resistance mechanism is mostly unknown, and this arises a strong de-
mand for imaging modalities that can study the hemodynamics changes
induced by therapies to identify the early signs of nonresponsiveness.
In therapies on human patients early identification of nonresponders is
essential to personalize the treatment and to avoid the resistance phase,
which results in more aggressive tumors [211].
There are several methods to measure oxygen level of tumors, but
due to invasiveness, depth of measurement, and utilized contrast/radiative
agents, these methods are not ideal for continuous, repeated measure-
ments [15]. There are also a number of techniques for the measurement
of blood flow in the tissue [212]. Doppler ultrasound has been applied to
measure the perfusion changes in the mouse tumors due to cancer ther-
apy, but its information is limited to the tumor surface [213, 214]. Laser
Doppler can noninvasively monitor the flow change, but the penetration
depth is very low and it is limited to surface measurement [215]. Sim-
ilarly, there are also imaging technologies in microvascular assessment
such as laser speckle flowery or optical coherence tomography [215–217]
that can image the surface of the tumor noninvasively.
Considering the limitation of current techniques for measurements of
deep tissue oxygenation and blood flow, we have deployed diffuse opti-
cal spectroscopy techniques to study hemodynamics changes induced by
antiangiogenic therapies on murine models. Changes in level of vascular-
ization alters the hemodynamics of the tissue, which can be correlated
to optical measurements of microvascular blood flow, blood volume or
oxygen saturation [43, 98]. During last decade many researchers demon-
strated that diffuse optics is a strong tool to monitor the hemodynamics
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changes induced by cancer therapies and have the potential to predict
therapeutic efficiency [52, 54, 95, 100, 101, 110, 142]. In this study we
have deployed a hybrid diffuse optics system that measures blood flow by
diffuse correlation spectroscopy (DCS) in addition to tissue oxygenation
and hemoglobin concentration by diffuse optical spectroscopy (DOS).
In this work, we have observed that early changes in tumor hemo-
dynamics induced by antiangiogenic therapies has correlation with the
time that each tumor starts to resist against therapy as well as final size
of tumor. These findings suggest that we can predict the output of ther-
apy and resistance time of the tumor, time-to-progress (TTP), which are
valuable information for better understanding of the tumor resistance
mechanism to antiangiogenic therapy, which in human treatment may
lead to personalized therapy with higher success.
4.2 Methods & materials
4.2.1 Optical device and data analysis
We have combined broadband near infrared spectroscopy and diffuse
correlation spectroscopy in a single self-calibrated probe. The full de-
scription of the device and probe is given in chapter 3. In DOS setup
in order to prevent edges of CCD, we have used 6 source-detector sep-
arations (2.5- 5.0 mm). DCS also utilizes 6 optode distances (2.9- 5.0
mm). We have also deployed a control probe which is located on a
healthy tissue of the body (a muscle) to monitor the global hemody-
namics changes during the anesthesia. In the control probe both DCS
and DOS have only one source-detector pair with ∼ 4 mm separation. In
summary DOS measures oxygen saturation and hemoglobin concentra-
tion and DCS measures blood flow in the tissue. In every measurement,
in order to have better statics of the optical properties of tumor we have
re-positioned the probe 10 times and took 11 acquisitions. The detailed
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description of fitting and data analysis is in section 3.6.
4.2.2 Animal models and treatment procedure
Fourteen immunosuppressed male athymic nude mice were measured
in this study. Seven mice received the antiangiogenic therapy twice per
week and the rest were as control group and were receiving placebo with
the same frequency as treated animals.
Orthotopic implantation of renal cell carcinoma (RCC) tu-
mors: Male athymic nude mice were purchased from Harlan Labo-
ratories. Mice were housed and maintained in laminar flow cabinets
under specific pathogen-free conditions. All the animal studies were
approved by the local committee for animal care. Fresh surgical spec-
imens of RCC were obtained after surgical resection from the Hospital
Universitary de Bellvitge (ĽHospitalet de Llobregat, Barcelona, Spain)
and placed in Dulbecco’s Modified Eagle’s Medium (DMEM), BioWhit-
taker, supplemented with 10% FBS (Fetal bovine serum), 50 units/mL
penicilin and 50µgr/mL streptomycin sulfate. These animal models are
based on orthotopic implantation of little pieces (2 x 2 x 2 mm3) of
human RCC tumor biopsies by surgical implantation into the original
neoplastic organ on immunosuppressed nude mice, following studies pi-
oneered by Dr. G. Capellá [218, 219]. Briefly, 5-weeks-old male mice
weighing 18-22 gr was anesthetized by isoflurane inhalation. A small
midline incision was made and the kidney was exteriorized. A piece of
tumor was implanted on left kidney using prolene 7-0 surgical suture.
The kidney was returned to the abdominal cavity and the incision was
closed with wound clips. Different tumors were perpetuated in mice by
consecutive passage according to the growth rate of each tumor type.
For our study, we use a renal cell carcinoma of clear cell histology (REN
28), Fuhrman grade 4/4 and pathological staging pT3pN1.
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Biological point of view: We have developed several advanced mouse
models of renal cell cancer (RCC), human tumorgraft RCC mouse mod-
els, designed to better resemble the human pathology and show more
parallelism in their responses to therapies (in particular when targeting
components of the tumor stroma). These little human tumor biopsies
grow in mice preserving the stromal architecture (even when it is re-
placed by mouse stroma), and they can be passaged (and expanded) to
many new recipient mice by re-implanting a piece of tumor to many new
animals (commented by Garber [220]). Therefore, these mouse lines pre-
serve a stromal rich tumor structure in the growing tumors, which have
a very high resemblance to the original human tumor that was in the
patient (figure 4.1). Thus, these animal models allow for more relevant
studies of the tumor responses to treatment than standard xenograft
models because they maintain the tumor-stromal proportion, structure
and many of their functional.
Legalities on animal models An animal research project protocols
for the tumorgraft models have been evaluated and accepted by IDI-
BELL’s animal research committee and have been registered and ac-
cepted by the “Animal Experimental Comission” from the local Catalan
government and the “Comisión de Ètica en Experimentación Animal”
from the national Spanish government (Protocol number 4899, PI:Oriol
Casanovas).
Antiangiogenic treatments The antiangiogenic drug used is very
specific monoclonal antibody that binds and blocks mouse-VEGFR2
signaling, named DC101. This antibody has the advantage of having a
species-restricted activity, as it does neither recognize nor block human-
VEGFR2 [88, 221, 222]. Therefore, when used in the tumorgraft models,
we are sure that this drug is not affecting the tumor cells directly but
rather it only has an antiangiogenic effect. The blocking antibody of
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REN 28 
Biopsy 
REN 28 
XenoGraft 
Human tumor biopsy Tumorgraft in mice 
Fig. 4.1 Newly developed tumorgraft mouse model to study antian-
giogenic therapies. Histological H&E sections of renal cell carcinoma
(Ren28) demonstrate high similarity in the tissue structure and pat-
tern between human primary tumor biopsy (left panel) compared to
its respective mouse tumorgraft tumor (right panel). Arrows indicate
stromal structures in the form of trabeculae and clusters found in both
tumors (human biopsy and mouse Tumorgraft). Credits: Dr. Gabriela
Alejandra Jimenez from Dr. Oriol Casanovas’s lab.
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VEGFR2 (DC101) can be obtained in large scale by purification from
supernatants of the hybridoma DC101 in culture (modified from ATCC),
and is used at the dose of 1 mg/animal by intraperitoneal injection twice
a week, as previously described [209, 210]. For each mouse when the
tumor volume reached ∼ 1000 mm3 the therapy was started (DC101 or
placebo). The mice kept receiving the therapy/placebo up to the time
that due to the tumor size or mouse weight loss, we had to stop the
measurement and sacrifice the animal.
4.3 Results and discussions
4.3.1 Physiological characterization of the tumor
In RCC tumors, we have measured hemodynamic properties such as
oxygen saturation, total hemoglobin concentration and blood flow index.
In figure 4.2, the average of these parameters over all mice measured all
days on tumor and a control muscle (shoulder muscle) are presented.
The blood flow index in tumor is 25.1% higher than the muscle (P <
10−4). Measured total hemoglobin concentration in tumor is 22.8 µM
lower than healthy shoulder muscle (P < 10−4). Malignant tumors are
usually expected to be hypoxic [133, 223]. In the case of RCC tumors
we have observed that blood oxygen saturation in tumor is 9.1% higher
than normal tissue (P < 10−4). It may be explained by the existence
of blood shunts in RCC tumors which are the closed arterioles passing
throughout the tumor without having the chance of oxygen exchange
[224].
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Fig. 4.2 The optically measured hemodynamic properties of the RCC
tumor in comparison with a control muscle. The reported difference in
all three cases are statically significant (P < 10−4). [Left] Blood oxygen
saturation in the tumor is 9.1% higher than healthy shoulder muscle.
[Middle] The total hemoglobin concentration in the tumor is 22.8 µM
lower than healthy shoulder muscle. [Right] The blood flow index in the
tumor is 25.1% higher than healthy shoulder muscle.
4.3.2 Correlation between measured parameters by
DCS and DOS
Total hemoglobin concentration (THC) and blood flow index (BFI) are
measured by DOS and DCS respectively, which are independent sepa-
rate devices. Figure 4.3 shows the measured values of THC and BFI
for all mice (treated and control) over all days are correlated with each
other. The agreement between measured physiological parameters by
two independent devices validates our measurements. For treated tu-
mors the correlation coefficient is r = 0.45 and it is statically significant
(p < 0.001). In control tumors the correlation coefficient is r = 0.67 and
it is statically significant (p < 0.001).
4.3.3 Early blood flow changes induced by antian-
giogenic therapy
Figure 4.4 demonstrates the evolution of measured blood flow index in
treated and control tumors over time. Similar plots for other optical and
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Fig. 4.3 Total hemoglobin concentration versus blood flow index over all
mice in all days. The measured values from treated mice are presented
by orange stars and control animals by green circle. In both control
and treated groups the measured total hemoglobin concentration (from
DOS) and blood flow index (from DCS) have positive correlation. For
treated tumors the correlation coefficient is r = 0.45 and it is statically
significant (p < 0.001). In control tumors the correlation coefficient is r
= 0.67 and it is statically significant (p < 0.001).
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physiological parameters such as absorption coefficient, reduced scatter-
ing coefficient, total hemoglobin concentration and oxygen saturation
are presented in Appendix B. In figure 4.4, the number of measurement
days for each mouse is different because they have been sacrificed in
different days after start of the study. Each point is average of all 10
measured locations on the tumor. While the BFI of control animals
slowly decrease, in all treated animals an initial drop of blood flow is
observed. This initial decrease observed in all mice after the first ses-
sion of therapy. In some of them the initial drop continues up to the
second session of treatment. The initial decrease of BFI is followed by
an increase in blood flow. We will investigate the correlation between
the maximum decrease of blood flow (initial change of blood flow) with
the outcome of the therapy following in this chapter.
4.3.4 Tumor size and time-to-progress (TTP)
Figure 4.5 shows the measured size of tumor by palpation during the
therapy. The number of measurement days for each mouse is different
because they have been sacrificed in different days after start of the
study. The tumors of control mice grow gradually but treated tumors
do not grow for one or two weeks and start to progress afterwards.
The time that takes for each tumor to get resistant to the therapy and
start to grow is called time-to-progress (TTP). To calculate the time of
progress a threshold tumor volume is defined. The threshold volume is
the average plus two times standard deviation of initial volume of all
tumors. TTP of each mouse is the time that takes for the tumor to reach
the threshold volume. Following in this chapter we will investigate the
possibility of early prediction of TTP.
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Fig. 4.4 Blood flow changes of both treated (top) and control mice (bot-
tom) are presented over all days of measurement. The number of mea-
surement days for each mouse is different because they have been sac-
rificed in different days after start of the study. All the treated animals
have an initial drop in the blood flow.
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Fig. 4.5 Tumor size measured by palpation from both treated (solid
orange lines) and control mice (dashed green lines) are presented over
the time. The number of measurement days for each mouse is different
because they have been sacrificed in different days after start of the
study. The tumors of control mice grow gradually but treated tumor
does not grow for one or two weeks and start to progress afterwards.
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4.3.5 Extracted tumor weight and histology results
After sacrificing each mouse, the tumor was extracted for the measure-
ment of its volume and volume and to prepare it for histological studies.
The measured extracted tumor weight is for both treated and control
group is presented in figure 4.6. In average the extracted tumors from
the treated animals are lighter than control ones.
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Fig. 4.6 The extracted tumor weight of treated and control group. In
average the extracted tumors from the treated animals are lighter than
control ones.
In this study we have used cluster of differentiation 31 (CD31) stain-
ing to measure the micro-vessel density (MVD) in the tumor. Figure 4.7
demonstrates the measured MVD in the extracted tumor measured by
CD31 staining. In average tumors of treated mice have lower MVD in
comparison to control group.
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Fig. 4.7 Micro-vessel density (MVD) in the extracted tumor measured
by CD31 staining. In average tumors of treated mice have lower MVD
in comparison to control group.
4.3.6 Early blood flow changes correlates with ex-
tracted tumor weight and histology results
It is shown in figure 4.4 that all the treated mice showed an initial de-
crease in the blood flow index. In order to investigate the predictability
of the optically measured data, the correlation between the maximum
decrease of blood flow (initial change of blood flow) with the outcomes
of the therapy are inquired. One of the standard outcomes of therapy
in experimental oncology is the weight of extracted tumor. Figure 4.8
demonstrates that initial blood flow changes has a strong correlation
with the the extracted tumor weight. It shows that larger drop of blood
flow is an indicator of smaller tumor. The correlation coefficient r = 0.9
and p-value is equal to 0.006.
Figure 4.9 shows the correlation between the measured MVD and
the initial change of blood flow index. The correlation coefficient r =
-0.8 and p-value is equal to 0.04. It can be observed that mice with
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Fig. 4.8 There is a positive correlation between initial change in blood
flow and the extracted tumor weight in the treated mice.
larger initial drop of blood flow have higher values of MVD.
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Fig. 4.9 There is a negative correlation between initial change in blood
flow and the blood vessel density obtain by CD31 staining in the treated
mice.
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4.3.7 Early blood flow changes as a predictor of
TTP
TTP is an important therapeutic factor and knowledge about it, enables
the physicians to plan the duration of therapy. We have explained the
procedure of calculating TTP in section 4.3.4. In this section we have
investigated the correlation between TTP and initial change of blood
flow index. Figure 4.10 shows a good correlation between the initial
drop of blood flow index and TTP. The correlation coefficient r = 0.8
and p-value is equal to 0.03. One mouse, A1, is an outlier in this plot
and it is excluded from correlation calculation. Mice with higher drop
of blood flow starts evasive resistance earlier. This results suggest the
potential of optics to predict the resistance of the tumor.
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Fig. 4.10 There is a positive correlation between initial change in blood
flow and the time-to-progress (TTP) in the treated tumors. One mouse,
A1, is an outlier in this plot and it is excluded from correlation calcula-
tion.
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4.4 Conclusion
In this study we have applied diffuse optical spectroscopy methods for
hemodynamics monitoring of the murine tumors during antiangiogenic
therapy. We have shown that hemodynamics properties of the tumor
alters by starting the antiangiogenic therapy. These early changes shows
a strong correlation with the outcome of therapy such as tumor weight,
CD31 staining and time for the tumor to get resistant. These results
suggest that diffuse optics is an strong tool to understand the defense
mechanisms of tumor against antiangiogenic therapy. The main weak-
ness of this study is the limited number of mice and continuing the study
with larger number of tumors may lead us to develop optical parameters
to predict the success of therapy which results in personalized treatment
for each subject.

Chapter 5
Noninvasive characterization
of the healthy human of bone
marrow using diffuse optical
spectroscopies
5.1 Introduction
Hematological malignancies such as leukemias, lymphomas, and mul-
tiple myelomas are common, accounting for about ∼9% of all newly
diagnosed cancers [225, 226] and most of them have a poor prognosis
[227, 228]. In children and adolescents younger than twenty years, hema-
tological malignancies are the most common type of cancer, responsible
for more than 30% of all cancers [227, 228].
Most of these cancers originate in the bone marrow since this tissue
is the main site of blood cell formation. In the bone marrow, hematopoi-
etic stem cells (HSCs) differentiate into blood cells: red cells, white cells,
and platelets. Mutations that inappropriately activate HSC prolifera-
tion cause an uncontrolled growth of abnormal blood cells and lead to
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hematological malignancies. This high proliferating activity of HSCs
induces angiogenesis in the bone marrow [229–231] and increase in an-
giogenesis of the bone marrow has indeed been observed in patients with
progression of these malignancies [232–236]. It has also been shown that
the degree of angiogenesis is an important prognostic factor [237–240],
an indicator of the disease burden, and is associated with the treatment
outcome [241, 242].
Therefore, it is of interest to investigate the degree of vascularization
of the bone marrow which is important for better estimation of prognosis
and for personalization of the therapy procedure. Measurement of angio-
genesis is important for the follow up of treatment and screening during
the reemission phase. In the clinical routine, the most direct and com-
mon technique of angiogenesis evaluation is histomorphological analysis
of the bone marrow, basically the measurement of microvessel density.
It involves a bone marrow biopsy taken from the iliac crest or the ster-
num. However, biopsy has several limitations: it is invasive, it has
substantial inter-observer variability, and analyzes just a discrete site of
the whole bone marrow [243]. Dynamic contrast enhanced magnetic res-
onance imaging (DCE-MRI) is also applied to investigate the degree of
vascularization. Although DCE-MRI is noninvasive and has a relatively
high resolution, it is expensive and utilizes contrast agents, therefore
it is not suitable for screening and repeated measurements. Another
clinical technique to estimate the extent of the angiogenesis is measure-
ment of the angiogenic biomarker levels in a blood sample [244, 245].
However, the estimation of biomarkers achieved by blood extraction is
not targeted to a specific tissue and angiogenesis in other organs may
elevate it. Therefore, the level of angiogenesis in the bone marrow and
biomarkers in the blood are not necessarily correlated [246, 247].
In experimental studies, positron emission tomography (PET) and
single photon emission computed tomography (SPECT) have also been
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used to measure the blood flow in the bone often as a correlate of an-
giogenesis [248–250]. PET has also been used to image the proteins,
which are implicated in the angiogenesis procedure [251]. Despite the
good sensitivity of these techniques, high cost measurements in addi-
tion to exposure to radioactive agents make them limited for repeated
measurements. They have not been adopted for widespread clinical use.
Considering the importance of angiogenesis and the limitations of
current techniques, we hypothesise that the noninvasive diffuse opti-
cal spectroscopy techniques might be useful and practical to study the
hemodynamics of normal and malignant hemopoiesis as a potential cor-
relate of increased angiogenesis and proliferation. Increased angiogenesis
alters the hemodynamics of the tissue which can be correlated to opti-
cal measurements of microvascular blood flow, blood volume or oxygen
saturation [43, 98].
Furthermore, in subjects with hematological malignancies, the high
proliferating activity of the hemopoietic tissue is observed due to an-
giogenesis in the bone marrow [229–231]. Since high proliferation may
alter the hemodynamics of the tissue as well as its scattering coeffi-
cient, diffuse optics can be potentially utilized for screening purposes
to detect high risk subjects. Furthermore, the degree of angiogenesis
has been considered a predictive factor of response to treatment. In
this sense, it could be a promising noninvasive method for categorizing
the risk of the patient before the treatment. It can also be applied to
monitor the changes in bone marrow hemodynamics induced by the an-
tiangiogenic therapies which are emerging as effective treatments against
cancer [252, 253]. Following the response to the therapy may help to
personalize the therapy for each subject.
Diffuse optical spectroscopy is a noninvasive method that does not
use ionizing radiation or contrast agents [2]. The device and measure-
ments are relatively inexpensive and it is a suitable method for repeated
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measurements. It can be combined with other modalities such as MRI
[99] for simultaneous measurements to provide complementary informa-
tion.
While the bulk of diffuse optics in biomedicine was used on soft
tissue, the feasibility of applying optical methods on human bone tissue
have been investigated in several works [121, 122, 144, 153, 254–270].
Furthermore, it has been demonstrated that bone is an active tissue
whose hemodynamics is responsive to physiological changes such as cuff
occlusion [144].
Accessibility of the target tissue is the key concern in noninvasive dif-
fuse optical measurements since it can mostly measure the upper (∼1-5
cm) layers of tissue. In adults hematopoietic tissue exist mostly in flat
bones such as the pelvic girdle and the sternum. Manubrium, the broad,
upper part of the sternum is a common site for bone marrow biopsy as
it is accessible and rich in hematopoietic marrow [271]. We have identi-
fied it to be also suitable for noninvasive diffuse optical probes since it is
quite superficial with no overlying muscles and is sufficiently thick for ad-
equate probing. Therefore, we have applied diffuse optical spectroscopy
to measure the hemodynamics of the healthy manubrium noninvasively
by combining two diffuse optical methods; time resolved spectroscopy
(TRS) [51, 90, 150, 154] and diffuse correlation spectroscopy (DCS)
[2, 96] in a single probe. This combination enabled us to measure the
concentration of oxygenated and deoxygenated hemoglobin as well as
the blood flow index alongside the tissue reduced scattering coefficient.
In the future, with appropriate modeling, this may enable us to calculate
the rate of metabolic oxygen extraction. By this method, we charac-
terize the optical properties (absorption and scattering coefficients) and
physiological properties (hemoglobin concentration, oxygen saturation
and blood flow index) of healthy bone marrow by noninvasive measure-
ment of thirty two healthy subjects. We also investigate the effect of the
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location of the probed site on the manubrium, body mass index (BMI),
gender, thickness of the overlying tissue and age on the distribution of
the measured parameters. Our hypothesis was that the properties of
health tissue has a relatively narrow distribution which would enable us
to detect the changes due to pathologies. It can be used for screening
purposes in order to detect subjects with a high risk of malignancy and
it is repeatable which would make it a potential tool to monitor the
effect of the therapy. The results of this study is published in Farzam
et al. [157].
5.2 Methods & materials
5.2.1 Study population and the measurement pro-
tocol
All protocols and devices were approved by the ethical committee of
Hospital Clínic de Barcelona where all subjects were measured. Thirty-
two healthy subjects were recruited for this study (15 females and 17
males) and each subject has signed a written informed consent. Since
bone marrow properties depend on age [272, 273], in order to have a more
homogeneous group of people, an age range between 25-40 years old was
defined as the inclusion criteria 1. Adolescents are of great interest to
the study of hematological malignancies due to the high prevalence in
that population. However, due to ethical concerns related to informed
consent of minors, we have excluded them from this preliminary study.
The subjects were requested to fill a basic health questionnaire where
they were asked about their history of anemia, diabetes, lung diseases,
kidney diseases, hypertension, hyperlipidemia, atrial fibrillation, con-
1Nevertheless, two subjects near to range limits (24 and 42 years old) were mea-
sured and were included in the study population.
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gestive heart failure, coronary artery diseases, previous myocardial in-
fraction and smoking. Each subject reported whether they have any
other diseases and their current medications. Subjects with the history
of any type of malignant neoplasms or severe anemia were excluded from
this study. Among all subjects, two of them were under medication for
thyroiditis and one subject for asthma. These medications do not have
any known impact on the bone marrow hemodynamics, therefore, we
have included these subjects in the study. There were also three smok-
ers among the subjects who were included in the data, which may affect
the systemic hemodynamics. In Table C.1, Table C.2, and Table C.3
they are labeled by a star sign. Furthermore, before (in a few cases, af-
ter) the optical measurement, the vital signs (heart rate, arterial blood
pressure and arterial oxygen saturation) were measured to assure that
the subject is in normal health condition and to explore any correla-
tions with the results. The vital records are summarized in Table 5.1
and the physical characteristics in Table 5.2. Body mass index (BMI) is
calculated by dividing the weight [kg] by square of the height [m]. The
thickness of the tissue overlying manubrium skin was estimated by the
caliper skinfold measurement. These two parameters are highlighted
since they may effect the optical measurement.
Table 5.1 Vital records of the recruited subjects: median (1st − 3rd
quartile).
Arterial oxygen Heart rate Systolic pressure∗ Diastolic pressure
saturation (%) (bpm) (mmHg) (mmHg)
All 99 (97, 99) 74 (66, 84) 119 (114, 136) 71 (67, 76)
Females 99 (99, 99) 78 (69, 88) 117 (102, 118) 71 (68, 75)
Males 98 (97, 99) 73 (65, 80) 135 (120, 140) 72 (67, 80)
∗ The difference between males and females is statistically significant (P < 0.05).
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Table 5.2 Physical characteristics of the recruited subjects: median
(1st − 3rd quartile).
Age∗ Weight∗ Height∗ BMI∗ Skinfold/2
(year) (kg) (cm) (kg/m2) (mm)
All 30 74 172 23.3 4.7
(27, 33) (58, 84) (164, 180) (21.6, 26.7) (3.9, 6.2)
Females 29 58 163 21.4 4.4
(27, 30) (53, 62) (160, 169) (20.7, 23.4) (3.6, 4.8)
Males 32 79 180 24.5 5.1
(27, 35) (73, 86) (177, 183) (23.3, 26.8) (4.3, 7.0)
∗ Difference between males and females is statistically significant (P < 0.05).
For the measurements, the subjects were asked to sit comfortably
on a chair with the head tilted back. A hematologist with experience in
bone marrow biopsies located the manubrium and marked the outside
borders to guide the positioning of the optical probe. The height of each
manubrium was divided into four regions from top to bottom (neck to
breast) labeled as one to four. The markings and the probe placement
are illustrated in Figure 5.1. On each location, three measurements were
performed.
5.2.2 Device and probe
The custom-built TRS instrument consists of three pulsed lasers (Becker
& Hickl, Berlin, BHLP-700) emitting at 687, 785 and 830 nm with
pulse widths of 400, 350, and 450 pico-seconds respectively for each
wavelength and a repetition rate of 50 MHz. The pulses are sent to
the tissue using a 10 meter long fiber with a 90◦ bent tip and a core
diameter of 62.5µm (NA = 0.275). The diffuse light was collected
by a custom made bundle that consists of 54 graded index multimode
1Retrieved and adopted on December 30, 2013, from:
“http://commons.wikimedia.org/wiki/File:Manubrium_lateral.png”
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TRS source
DCS source
DCS detectors
TRS detector
X
X
Optical probe
3 cm
1.
5 
cm
Compressed skin
Manubrium
Fig. 5.1 (Left) The photograph of the manubrium of a female subject.
The lines show the outer border of the bone marked by a hematologist.
The height is measured and divided into four regions. The dashed/solid
rectangles indicate the approximate probe positions. (Right) The lo-
cation of sternum in the upper part of the skeleton. The drawing is
adopted from the Wikimedia Commons.1 The probe is pressed to the
manubrium so that the skin on the contact area is compressed. (Top)
The schematic of the probe with one source and one detector for TRS
(source-detector separation = 2.5 cm) and one source and four detectors
for the DCS device (source-detector separation = 2.5 cm).
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fibers and delivered to a hybrid photo multiplier tube (PMT, Becker &
Hickl,Berlin, HPM-100-50). A standard time-correlated single photon
counting (TCSPC) setup (Becker & Hickl, Berlin, Simple-Tau 130) is
used to record and store the distribution of the time of flights of the
diffuse photons [150].
The DCS part of the setup uses a single longitudinal mode laser as
the source (CrystaLaser, Reno, NV, USA) at 785 nm whose coherence
length (> 15 m) is much longer than the distribution of typical photon
path lengths. The laser light is delivered to the tissue through a mul-
timode fiber with a core diameter of 200µm (NA = 0.22). Since DCS
uses single mode fibers of 5.8µm core diameters for collection which
limits the detected photon count rate, we bundle four fibers together
to improve the signal-to-noise ratio. Four photon counting avalanche
photodiodes are used as detectors (Excelitas, Quebec, Canada) whose
output is fed to a digital correlator (Correlator.com, New Jersey, USA)
to obtain the autocorrelation functions. Details of the DCS system is
discussed in various reviews [2, 27].
Time resolved spectroscopy (TRS) and diffuse correlation spectroscopy
(DCS) are combined in a single probe as illustrated in Figure 5.1. For
both, TRS and DCS, we use a source-detector separation of 25 mm.
For each location there were three acquisitions with an averaging time
of three seconds for DCS and three seconds per wavelength for TRS
amounting to approximately 12 seconds per measurement.
5.2.3 Data analysis
The experimental data is fitted with a solution of the diffusion approx-
imation for a semi-infinite homogeneous medium [147] to extract the
values of the reduced scattering (µs′) and absorption (µa) coefficients
for each wavelength. For more details look at chapter 2, section 2.4,
equation 2.9.
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In this process the theoretical curve is convoluted with the instru-
ment response function. The fitting range includes the points with a
number of counts higher than 80% of the peak value on the rising edge of
the curve and 1% on the tail. The fitting was performed by “fminsearch”
function of Matlab (Mathworks Inc, Massachusetts, USA). The relation
between absorption coefficient with concentration of chromophores is
presented in at chapter 2, section 2.5, equation 2.10. In this study oxy,
deoxy and water were assumed as the only absorbers in manubrium.
The water concentration in the bone was assumed to be 30% [274] and
oxy- and deoxy-hemoglobin concentrations were measured (cHbO2 , cHb).
The total hemoglobin (THC) concentration and oxygen saturation
information are calculated from concentration of oxygenated hemoglobin
(cHbO2) and deoxygenated hemoglobin (cHb) (look at section 2.5).
The theory behind DCS technique and the measurement of blood
flow index (BFI) is described at chapter 2, section 2.6. For the DCS
fitting we have used the “fminsearch” function of Matlab. The measured
µa and µs′ by TRS for each subject (averaged over all locations and
acquisitions) was introduced as an input for DCS analysis.
5.2.4 Statistical analysis
As a first step, we have explored the measured parameters to check if
the data has a normal distribution. The normality was tested using
a two sided “Shapiro Wilk” test. We have cross-checked the results
of “Shapiro Wilk” test by quantile-quantile plots. Both tests were in
agreement with each other.
For each measured parameter (µa, µs′, THC, blood flow index, and
oxygen saturation) the median as well as 1st − 3rd quartile values are
reported.
To examine the correlation between different measured parameters
we have fitted a linear mixed effects (LME) model [275, 276] using pack-
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ages “lme4” [277] and “lme4test” [278] in R (open source statistical com-
puting language [279]). This method was utilized since it does not have
a strict normality assumption [275]. In all the analysis, the normality
of the residuals were examined visually and no obvious deviations from
normality were revealed. We rejected results in which the full model did
not differ significantly from the null model.
To test the dependency of the optical parameters on the location of
the probe we have fitted an LME with the location as the fixed effect.
The subject was considered as the random effect in this model. In this
analysis, the first location is considered as the reference.
The correlation between measured physiological parameters (blood
flow, blood volume and oxygen saturation) were also investigated by
LME. Since we have observed a dependency of measured parameters on
the location of probe, here both location and measured parameter were
fixed effects and subject was the random effect.
We have applied LME model to study the effect of BMI, skinfold
value, and age of the subjects on the measured physiological parameters.
In these models the parameter under the investigation (BMI, skinfold,
age) and the location of the measurement were the fixed effects and the
subject was the random effect.
Furthermore, the effect of gender on the measured parameters was
examined. Since we have observed a difference between BMI of males
and females and a significant effect of BMI on the measured parameters,
we have considered gender, BMI and location as the fixed effects. Here
the subject was the random effect.
At the end, in order to investigate the effect of our assumptions on
the results, we have calculated the hemodynamic parameters (THC and
oxygen saturation) assuming different concentrations of chromophores
(bone mineral and lipid). The difference between the distribution of
physiological parameters under different assumptions was investigated
82 Bone marrow characterization
by student’s t-test. Throughout this study, “p-values” less than 0.05
were considered statistically significant to reject the null hypothesis.
5.3 Results
5.3.1 The distribution of the measured optical and
physiological parameters
Figure 5.2 shows the histogram of the distribution of the measured
parameters for all subjects over four locations on the sternum. The
Shapiro-Wilk test shows that the values of measured THC and blood
oxygen saturation are normally distributed while the blood flow index
does not have a normal distribution. For all three wavelengths µa values
are normally distributed and µs′ distributions were not normal.
The summary of all the measured optical and physiological parame-
ters are listed in Table 5.3. Each parameter is presented with its median
and 1st − 3rd quartile range. For completeness, the data from each in-
dividual subject is presented in Appendix C; Table C.1, Table C.2 and
Table C.3.
Table 5.3 Median and inter-quartile range values for the measured phys-
iological parameters.
λ = 690 nm λ = 785 nm λ = 830 nm
µa (cm−1) 0.14 (0.12, 0.17) 0.15 (0.12, 0.17) 0.16 (0.13, 0.18)
µs
′ (cm−1) 10.1 (9.7, 10.9) 9.6 (9.0, 10.2) 8.7 (8.3, 9.5)
BFI (cm2/s) 5.0×10−9 (4.2×10−9, 7.4×10−9)
THC (µM) 77.3 (62.2, 88.6)
Oxygen saturation (%) 71.1 (69.5, 72.3)
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Fig. 5.2 The distribution of the measured hemodynamics over four loca-
tions on the manubrium for all subjects. (A-C) In each wavelength µa
has a normal distribution. (D-F) µs′ does not have a normal distribution
in any wavelength. (G) The blood flow index is not normally distributed.
(H) Total hemoglobin concentration values are normally distributed. (I)
Blood oxygen saturation values are normally distributed.
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5.3.2 The sensitivity of the measurements to the
location of the probe
The distribution of the measured physiological parameters over four
measured locations are illustrated in Figure 5.3. The intercept is the
LME fitted value for the location 1 and the slope shows the change
in comparison to the location 1. In Table 5.4 the fitted value for the
first location (intercept) and the slope (changes between two consecutive
locations) are listed. In all cases, both the intercept and the slope are
statistically significantly different (P < 0.05) from zero indicating a clear
yet small dependence on the location.
Table 5.4 The fitted value for the first location (intercept) and the slope
(changes between two consecutive locations). All cases show statistically
significant changes (P < 0.05).
λ = 690 nm λ = 785 nm λ = 830 nm
µa (cm−1) 0.151 (- 0.005) 0.154 (- 0.003) 0.165 (- 0.004)
µs
′ (cm−1) 11.0 (-0.2) 10.2 (- 0.2) 9.4 (- 0.2)
BFI (cm2/s) 4.8 ×10−9 (+ 0.3 ×10−9)
THC (µM) 80.4 (- 1.8)
Oxygen saturation (%) 69.8 (+ 0.4)
5.3.3 Correlation between the measured parame-
ters
Figure 5.4 demonstrates how measured physiological parameters are cor-
related with each other on a specific location (location 3). From this
point on, the location is considered as a fixed effect in the LME fitting
(see Section 5.2.4) leading to a positive correlation between blood flow
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Fig. 5.3 Measured parameters for 32 subjects over 4 locations on
manubrium. For clarity points are moved slightly along the x-axis
(“dodging”). (Left) total hemoglobin concentration (µM). (Middle)
blood flow index (cm2/sec). (Right) oxygen saturation (%).
and total hemoglobin concentration (P = 0.01) yet the changes are small.
Moreover, the subjects with higher blood flow have a higher blood oxy-
gen saturation (P < 10−4). The correlation between total hemoglobin
concentration and oxygen saturation is not statistically significant (P =
0.1). In all the subsequent plots and analysis, we will focus on one of
the central locations, location 3.
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Fig. 5.4 Correlation between the measured physiological parameters.
The plot represents measured values and the fitted line for the location
3 of the manubrium. (Left) Subjects with higher blood flow have higher
total hemoglobin concentration. (Middle) Total hemoglobin concentra-
tion and oxygen saturation are not correlated. (Right) Subjects with
higher blood flow have higher oxygen saturation.
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5.3.4 The sensitivity of the measurement to the
physical condition of the subjects
For each subject we have performed the skinfold measurement on the
manubrium area to estimate the thickness of overlying tissue. As it is
shown in Figure 5.5 there is a positive correlation between BMI and skin
thickness, as may be expected, since the skinfold measurement includes
the overlying adipose layer (P < 10−4).
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Fig. 5.5 There is a positive correlation between BMI and skinfold value
on the manubrium (P < 10−4).
Figure 5.6 compares the measured physiological parameters (THC,
BFI, and oxygen saturation) with the thickness of overlying tissue (skin-
fold value) in a central location of the manubrium (location 3). None
of the physiological parameters have shown a significant correlation to
the skinfold value.
Figure 5.7 demonstrates that the measured THC and oxygen satu-
ration are dependent on the BMI of the subject. There is a negative
correlation between BMI and THC (P < 10−4) and there is a positive
correlation between BMI and the oxygen saturation (P = 0.003 ). De-
spite the correlations observed for the total hemoglobin concentration
and the oxygen saturation, no correlation was observed between BMI
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Fig. 5.6 There is no significant correlation between the skinfold value
and (Left) total hemoglobin concentration. (Middle) blood flow index.
(Right) oxygen saturation. The plot represents measured values and the
fitted line for the location 3 of the manubrium.
and blood flow index. The plot represents measured values and the
fitted line for the location 3 of the manubrium.
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Fig. 5.7 (Left) BMI has a negative correlation with total hemoglobin
concentration (P < 10−4). (Middle) There is no significant correlation
between BMI and the blood flow index (P = 0.7). (Right) BMI has
a linear correlation with the oxygen saturation (P = 0.003). The plot
represents measured values and the fitted line for the location 3 of the
manubrium.
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5.3.5 The dependency of the physiological param-
eters on gender
To test the dependency of the physiological parameters on the gender,
we have fitted an LME model to the data. If gender is considered as the
only fixed effect then the oxygen saturation in the males is 2% higher
than in the females. Since BMI is an influential parameter, and two gen-
ders have significantly different BMIs (Table 5.2), both BMI and gender
were considered as the fixed effects. In this case there is no significant
difference between genders on any of the measured parameters (P =
0.4). In figure 5.8 the box-plot of measured parameters for each gender
is presented.
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Fig. 5.8 The distribution of the measured physiological parameters by
gender. (Left) total hemoglobin concentration, (Middle) blood flow in-
dex (BFI), (Right) blood oxygen saturation.
5.3.6 The dependency of the physiological param-
eters on age
We have chosen the subjects from a controlled range of age (24-42 years)
to try to avoid the dependency of the measurement on the age of sub-
jects. Figure 5.9 demonstrates that in the collected range of ages the
measure physiological parameters do not depend on the age.
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Fig. 5.9 There is no significant correlation between age and (Left) total
hemoglobin concentration. (Middle) blood flow index. (Right) oxygen
saturation. The plot represents measured values and the fitted line for
the location 3 of the manubrium.
5.4 Discussions
In this work, we have studied the optical and physiological properties
of the healthy manubrium bone as a site indicative of the red bone
marrow hemodynamics in the body. We first discuss the quality of the
measurements and whether the bone marrow is the main contributor to
our optical signal. Then the distribution of the measured parameters on
the healthy subjects is reviewed, the sensitivity of measured parameters
to the location of probe on the manubrium is discussed and the correla-
tion between measured physiological parameters and characteristics of
subjects such as BMI, skinfold value, age and gender is investigated.
The quality of the measurements and the probed tissue vol-
ume: In each measurement, an experienced hematologist located the
manubrium and guided the placement of the probe. We were able to
obtain data with sufficient signal-to-noise ratio from each measurement
and the fitting for both DCS and TRS device had good quality indi-
cating that the data fits the model well and there are no systematic
deviations from the model. The source-detector separations were 25
mm for both modalities.
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Manubrium is a superficial tissue that does not have any overly-
ing muscle. Its average size is 50 × 50 mm2 with thickness of ≈ 11.2
mm in females and ≈ 12.6 mm in males [280]. The manubrium is
not homogeneous in thickness and these numbers were measured on
two points which represent the average of extreme values (thinnest and
thickest part) of the manubrium. The thickness of combined skin and
the manubrium is approximately 15.6 mm and 17.7 mm respectively for
females and males. On average, the depth of optical penetration with
our probe is greater than the thickness of the skin and less than the
combined thickness of the skin and the manubrium. However it has
been reported that manubrium in the thinnest part can be less than 10
mm [281, 282]. To study this point we have simulated a medium (data
not shown) with similar optical properties as manubrium and we have
calculated the probability of detecting a photon which has penetrated a
certain depth. We observe that less than 20% of detected photons had
penetrated more than 1 cm assuming a homogeneous medium. However,
due to the presence of thymus and large vessels below the manubrium
we expect a lower contribution to our signals. Finally, change of µa be-
tween 2 consecutive locations, on average, is ∼3% (Table 4). We know
that manubrium is thickest on the location 1 and narrower in locations
2-3, and again gets thicker in location 4. However, µa drops unidirec-
tional from location 1 to 4. This suggests that in thinner parts we are
not probing different tissue. This small yet significant location depen-
dency is not due to variation in thickness. Therefore, it is a reasonable
assumption to consider manubrium bone and its rich red bone-marrow
content as the the dominant contributor to our signal.
Furthermore, to double check this assumption, for one subject, we
have located the manubrium by an ultrasound and compared its dimen-
sions to the average which was well within the average and to the borders
defined by the hematologist. Two sets of data were taken, one based
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on the hematologist’s assumptions and one guided by the ultrasound.
The measured parameters in both cases did not show any significant
differences (data not shown).
The distribution of the measured parameters: Bone is a rela-
tively understudied organ for diffuse optics. It is often considered a nui-
sance, for example, when dealing with the measurements on the adult
head [47, 51]. However, a few groups have measured in vivo human
bones to investigate absolute values of µa and µs′ [144, 153, 269]. The
first study [153] has investigated the calcaneus bone (µa ≈ 0.07 and
µs
′ ≈ 14 (cm−1) for λ = 785 nm), and the second one [269] has mea-
sured the finger bone (µa ≈ 0.20 − 0.25 and µs′ ≈ 20 − 25 (cm−1) for
λ = 785 nm). The last study [144] has investigated the patella bone and
they have reported µa ≈ 0.035 and µs′ ≈ 5.4 (cm−1) for λ = 785 nm.
The reported µa, µs′ in this study (µa ≈ 0.15 and µs′ ≈ 9.6 (cm−1) for
λ = 785 nm) is in the range of the previous measurements but, we note
that, the reported values from different studies cover a wide range. This
may be due to differences in the tissue and bone structure in different
sites and also the limited number of subjects in all studies.
Absorption coefficient and the physiological parameters derived from
it (total hemoglobin concentration and oxygen saturation) have normal
distributions. The median of THC value is 77.3 (µM) with the quar-
tile range (QR) of 62.2-88.6 (µM). This value is much higher than the
measured THC in patella bone (≈ 18µM) [144]. It can be explained
by the higher red marrow cellularity in manubrium in comparison to
the patella. Since hematopoietic tissue is physiologically more active
compared to compact bone, it has a wider vasculature niche, i.e. is bet-
ter perfused, to provide it with oxygen and nutrition. Higher vascular
level of the manubrium suggests higher THC values and our measure-
ments confirm it. The median oxygen saturation of all subjects is 71.1%
(QR:69.5-72.3%) which is in the range of the oxygen saturation observed
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in the patella.
In contradiction to other parameters, the blood flow index does not
show a normal distribution. This might be partially due to the rela-
tively higher standard deviation of the absolute values from the DCS
measurements or it may reflect the underlying physiology. We note that
an overwhelming majority of the DCS studies, to date, have reported
relative changes in blood flow with respect to a reference tissue or time
point since the DCS results depend on the optical parameters of the
tissue [2, 26, 47, 170]. Our study stands out in this aspect since we use
the TRS values for more accurate analysis of the DCS data. However,
DCS is a highly sensitive measurement of the local blood flow, and, in
soft tissues, this may depend on the probe pressure as was documented
for the scalp by [283]. We discuss this point further in the following
paragraphs.
The knowledge about the range of the measured physiological pa-
rameters and their distribution enables us to define the healthy range
to detect the subjects with high risk of hematological malignancies since
a high proliferating activity of the hemopoietic tissue due to malignancy
is related to angiogenesis [229–231] and can cause high hemoglobin con-
centration or high blood flow in the bone marrow. This will be the topic
of our future studies.
One shortcoming of our study is that we have assumed water, oxy-
, and deoxy-hemoglobin as the only major absorbers due the limited
number of wavelengths that were utilized. In fact, the water concen-
tration was kept constant at 30% [274]. Other significant absorbers in
manubrium could be the lipids and the bone mineral which were not
considered in the above analysis. Errors in these estimates could effect
the derived parameters such as the total hemoglobin concentration and
the blood oxygen saturation.
To further investigate this point, we have calculated the hemoglobin
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concentrations for different assumptions of lipid and bone concentrations
started from 5%, since assuming lower than 5% of lipid and bone does
not practically change any of measured values. It has been shown [272,
284] that bone marrow is made up of ∼ 30− 40% fat in the people with
same age range as the subjects of this study. To study more extreme
cases we have assumed 50% fat for the upper limit of the assumed fat
concentration. Previous, studies on sternum have demonstrated that it
has less than 14% bone mineral in healthy subjects [285]. Here we have
assumed 20% as the upper range for the mineral concentration. The
spectra of the lipid and the bone mineral were obtained from Ref. [286]
and Ref. [153] respectively.
Table 5.5 The effect of assuming different concentrations of lipid and
bone mineral on total hemoglobin concentration and blood oxygen sat-
uration calculations.
THC (µM) Oxygen saturation (%)
Only water 77.3 (62.2, 88.6) 71.1 (69.5, 72.3)
Lipid 5% 77.1 (62.4, 88.5) 71.1 (69.4, 72.3)
Lipid 50% 75.7 (60.7, 87.1) 70.7 (69.0, 72.0)
Bone 5% 76.4 (61.3, 87.7) 71.4 (69.8, 72.6)
Bone 20% 73.6 (58.6, 85.0) 72.2 (70.7, 73.6)
Manubrium is mostly red marrow with a soft and spongy inner
structure which suggests that it has a low concentration of bone min-
eral [271, 285]. However, even assumption of 20% bone mineral does
not introduce a significant difference in the distribution of measured
hemoglobin concentration (P = 0.4) and the averaged change in the
oxygen saturation is less than 1.5%. In a study on an elder group of
people (67–101 years) who are expected to have a higher fat content
(fat content increases by aging), the average percentage of measured fat
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was 50% [284]. It demonstrates that assuming 50% as the upper limit
is a reasonable assumption. Even the extreme assumption of 50% for
fat content does not change significantly the distribution of measured
hemoglobin concentration (P = 0.7) and oxygen saturation (P = 0.5).
Table 5.5 demonstrates that assumptions of extreme values for bone
or mineral concentration changes the measured THC in the range of
73.6-77.3 µM and oxygen saturation between 70.7-72.2%. For all as-
sumed concentrations of lipid and bone, both THC and blood oxygen
saturation are normally distributed.
The dependency of the measured parameters on the probe
location: As it was mentioned the height of manubrium was divided
to four locations and we measured the locations from top to bottom
(location 1-4). The measured parameters have a slight change over the
first to last location of probe (see Table 5.4). Although the change is
statistically significant, it is less than 5% (between two locations).
Since all the measurements were done in the same order, to test the
repeatability of the measurements when the order is changed, we have
repeated the measurements on two subjects. Here, we measured the
manubrium four times per subject; two measurements top to bottom
and two measurements bottom to up. The results indicate that the
measurement order is not an effective parameter (Figure 5.10).
Small dependency of the measured value on the location of probe
suggests that in the next series of measurement on the healthy or ma-
lignant manubrium very precise locating of probe is not necessary. We
can approximately put the probe on the center of manubrium. Since
the measured values do not depend on the order of measurement, we
can relocate the probe couple of times to have an average value of all
positions near to center of manubrium for each subject.
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Fig. 5.10 Four measurements on four locations. Crosses are measure-
ments from top to bottom and circles are representing measurements
from bottom to top. Orange is the first measurement and blue the sec-
ond time. The plot demonstrate the independency of the results on the
order of measurements. (Left) Absorption coefficient. (Middle) Scatter-
ing coefficient. (Right) Blood flow index.
Correlations between the measured parameters: Figure 5.4 demon-
strates the correlation between measured physiological parameters. Oxy-
gen saturation and hemoglobin concentration increases (however the
change is small) when the blood flow increases. These are within ex-
pectations. The lack of or small correlation between parameters reflects
the differences in the baseline metabolism of the subjects. It strengthens
our motivation to use hybrid diffuse optics for this study.
The sensitivity of the measurement on the overlying tissue and
the pressure on it: In this measurement the skin-fat tissue is a
non-desirable volume that is located between the optical probe and the
manubrium. We try to minimize the partial volume effect of this super-
ficial tissue. The partial volume effect problem in this study is similar
to the brain measurements with less complication, because in the brain
measurements there are several non-desirable layers (skin-fat, skull and
cerebrospinal fluid) some of which (skull) are not directly accessible. De-
spite all these layers the penetration of near infrared light in the brain
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is well-validated [47]. [283] demonstrated that the application of pres-
sure to the optical probe (which is transmitted to the tissue in contact
with the probe) would alter the partial volume effect contributions from
the scalp and minimize them at the highest pressures. With the goal of
minimizing the partial volume effect we have have applied high (but still
comfortable) probe pressures. The target tissue in this study is a bone.
While the probe pressure compresses the overlying tissue and alters the
hemodynamics, due to the rigid structure of the manubrium we do not
expect its hemodynamics to be affected by pressure. Furthermore, we
have tested the effect of probe pressure on the manubrium by putting a
load sensor between the manubrium and optical probe (Figure 5.11).
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Fig. 5.11 The effect of probe pressure on the measurement of (Left)
total hemoglobin concentration and (Right) blood flow index. In the
low pressure regime the measured values are sensitive to the pressure
increases until the pressure reaches to a threshold value. After the
threshold, the increase in probe pressure does not change the measured
THC or blood flow index.
In the low pressure condition, an increase in pressure led to a higher
THC (lower BFI) up to a certain pressure threshold. The increased
probe pressure “squeezes out” the superficial blood and, therefore, we
probe a larger portion of the manubrium which has a higher THC than
overlying tissue (skin and fat) and lower blood flow. This, in turn,
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leads to the observed changes. After reaching the threshold, there is a
plateau and pressure change does not affect the measured parameters.
Therefore, in the measurement of subjects we kept the pressure at the
highest possible, comfortable amount. Considering our probe design,
fibers tips protrude out of the probe surface, presumably such a pressure
compresses the overlying tissue on the measured area (Figure 5.1) and
minimizes the skin effect. A future probe may include a calibrated load
sensor to equalize this effect between subjects.
The sensitivity of the measurement to the physical condition of
the subjects: Figure 5.6 demonstrates that the measured physiolog-
ical parameters are not sensitive to the thickness of overlying tissue. On
the other hand, skinfold values are highly correlated with BMI and peo-
ple with higher BMI have lower hemoglobin concentration (Figure 5.7).
This correlation can be explained by following two conjectures. First of
all, it has been shown that bone mineral density (BMD) is decreased
in people with higher BMI [287, 288], this decrease in BMD of bone
marrow may reduce the measured absorption coefficient. As long as we
are not considering bone mineral in our chromophores, this reduction is
reflected in the measured hemoglobin and consequently make the THC
and BMI correlated. Secondly, in a recent study [289] the correlation
between serum lipid levels and bone marrow fat is observed. BMI and
serum lipids also have positive correlation [290]. It can be concluded
that in subjects with higher BMI, the red marrow cellularity would be
lower. As red marrow is metabolically more active than marrow fat and
is expected to have higher blood supply. Therefore, a lower THC is
expected in the subjects with lower red marrow cellularity.
In Figure 5.6, one can observe a positive correlation between BMI
and oxygen saturation. Since tissue with lower cellularity is physiolog-
ically less active, the oxygen consumption will be lower therefore the
oxygen saturation increases.
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However, to validate these hypotheses we need measurements with
more wavelengths to be able to calculate the fat and bone mineral con-
centration for each subject individually. Then, we can investigate the
correlation between BMI and lipid or bone concentration.
The dependency of the parameters on the gender of subjects:
Optical parameters (µa and µs′) as well as THC and BFI do not show
any dependency on the gender of subjects while,as it is shown in figure
5.8, oxygen saturation in females is lower than males (≈ 2%, P = 0.02).
This observation can be explained as the effect of BMI on oxygen sat-
uration. In Figure 5.7, it is shown that subjects with higher BMI have
higher oxygen saturation. On the other hand, males have higher BMI
in comparison to females (Table 5.2). Since BMI can influence the sat-
uration and genders are different in BMI, we should rule out the effect
of BMI. We have performed this by fitting an LME in which has BMI
in addition to the gender and location of the probe as fixed effects. The
results demonstrate that gender does not have a significant difference in
oxygen saturation and BMI is the dominant parameter.
The dependency of parameters on the age of the subjects:
Although hematological malignancies are the most common cancer in
children and adolescents, due to ethical concerns we did not measure on
this group of subjects. The effect of aging on the composition of bone
marrow is well studied [272, 273, 291]. In this study, we have measured a
narrow range of age (24-42) in order to avoid any significant dependency
of measured parameters on age. The correlation plots also shows that
the chosen range of age is tight enough to have no significant correlation
between measured optical parameters and age.
Outlook to the future: This study aimed to characterize the opti-
cal and physiological properties of healthy bone marrow with the goal of
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applying diffuse optics to study hematological malignancies. In the fu-
ture, regarding this goal, we will characterize the same tissue on a group
of patients with a specific type of hematological malignancy. The distri-
bution of measured parameters on the healthy tissue will be compared
with the the distribution on the malignant tissue. It is also interesting
to observe the effect of antiangiogenic therapy on the measured param-
eters.
5.5 Conclusion
Since hematological malignancies affect the red bone marrow, we have
sought to investigate a noninvasive optical technique for the manubrium
as a site, rich of red bone marrow in the adults. For the first time,
we have characterized the optical and hemodynamics properties of the
manubrium in thirty-two healthy subjects using TRS and DCS. This
study is the first step in the path of applying optics for the studies
on bone marrow cancer. The distribution of optical and physiological
parameters in the healthy bone marrow is demonstrated. Measuring the
same parameters in the patients with hematological malignancies will
illustrate the difference between distribution of measured parameters
on the healthy and malignant marrow. It can be applied for screening
purposes to detect subjects with high risk of hematological malignancies.
We can also monitor to changes in optical and physiological parameters
induced by antiangiogenic therapies to predict the effect of treatment
and personalize the therapy.

Chapter 6
Hemodynamics of the human
patella during rest and cuff
inflation
6.1 Introduction
Tissue vascularization and local micro-vascular hemodynamics play a
vital role in the health of the skeletal system. Noninvasive, quanti-
tative and practical measurements of hemoglobin concentration, blood
oxygenation, blood flow and metabolism in the bones could improve our
fundamental understanding of bone function with potential applications
in diagnosis and treatment of bone diseases [120–122]. However, due to
the nature of the bone itself which is hard and covered by other tissues,
it is difficult to investigate its circulation continuously, noninvasively
and over long periods of time [250, 292]. Several groups have investi-
gated the possibility to use near-infrared spectroscopy as a noninvasive
technique to monitor hemodynamics of human bone [121, 122, 153, 255–
257, 260, 261, 263, 264, 266–270]. Mechanical plethysmography is a
technique based on measurement of the volume changes; applying ve-
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nous occlusion to the arm causes arterial blood to enter to the forearm
and accumulate there. It leads to a linear increase in the forearm vol-
ume over time. Based on a model, one can calculate the arterial flow by
measuring the increased volume in a certain time interval [293]. It is a
useful technique to study the bulk blood flow into an extremity.
Most of the studies that are mentioned above using near-infrared
light had utilized a similar technique, photoplethysmography (PPG), to
study the physiology and hemodynamics of bone. PPG is based on a
simple, noninvasive device that can measure blood volume changes in
the vasculature. It consists of light emitting diodes (LEDs) as source,
and photodiodes as detector both working in the red or near infrared
regime [294]. The emitted light interacts with tissue experiencing re-
flection, absorption, many scattering events, and even fluorescence [1].
The main absorbers are the hemoglobin species making the technique
sensitive to the blood volume. The scattering of light, on the other
hand, in tissue occurs at the cell membranes, vessel walls and at the
boundaries of media with different refraction indices [295]. Therefore,
blood volume and vessel wall movements, by changing absorption and
scattering of the underlying tissue, can alter the detected intensity in
the detectors [294, 296]. In fact, the measured PPG signal has both
fluctuating (“AC”) and static (“DC”) components. AC is the pulsatile
component and its frequency depends on the subject’s heart-rate. In
each cardiac cycle, the heart pumps blood into the arteries which causes
increased blood volume and vessel wall movements in arterial and ve-
nous blood vessels. These changes originate the “AC” component of the
PPG signal. The amplitude of the “AC” component depends on the
vascular distensibility [297]. Furthermore, since oxygenated hemoglobin
has a different absorption spectrum than the deoxygenated hemoglobin,
.changes in blood saturation causes unequal alterations in different wave-
lengths. This enables PPG to follow changes in the arterial, pulsatile,
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blood oxygen saturation.
The DC component varies slowly due to slow changes in scatter-
ing and absorption of tissue induced by respiration, metabolism, blood
pressure or any other vasomotor activities [294]. Since specific diseases
change the shape of the PPG signal, PPG can be applied to diagnose
vascular diseases [298]. The potential of PPG as a diagnosis tool was
noticed decades ago where measured blood volume changes by PPG was
validated with simultaneous mechanical plethysmography measurement
[299].
Recently some studies [121, 266, 267] have assumed another possible
source for the pulsatile PPG signal from the bones; the changes in the
orientation of the light scatterers, in this case the red blood cells (RBCs).
They have reached this conclusion by assuming that the blood vessels in
the bones do not have the possibility to change in size as bones are rigid
structures. Therefore, they have suggested that the observed pulsations
in the recorded light intensity from the bone measurements are due to
the changes in the RBC orientations caused by blood flow changes over
each cardiac cycle. Based on these results, they have applied PPG to
measure blood flow changes in rigid structures such as bones [121, 266,
267]. Further experiments have confirmed this hypothesis for different
human bones [254] where it was shown that the RBC count that was
estimated by large source-detector separation laser Doppler flowmetry
(LDF) does not change during heart pulsations while blood speed is
altered. In this work, we investigate this hypothesis using a state-of-the-
art frequency domain near infrared spectrometer (FD-NIRS) [140, 300]
which can separate the absorption (µa) and scattering (µs′) coefficients
on the human patella. Patella is the most superficial part of the knee
and since it does not have any muscle or other tissue (except skin) on
top, the optical signal is dominated by the signals from this bone. In
order to further confirm that the changes are due to arterial pulsations,
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we apply an arterial cuff occlusion to the ipsilateral thigh. We also take
advantage of the multi-wavelength system to quantify the changes in
oxy- and deoxy-hemoglobin,and oxygen saturation during each cardiac
cycle as well as the slower changes due to the cuff-occlusion. We compare
our findings to those from the literature on leg muscles. The ultimate
goal is to explore the possibility of using FD-NIRS to monitor bone
hemodynamics noninvasively. The results of this study is published in
Farzam et al. [144].
6.2 Methods & materials
6.2.1 Device and probe
We have used a customized, commercial frequency domain spectrometer
(Imagent, ISS, USA, www.iss.com). The unit was customized to have
fifteen laser sources at three wavelengths, i.e. groups of five lasers at
∼690, ∼785 and ∼830 nm that are intensity modulated at 110 MHz.
Two photo multipliers (PMTs) are used to collect the light in the reflec-
tion geometry. For a review of the analysis methods for the frequency
domain measurements that we utilize, see [2]. A self-calibrating probe
(Figure 6.1) was utilized to obtain absolute values of the absorption
and scattering coefficients at each wavelength [119]. All sources (S1,
S2 ... S5) are located on the circumference of a circle with a radius of
1 cm. Detector D2 is at the center of the circle so it is at the same
distance from all sources and, in ideal conditions, the intensity and the
phase delay detected by D2 from all sources should be the same. Since
the laser power, fiber transmissions, skin color and other factors are
not the same in different source positions, the detected intensity and
the phase-delay would be different. By considering one of the sources
as the reference and assuming that the tissue is homogeneous, we can
find calibration (“coupling coefficients”) factors for all the other sources.
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Fig. 6.1 The placement of the probe on the knee and the schematic of
the self-calibrating probe with two detectors (D1, D2 ) and five sources
(S1, S2 ... S5). The source-detector separations are from 1 to 3 cm in
steps of 0.5cm.
Then these calibration factors are applied to the measured intensity and
the phase delay by the main detector (D1) which is then utilized in a
multi-distance fit as described below.
As shown in Figure 6.2, in order to synchronize the data acquisition
with the heartbeat, the device was gated by the R-peak of the cardiac
cycle from an electrocardiograph. At each trigger eight measurements,
each an average of 14 acquisitions, were recorded during the cardiac
cycle. This allowed us to average the pulsations from multiple cardiac
cycles (up to 2000) without being dependent on the heart-rate being
constant.
6.2.2 Measurement protocol
The measurements were performed on eight healthy male subjects (age
34.4 ± 9.6 years, body weight 77.6 ± 6.9 kg, and height 1.79 ± 0.07 m).
Subjects were asked to lay supine and the optical probe was centered
over the right patella and attached to the skin with medical tape. The
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knee was bent 20 degree by means of an anatomical support placed
under the popliteal fossa. A pressure cuff was placed around the right
thigh. The subject’s leg was then covered with a black blanket to avoid
external light and to maintain a comfortable temperature. The three
electrodes of the electrocardiograph (CardioLab4, Francesco Marazza,
Hardware & software, Italy) were placed on the subject’s chest.
The subject was asked to rest in this position for a minimum of 15
minutes before the measurements have started. The pulsatile compo-
nent was studied during 30 minutes of additional rest after which the
subject was allowed minimal motion for comfort. This thirty minute
period is further utilized to estimate the average optical properties of
the healthy patella. The second set of measurements were performed
five minutes at rest and then five minutes of arterial occlusion with the
cuff pressure set at 260 mmHg to ensure adequate blockage [301].
30 min 2 min 5 min 5 min
rest rest
(baseline)
cuff
. . .
1 2 8
delay
time1
time2
. . .
R
trigger
1 2 8. . .
R
trigger
Fig. 6.2 Measurement protocol: 1) 30 minutes measurement of rest (no
occlusion), 2) couple of minutes relaxing time for subject to adjust their
leg, 3) 5 minutes measurements of rest as baseline (no occlusion), 4) 5
minutes cuff occlusion. The inset shows the triggering of the instrument
by the “R-peak” and the eight measurements during each cardiac cycle.
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6.2.3 Fitting method
Theory and calculations
We have utilized the frequency domain solutions of the photon diffusion
equation in the semi-infinite geometry to obtain the wavelength (λ) and
time (t) dependent optical properties of the tissue [2]. To calculate
µa(λ, t) and µs′(λ, t) of the probed tissue volume, we fit this theory to
the measured (and calibrated, see below) intensity and phase for each
of the three wavelengths (690, 785, 830 nm) using a multi-distance ap-
proach. For more details look at chapter 2, section 2.4, equation 2.6.
The measured absorption coefficients (µa(λ, t )) are related to the differ-
ent tissue chromophores as described at chapter 2, section 2.5, equation
2.10. Here we have assumed only water, oxy- and deoxy-hemoglobin
the chromophores in the patella. The water concentration in the bone
was assumed to be 15% [153, 274, 302] and oxy- and deoxy-hemoglobin
concentrations were measured over time (cHbO2(t) and cHb(t)). The to-
tal hemoglobin concentration (THC) was assumed to be sum of oxy-
genated and deoxygenated hemoglobin, i.e. THC(t) = cHbO2(t)+ cHb(t)
and blood oxygen saturation (SO2(t) =
cHbO2 (t)
cHbO2 (t)+cHb(t)
× 100) were also
calculated and reported.
Even though the frequency domain method is a well-validated and
utilized method, we have tested our specific approach for self-calibration
and our optimization codes using simulated data. We have simulated a
medium with similar physiological properties to what we have measured
on the knee–cap: THC = 20 µM , SO2 = 65%, and water concentration
= 15% [153, 274, 302]. This results to µa = 0.042, 0.041 and 0.043
(cm−1) respectively for 690, 785, and 830 nm. We also assumed that
the simulated media has similar scattering properties to our values from
knee measurements: µs′ = 7.0, 5.0 and 4.0 (cm−1) respectively for 690,
785, and 830 nm. The assumed probe geometry in this simulation is
the geometry of utilized probe in the measurement of knee which is
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described in Figure 6.1. Noise and random calibration coefficients were
introduced to create a realistic numerical data set.
In order to test the self-calibration probe, a non-zero random number
between zero and one was assigned for each source and each detector
as a multiplicative amplitude calibration factor. Similarly, for phase,
a random, additive calibration factor up to one radian was assumed.
The simulated data for each of the source-detector pairs received these
multiplicative and additive calibration factors.
Then, we have introduced random noise to the calculated in-phase
and quadrature components of the simulated data. In order to estimate
the required noise level for the simulation, we have studied a liquid
phantom measurement with more than 2000 acquisitions. The measured
noise in amplitude and phase are respectively 0.05% and 4.4 × 10−4
radian for an acquisition time of 10 ms/channel. The amplitude noise
is in good agreement with the company specified value. Noise in the
phase is proportional to the square root of acquisition time. In this
study the acquisition time was 3.2 ms/channel. A simple calculation,
gives the expected phase noise to be ≈ 7.7× 10−4. We have introduced
1% noise to in-phase and quadrature components of the simulated data,
which produces a phase noise of ≈ 7.7× 10−3 and an amplitude noise of
≈ 1.7%. Therefore, the simulated noise in both phase and amplitude is
greater than the expected values from the in vivo experiment. Thousand
data sets were generated according to this algorithm, and we have fitted
the theory to each of them separately.
The first step in the analysis was to apply the above-mentioned self-
calibration method for the sources that are equidistant from one of the
detectors. This allowed us to recover the relative values of all the source-
calibration coefficients and introduce them to the measurements from
the other detector.
The photon diffusion model is then fitted with µa and µs′ as the
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unknowns to this calibrated data by minimizing the χ2 using non-linear
least square curve fitting implemented by function “lsqcurvefit” in MAT-
LAB (Mathworks Inc, Natick, Massachusetts, U.S.A.).
Figure 6.3 shows the results of this procedure from one example
data-set. The left side shows the uncalibrated data where the effect
of the calibration coefficients is visible. The middle shows the result
of applying the self-calibration method where mainly the effect of the
noise is visible. Overall, the result of the fitting (right column) is in
good agreement with the simulated tissue properties with a less than
1% error in the calculated optical properties and the hemodynamics
parameters. We have also tested the crosstalk between µa and µs′ es-
timates by applying a small (≈ 0.5%) change to either µa or µs′ while
the other was fixed in the simulated data. The result of fitting was pre-
cise enough to detect changes less than ≈ 0.5% in one of them without
seeing a cross-talk in the other. Finally, we have also applied changes
to both µa and µs′ (both increase, both decrease, one increases and the
other decreases) of ≈ 0.5% and the algorithm was able to separate the
changes in µa and µs′ in all of these conditions.
We note here that, despite this high level of noise (higher than the
instrumental noise), the algorithm was able to resolve absorption and
scattering changes from each other due to the large data-set (1000 sim-
ulations) which is the case for our studies. The real scenario has an
order of magnitude less instrumental noise but more physiological noise
(each cardiac cycle is not identical) and some uncertainties in the source-
detector separations due to the use of a flexible probe.
Finally, in the in vivo data analysis, in the last step, we have removed
outliers that are defined as having either the amplitude or phase more
than four times the standard deviation of all points away from the mean.
We have performed the removing procedure over each wavelength (3
wavelengths), each separation (5 separations) and each point (8 points)
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Fig. 6.3 Simulated phase and intensities (λ = 690 nm) normalized by the
mean value. Left-column: before calibration where each line corresponds
to one simulated measurement. Middle-column: after self-calibration.
Right-Column: demonstration of fitting quality on fitted one curve.
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over all measurements (up to 2000 measurements). In case of detecting
an outlier in any measurement the whole measurement (all separations,
wavelengths and points corresponding to that measurement) has been
removed.
6.2.4 Time-scale equalization
Even though we have gated the data acquisition by each heartbeat,
since the heart-rates (HR) of different subjects are vastly different and
the pulsatile changes in the signal are “squeezed” to fit these varying
in-between cardiac cycles period (Htime [ms]), we needed to take an
additional step of a time-scale equalization in terms of the total fraction
ofHtime for each measurement points. Furthermore, each measurement
point (n = 1, 2, . . . , 8) corresponds to a different cardiac cycle fraction
(Xn).
There is a constant delay (≈ 150 ms) between the ECG trigger and
the start of measurement, which consists of the electronics delay and
warm up time of the detectors. The duration of the measurement for
each point is ≈ 48 ms. We assign each measurement to the middle of this
48 ms (See Figure 6.2). Therefore, each of the eight measurement point
takes place at time (timen) given by timen = ((n− 1/2) ∗ 48+150) and
corresponds to Xn = timenHtime =
((n−1/2)∗48+150)
Htime
. There after, each point
is assigned to an Xn value where the maximal value, X8 = Hfraction,
corresponds to the maximal fraction of the in-between beats period. All
data is reported in this time scale.
6.2.5 Statistical analysis
All the data were analyzed using a linear mixed effects (LME) model
[275] using packages lme4 and languageR in R (open source statistical
computing language, http://www.r-project.org). To assess the validity
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of the mixed effects analyses, we have performed likelihood ratio tests
comparing the models with fixed effects to the null models with only the
random effects. We rejected results in which the model including fixed
effects did not differ significantly from the null model. Throughout this
chapter, we present Markov Chain Monte Carlo (MCMC-estimated) p-
values that are considered significant at the α = 0.05 level. For all fitted
LMEs, the normality and homogeneity was checked by visual inspections
of residuals against fitted values. The results of this study are reported
in two main parts.
Hemodynamics response of the patella bone to cuff occlusion:
In this part the changes in THC (ratio) and oxygen saturation (dif-
ference) during baseline and cuff occlusion are reported. The transi-
tional periods while the cuff was inflated/deflated were removed from
the data. Then data during the baseline (denoted by BL, defined as the
≈ 5 minutes measurements during rest), at the immediate beginning
of the cuff occlusion (denoted by CB, defined as the first 50 cardiac
cycles immediately after the cuff occlusion) and at the end of the cuff
occlusion (denoted by CE, defined as the last 50 cardiac cycles of the
cuff occlusion periods) were calculated for each parameter. To assess
changes in saturation and hemoglobin concentrations, we fit an LME
model to data to compare different conditions (BL, CB, CE). In these
analyzes BL was considered as the reference and changes were reported
in comparison to it. While the condition was the fixed effect, subject
was considered as the random effect. The intercept is the fitted value
for the baseline and the slope shows the change in comparison to the
baseline.
The pulsation of the optical and the physiological properties:
In this part of study, for all subjects, the change over time is assessed. To
fit a model on the measured parameters, first all curves are normalized
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by dividing each time point by the averaged value of the signal during
the pulse – the ratio of change relative to mean is denoted with “r”. In
case of oxygen saturation and phase, the normalization is applied by
subtracting the mean of the data during one pulse from each time point
of the pulse – the change relative to mean is denoted by “∆”. Then, we
have compared the shape of the normalized pulses to well characterized
PPG signals. Each PPG signal has a pulse transit time (PTT), that
varies between subjects, organs and even in different postures [294, 303].
After PTT, pulse rises to a peak (in some cases there is a dual-peak),
and after the peak it falls down again. Since there is a time delay
between start of a cardiac cycle and start of our measurement (≈ the
first 20% of whole cycle is missed), we do not observe PTT in our
pulses. The pulse we measure starts from rising mode, meet one peak
and falls down. After visual inspection of pulses and fitting different
functions to them, we conclude that a sinusoidal function is sufficient to
describe our signals. For each parameter we have defined a sinusoidal
function to be fitted to the data from all subjects. We have applied
a two step fitting. First, a sinusoidal function was fitted to data of
all subjects (for each subject we averaged all pulses). We recorded the
obtained phase (Φ0). In the second step, we have defined a sinusoidal
function with this known phase (A sin(Φ0) + B) to be used by LME.
Since we are not interested in the specific shape of the cardiac cycle
driven pulsations but rather their existence or absence, a sinusoidal
function with two free parameters of amplitude (A) and intercept (B)
is a reasonable approximation. We are most interested in whether the
amplitude, A, is significantly different from zero. While the cardiac
cycle fraction (time from start of a cardiac cycle) was the fixed effect,
subjects were used as a random effect. We have confirmed the absence
of a trend during cuff occlusion by fitting the same sinusoidal function
and obtaining non-significant fits (p > 0.05). For each parameter we
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report the measured change during one cardiac cycle by calculating the
difference between maximum and minimum of fitted curve. Depending
on subject heart-rate the measurement has started in different time of
cardiac cycle.We have measured each subject from 150 ms after start of
a cardiac cycle until 534 ms after start of cardiac cycle (Figure 6.2). We
know that different subjects have different heart-rates. For example if a
subject has 80 beat
min
, then for him each cardiac cycle will take, on average,
750 ms. This implies that the moment we have started our measurement,
it has been 150750 → 20% of a cardiac cycle. We will continue until 534
ms after the start of cardiac cycle which means 534600 →∼ 70% of cardiac
cycle. Therefore, for this subject our measurement covers 20 − 70% of
his cardiac cycle. In different subjects, based on their heart-rate the
measured range of their cardiac cycle is different. The conversion of
each point to the corresponding cardiac cycle percentage is explained
in section 2.4. Different cardiac cycle fractions in the start point of
different subjects makes it non-trivial to define the beginning of the
fitted line. We averaged the start points of all subjects and the fitting
has started from the average value.
6.3 Results
An example fitting quality: Figure 6.4 shows an example of the
fitted theory to the measured data from a representative subject at
λ = 690 nm. The residuals are also shown indicating that the calibrated
data fits the model reasonably well without any systematic deviations
from the model. These fits were applied to all data points individually
for each pulsation resolved data.
The characterization of the optical and physiological proper-
ties of the patella (knee-cap bone): The absolute values of mea-
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Fig. 6.4 An example of the fitted theory to the measured data from a
representative subject at λ = 690 nm. (Top) The normalized phase
and amplitude and the fitted curves. (Bottom) The residuals of the fits
indicating that the fits are accurate without a systematic error.
sured absorption and scattering coefficients for three wavelengths (690,
785, and 830 nm) are reported in Table 6.1. The values are averaged
over eight subjects and the reported error is the standard deviation. As
mentioned in the measurement protocol, all eight subjects were mea-
sured for ≈ 30 minutes of rest, the reported values are the averages
of this time range (≈ 30 minutes). In Table 6.1 the calculated values
for total hemoglobin concentration and tissue oxygen saturation is re-
ported. The measured µa, µ′s, THC, and SO2 for each subject are listed
in the Appendix D (Table D.1, Table D.2 and Table D.3). We have
also reported the µa and µ′s values after ≈ 4 minutes of cuff occlusion
in Table D.4 and Table D.5 in the Appendix D.
The hemodynamics response of the patella to thigh cuff occlu-
sion: Figure 6.5 shows the typical response to cuff occlusion. Oxygen
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Table 6.1 The measured values of µa and µs′ (three wavelengths), total
hemoglobin concentration (THC) and oxygen saturation (SO2) averaged
over 8 subjects.
λ = 690 nm λ = 785 nm λ = 830 nm
µa (cm−1) 0.038 ± 0.009 0.035 ± 0.009 0.044 ± 0.009
µs
′ (cm−1) 7.4 ± 0.8 5.4 ± 0.8 4.4 ± 0.8
THC (µM) 18 ± 4
SO2 (%) 65 ± 9
saturation slightly increases after the inflation starts – presumably due
to slow inflation of the cuff where the venous output is first occluded
allowing inflow of arterial blood for a brief time period – and after full
occlusion it drops gradually. We characterize the response according
to the three periods (BL, CB and CE) as described above. When
comparing the BL period, and CB, i.e. the first 50 cardiac cycles,
oxygen saturation shows 3.4% increase (p < 0.0001) with a confidence
interval (CI) of 2.8-4.0%. Although in the beginning of cuff, saturation
increases, comparing BL and CE shows 8.2% (CI:7.6-8.8%) decrease
in oxygen saturation at the end of the occlusion. In comparison be-
tween CB and CE, there is 11.6% (CI:12.4-10.8%) decrease in oxygen
saturation during cuff occlusion.
As Figure 6.5 demonstrates that, in general, the application of the
cuff causes a considerable increase. Comparing BL to CB, THC in-
creases 13.5 µM (CI = 12.9−14.1, p < 0.0001). The comparison of BL
to CE period, THC increase is 16.1 µM (CI = 15.4−16.7, p < 0.0001).
THC change from CB to CE is 2.5 µM (CI = 1.7 − 3.3, p < 0.0001)
which shows a slow increase during cuff inflation. The µa and µ′s values
after ≈ 4 minutes of cuff occlusion is reported in Table D.4 and Table
D.5 in the Appendix.
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Fig. 6.5 Representative data showing the hemodynamic changes of the
patella during cuff-occlusion. Vertical dashed lines from left:1st− start
of inflation, 2nd− end of inflation. From pulse zero to the first vertical
dashed line corresponds to 5 minutes, and from the first vertical dashed
line to last pulse, corresponds to 5 minutes of occlusion.
The pulsatile behavior of the optical and physiological param-
eters during rest and arterial-occlusion: Figure 6.6 illustrates
the average raw data from a representative subject . We have observed
a clear pulsation of the AC amplitude (p < 0.001) but no significant
changes in phase during rest (Left-column, p = 0.337). We have at-
tributed the origin of the pulsations of the data to the cardiac cycle
using the leg cuff occlusion data (right column), where, as expected,
the pulsations disappeared (p = 0.273 & p = 0.123 respectively for AC
amplitude and phase during cuff).
Figure 6.7 shows the pulsation of µa(t) and µs′(t) (λ = 690 nm)
during a cardiac cycle period. Dashed lines represent the behavior of
each subject where for each subject all pulses were averaged. Solid line
is the LME fit with the sinusoidal equation to the data of all subjects
and pulses. In these figures all pulses are normalized by the mean value.
Considering p-values of each fit, there are significant pulsations in both
µa and µs′ during rest, and applying the cuff removes the pulsations –
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Fig. 6.6 An example of measured amplitude and phase between two
consecutive pulses for λ = 830 nm and source–detector = 2cm. In this
figure, the data for each pulse is normalized by the mean value, and the
average of all normalized pulses is plotted. Top-left: pulsation of the AC
amplitude during rest (AC amplitude decreases up to 10%), Top-right:
by applying the cuff occlusion the pulsation of the AC amplitude dis-
appears. that confirms the physiological origin of pulsations as arterial
pulsations. Bottom-row: There is no pulsation in the phase during rest
(left) or during occlusion (right).
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there are just noisy fluctuations. Table 6.2 summarizes the changes ob-
served in the optical properties for all three wavelengths. The reported
change is the subtraction of the maximum and minimum (the minimum
occurs in the first point) of the fitted sinusoidal curve. Although there
are significant pulsatile behavior visible for µs′ during rest, its amplitude
is up to a factor of ten smaller than µa. Since subjects have different be-
ginning of measurement (depending on their heart-rate, look at section
2.4.), defining the start of fitted curve is not trivial. Here, we have av-
eraged beginning time of all subjects and considered the averaged value
as the beginning of the fitted curve.
Table 6.2 Maximum change in fitted sinusoidal during the averaged mea-
sured cardiac cycle for all subjects for both µa and µs′ in three wave-
length (rest). There is no significant change in µa and µs′ during cuff
inflation (NA = Not Applicable).
Rest Cuff
λ (nm) 690 785 830 690 785 830
rµa 1.6% 2.5% 3.5% NA NA NA
P < 0.0001∗ P < 0.0001∗ P < 0.0001∗ P = 0.15 P = 0.57 P = 0.07
rµs
′ 0.3% 0.5% 0.3% NA NA NA
P < 0.0001∗ P < 0.0001∗ P < 0.0001∗ P = 0.62 P = 0.52 P = 0.99
rTHC 3.1% (P < 0.0001∗) NA (P = 0.06)
∆SO2 0.7% (P < 0.0001∗) NA (P = 0.52)∗ Significant pulsation.
Figure 6.8 shows the pulsations in the oxygen saturation and THC.
In the rest period, THC increases by 3.1%, and oxygen saturation in-
creases by 0.7% , while during occlusion the pulsation disappears and
only noisy fluctuations are observed. The disappearance of the pulsa-
tion by applying cuff occlusion suggests that the origin of the observed
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Fig. 6.7 The pulsation of rµs′ and rµa at λ = 690 nm during measured
fraction of a cardiac cycle at rest and noisy fluctuations of these param-
eters during cuff occlusion. Dashed lines are the average of all pulses for
each subject and the solid line is the LME fit to all subjects and pulses.
Top-left: pulsation of rµa during rest. Bottom-left: The pulsation of
rµs
′ during cardiac cycle. Although it is much smaller than rµa, it is
statistically significant. Top-right: There is no pulsation in rµa during
cuff occlusion. Bottom-right: There is no pulsation in rµs′ during cuff
inflation (n = number of subjects).
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pulsations is the cardiac cycle.
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Fig. 6.8 The pulsation of rTHC and ∆SO2 during rest and the noisy
fluctuation of these parameters in occlusion time. Dashed lines are the
average of all pulses for each subject and solid line is the LME sinusoidal
fit to all subjects and pulses. Left: pulsation of rTHC and ∆SO2 during
rest. Right: The disappearance of the pulsation by applying cuff occlu-
sion suggests that the origin of the measured pulsations is the cardiac
cycle. n = number of subjects.
6.4 Discussion
In this work, we study the optical and physiological properties of the
healthy patella bone, their pulsatile behavior in response to the cardiac
cycle and their response to full arterial cuff occlusion. We now compare
our study to previous reports. A few groups have measured in vivo
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human bone tissue to investigate absolute values of µa and µ′s [153, 269].
The first study has investigated the calcaneus (µa ≈ 0.07 and µ′s ≈ 14
(1/cm) for λ = 785 nm), and the second one has measured the finger
bone (µa ≈ 0.20− 0.25 and µ′s ≈ 20− 25 (1/cm) for λ = 785 nm). The
reported µa , µ′s in these studies are higher than what we have observed
(µa ≈ 0.035 and µ′s ≈ 5.4 (1/cm) for λ = 785 nm). This may be due
to differences in the tissue and bone structure in different sites. The
subject numbers are quite limited in all studies (including ours) and the
methods are different. We stress that our findings are in the general
ranges observed in healthy tissues and bones.
One of the main challenges in this study is to prove that the signals
are indeed originating mainly from the bone and not the skin or other
superficial tissues below the probe. This hypothesis has been studied
by Naslund et al. [266] on the patella bone and it has been shown
that if the source-detector separation is large enough (in their study it
is 2.5 cm) and the wavelength belongs to near infrared regime (in this
regime photons will experience many scattering events and the penetra-
tion depth is higher), the signal is not sensitive to the superficial tissue
– the harmonic DC change due to autoregulatory activity disappears
[266].
In our case, the source-detector separations varied between 10 −
30 mm and an average patella is 45×34 mm2 with ≈ 22.5 mm thickness
[304]. Therefore, it is a reasonable assumption to consider patella bone
as the dominant contributor to our signals. Roughly, the depth of optical
penetration with our probe is greater than the thickness of the skin and
less than the combined thickness of the skin and the patella, i.e. we are
probing a tissue volume which does not extend below the patella. In the
analysis we use all source–detector separations to fit the theory to the
measured amplitude and phase (look at Figure 6.4). Therefore we can
not compare the results of small and large separations, and only raw data
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comparison is possible. The qualitative analysis of the raw amplitude
data from the shortest and longest source–detector separations did not
reveal any difference beyond those expected by the physics of the photon
diffusion model. Detailed analysis of this is beyond the scope of this
study.
We have reported our findings in two main parts, the pulsatile be-
havior of the patella and its response to the cuff occlusion. We now
discuss the result of each part separately.
Pulsatile behavior of the optical and physiological parameters:
Our focus was to investigate whether there were any changes in the
absorption and the reduced scattering coefficients at all wavelengths
that were suggestive of being related to the cardiac cycle. We have
also investigated the resulting changes (or lack of it) in blood oxygen
saturation and hemoglobin concentration.
In normal conditions, i.e. during non-occluded resting periods, a pul-
satile behavior was detected in the AC amplitude. The pulsatile behav-
ior of measured AC amplitude disappeared by applying cuff occlusion.
When the cuff pressure is much higher than the arterial pressure, the
arterial blood does not enter the tissue below the occluded part; then we
can hypothesize that there should not be any pulsations in the signals
that are related to the cardiac cycle. We have applied a cuff pressure of
260 mmHg. Since the pressure that tourniquet applies to the tissue is
higher than systolic pressure, it will block the blood flow and is equiv-
alent to full occlusion [301]. In our measurements, the pulsation of the
AC amplitude disappeared during occlusion and the cardiac-cycle origin
of the observed pulsatile behavior has been confirmed. The phase did
not show any pulsation during rest or cuff.
The photon diffusion model tells us that the phase-delay has a direct
relation with µs′ increase and a reverse relation with µa increase. From
the flat detected phase we can assume that both µa and µs′ have changed
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in the same direction, and the phase increase caused by one of them has
compensated the effect of the other. Since the AC amplitude decreases
during cardiac cycle, we can predict µa increases and therefore, µs′ also
increases. This was confirmed by the fitted results shown in Figure 6.7.
As expected both µa and µs′ have pulsatile behavior during each cardiac
cycle, but the changes in µa is up to one order of magnitude bigger than
µs
′. These changes also disappear during cuff.
Table 6.2 demonstrates that different wavelengths have different am-
plitude in the pulsation and the changes are wavelength-dependent. It
implies a physiological origin for the pulsation. we translate the change
in µa in different wavelengths to physiological parameters (hemoglobin
concentration and oxygen saturation). In Figure 6.8, we observe that
both hemoglobin concentration and oxygen saturation show pulsatile be-
havior during a cardiac cycle. As expected these pulsations disappeared
by applying the cuff occlusion. The pulsation of the THC suggests that
although the patella is a rigid bone, the vasculature in this bone can
dilate and the THC can increase.
This result is in contradiction with the assumption of previous works
[121, 266, 267] where they have assumed that the THC in the bone is
constant and the pulsation in the bone is an indicator of the changes in
blood flow. This hypothesis was further evaluated, by applying laser-
Doppler flowmetry (LDF) to measure changes in RBC count and veloc-
ity in rigid bones during a cardiac cycle [254]. It has been shown that
the RBC concentration is constant and this study has not detected any
physiological origin for pulsations but blood velocity.
In another study it has been shown that the physiological parameters
(hemoglobin concentration and oxygen saturation) can change in the
rigid bone [258], the constant RBC count in latter work [254] has been
explained by differentiating fast and slow changes. In slow changes, like
response to cuff inflation, that we have observed in this study or in
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response to changes in the bed angle, reported by Binzoni et al. [258],
the interstitial fluid had some extra time to diffuse away from the bone.
In this way, this volume can be replaced by the blood (dilating vessels)
and an increase in THC occurs. Due to time constraints, we did not
record the recovery from the deflation of the cuff in all subjects. It was,
however, recorded in two subjects out of the eight which has revealed a
rapid recovery to the baseline upon deflation.
In fast events such as changes during a single cardiac cycle, the
pulsation may be too fast for the interstitial fluid to diffuse, and thus
the number of RBC count remains constant. However, the absence
of an observed physiological change in the number of RBCs during a
cardiac cycle in the large-source detector separation (interoptode) LDF
measurement [254], can be also caused by the non-sensitivity of LDF
to small changes. It is due to the fact that LDF at large interoptode
spacing is more sensitive to velocity changes than to the changes in the
RBC number. Small changes in µa and µs′ (in our case of 2.5% and 0.5%,
respectively) implies an estimated [261, 305] increase in the probability
to detect a moving RBC (this parameter is linked to the RBC count)
of 2.2× 10−4. This increase is probably too small to be detected by the
LDF method.
Further studies utilizing other optical techniques, for example using
diffuse correlation spectroscopy (DCS) [2, 33, 119], that measures the
blood flow in the same type of vasculature could help us to understand
the details of this physiology. In fact, PPG-like measurements with DCS
were utilized in forearm and wrist muscle [31] in the past to show phase
differences between blood flow and blood volume.
We note that in this study the pulsatile behavior of THC is demon-
strated but due to the fact that we have measured just a fraction of
the cardiac cycle (between 20% and 50%), we cannot observe the whole
cycle of physiological change in a complete cardiac cycle. In principle,
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the instrument could be adapted to measure the whole cardiac cycle by
utilizing a more complex triggering algorithm or by taking data contin-
uously at a higher rate and carrying out a Fourier analysis to filter out
the pulsatile component.
The patella bone during the rest and cuff-occlusion: We have
characterized the optical and physiological properties of patella in the
baseline. The absolute values of the measured absorption and scattering
coefficients for three wavelengths (690, 785, and 830 nm) are calculated
by averaging over eight subjects. We translate the difference between
different wavelengths to physiological properties (hemoglobin concen-
tration and oxygen saturation). The measured oxygen saturation in
baseline is 65% which is in the range of healthy human tissue and bones
[119, 153, 306]. The measured THC is less than skeletal muscle, ≈ 40µM
[119], and calcaneus bone, ≈ 25µM [153] which may still be in the range
of the physiological variations between subjects since both of the earlier
studies used a relatively small number of subjects.
We have also studied the physiological changes in response to arterial
cuff occlusion and during occlusion. In this bone measurement THC
increases during the occlusion. This is in accordance with the increase
in Hb and HbO2 previously observed in human tibia during arterial
occlusion [259]. It can be explained as following; since the femoral
artery is coming from thigh muscle to the knee, cuff pressure squeezes
the underlying muscle and the blood in the femoral artery is pushed to
the non-squeezed bones.
Oxygen saturation slightly increases after starting the cuff inflation,
and by completing the inflation, it drops gradually. Because of rela-
tively slow inflation, there was a time delay between the venous and
arterial occlusion, which causes initial increase of oxygen saturation.
This initial increase also caused by squeezed blood of femoral artery
entering the knee. After completing the cuff inflation the amount of
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oxygen in the tissue is constant and since bone is a live tissue, it con-
sumes part of oxygen in the blood. Therefore we observe a gradual
decrease of oxygen saturation. Our result of measurement on occluded
bone is in agreement with previous works [259, 262]. Oxygen saturation
decreases slowly during cuff inflation. In 5 minutes of occlusion, the
oxygen saturation has decreased 11.3%, while in leg muscle in 3 min-
utes it has decreased 17.1% [119]. Therefore, the data suggests that the
consumption of oxygen in bone is slower than muscle which implies a
lower metabolism in bone compared to the skeletal muscle. PPG studies
also demonstrate the difference between bone signal and other tissue,
e.g. in occlusion measurement, there is a significant difference between
bone and skin reaction to cuff deflation. While the AC component of
the skin returns to baseline value, the bone shows an increase in AC
component compared to the baseline [266].
An obvious shortcoming of this study is the limited number of sub-
jects which makes the statistical statements unsubstantial. However,
since the method is non-invasive and relatively straightforward to ap-
ply, this could be remedied in future studies.
6.5 Conclusion
We have demonstrated that FD-NIRS is a promising technique to study
the pulsations and the physiological properties of bones and normal tis-
sue. In the future, therefore, it may be applied to study vascular and
skeletal diseases. The optical and the physiological properties of the
patella were characterized, and it has been shown that the absorption
and scattering coefficients in the bone are not constant during a cardiac
cycle. They have “pulsatile changes”. The wavelength dependency of the
µa amplitude was translated to changes in the oxygenated and deoxy-
genated hemoglobin which leads to pulsation in the total hemoglobin
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concentration and the oxygen saturation. We have also studied the
patella bone response to cuff occlusion and a lower metabolism of the
bone compared to the skeletal muscle was observed.
Chapter 7
Multi-distance DCS to
simultaneously estimate the
absolute optical properties
and the blood flow index
7.1 Introduction
Diffuse correlation spectroscopy (DCS) or diffuse wave spectroscopy
(DWS) [2, 24–30, 47, 49, 53, 54, 307], is a relatively new technique
to measure blood flow in the microvasculature. It is noninvasive with
high-temporal resolution (up to 100 Hz) [308] and relatively large pen-
etration depth (up to several centimeters) [32, 56, 95, 96].
One of the main limitations of DCS is the influence of the assumed
optical properties of the medium on the calculated blood flow index
(BFI∼ αDb). Although a non-accurate absorption coefficient (µa) causes
an error in the calculated BFI, failing to estimate the scattering coef-
ficient accurately (µs′) will lead to dramatic errors in calculating the
blood flow [75, 170]. Since µa and µs′ changes in time and location
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and error in these parameters introduce error in BFI, DCS is normally
applied in tandem with a near infrared spectroscopy (NIRS) techniques
(hybrid devices).
In a general classification we can consider two categories in DCS ap-
plication: small optode distances (eg. small animal’s brain or tumors)
or large optode distances (eg. human brain, breast, muscle etc.).
DCSmeasurements with small optode distances: In small (smaller
than 20 mm) source detector separations DCS is usually combined multi-
distance frequency domain NIRS [35, 71, 77, 141]. Due to proximity of
source and detector, the phase shift is small and sometimes it is difficult
to detect and in several cases broadband NIRS [37, 43, 134] is used.
Measurement of absolute µa and µs′ in broadband spectroscopy re-
quires relatively complicated analysis and usually the results have con-
sider error. In small optode distances some studies have combined DCS
and a continuous wave (CW) NIRS to monitor changes in optical prop-
erties [38, 44, 74].
DCS measurements with large optode distances: The large
optode DCS (> 20 mm) is of interest in many categories such as cancer
studies (e.g, in breast) and mostly in human neurological [309–315].
In a few studies [75, 114, 155–157] DCS has been applied in con-
junction with time resolved spectroscopy (TRS). The absolute values of
static optical properties of the medium (µa and µs′) are measured with
TRS and they are used as inputs in DCS analysis. There are also hybrid
devices consist of DCS and multi source-detector separation frequency
domain NIRS [35, 41, 45, 71, 77, 83–85, 116, 117, 119, 132, 142, 143, 314].
Several DCS experiments were carried out with hybrid DCS and diffuse
optical spectroscopy (DOS) devices but in general it is difficult with
these systems to measure the absolute absorption and scattering coeffi-
cients.
Previously, it has been proposed that fitting µs′ or µa simultaneously
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with BFI was impractical from a single autocorrelation function [316].
Here we present an algorithm that relies on the assumption that the
estimated Db should be independent of the source-detector separation
in homogeneous or nearly homogeneous media. It enables us to estimate
the absolute value of µa, µs′ and BFI simultaneously, hence minimizing
the errors in the BFI estimation.
This approach was motivated by in vivo measurements on mouse
tumors where we combine broadband CW-NIRS with DCS in a single
probe [134]. The errors in the accurate estimation of µs′ with broadband
DOS was leading to BFI estimates that showed a systematic dependence
on the source-detector separation 7.1. First, the dependency of blood
flow on the optode distances was observed. To verify whether the sep-
aration dependency has a physiologic cause or analysis error, we have
examined different assumptions of µs′. The slope of measured blood flow
versus separation depended on the assumed µs′. This proves that the
an analysis artifact is causing the separation dependency of measured
BFI.
This observation was then repeated in homogeneous phantoms and
in numerical simulations. Figure 7.2 shows how non-accurate µs′ will
lead an error in measured BFI. Similarly figure 7.3 demonstrates the
effect of error in µa assumption in BFI estimation. The error gets more
pronounced in further separations from the source. Only true assump-
tion of optical properties (µa and µs′) will lead to accurate measurement
of BFI which does not depend on separation from the source. In this
work we will take advantage from the multi-distance DCS (MD-DCS) to
fit for static (µa and µs′) as well as dynamic (BFI) properties of tissue
simultaneously. The fitted µa and µs′ are the unique values that makes
BFI independent from source-detector separation. This multi-distance
DCS fitting (MD-DCS) will improve the measurement of BFI.
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Fig. 7.1 The blood flow measurement on a mouse tumor. The measure-
ment was performed on the mouse muscle for one hour. The plotted
values are average and standard deviation over all acquisitions in time.
[Left] Underestimation in µs′ causes the recovered blood flow index in-
creases with distance from the source. (positive slope). [Right] Over-
estimation in µs′ causes the recovered blood flow index decreases with
distance from the source. (negative slope).
7.2 Theory
Effective attenuation coefficient by DCS CW measurement
To determine the absorption and scattering coefficient of a media one
need to modulate the source intensity (frequency domain) or use a short
pulse (time domain) to study the changes in phase or pulse to calculate
µs
′ and µa. In DCS measurement the light source is CW laser usu-
ally in one wavelength (785 nm) and in few cases with 2-3 wavelengths.
Although we can not separate scattering and absorption coefficient of
medium with such a setup, by calibrating the sources and detectors
one can obtain the effective attenuation coefficient (µeff ) for each wave-
length (equation 7.1).
µeff =
√
3µaµs′ (7.1)
µeff can be obtained by fitting to Green’s function solution of dif-
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Fig. 7.2 The effect of µs′ error on BFI calculation (numerical simula-
tions). The simulated BFI = 1 × 10−8 ( cm2
sec
) and µs′ = 10 (cm−1),
µa = 0.1 (cm−1). Left: Error in µs′ causes a separation dependent
error in BFI. Right-up: An underestimation in µs′ leads to BFI overes-
timation. The error in BFI is getting larger in further separations from
the source. Right-center: Only correct µs′ assumption leads to obtain
accurate BFI which is independent of distance from the source. Right-
bottom: Overestimation in µs′ results in underestimation of BFI. The
error in calculated BFI gets more pronounced in larger separations from
the source.
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Fig. 7.3 The effect of µa error on BFI calculation (numerical simula-
tions). The simulated BFI = 1 × 10−8 ( cm2
sec
) and µs′ = 10 (cm−1),
µa = 0.1 (cm−1). Right: Error in µa causes a separation dependent
error in BFI. Right-up: An overestimation in µa leads to BFI overesti-
mation. The error in BFI is getting larger in further separations from
the source. Right-center: Only correct µa assumption leads to obtain
accurate BFI which is independent of distance from the source. Right-
bottom: Underestimation in µa results in underestimation of BFI. The
error in calculated BFI gets more pronounced in larger separations from
the source.
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fusion (equation 2.6) , or directly by simplified equation: ln(I(ρ)ρ2) =
−µeffρ+ln(I0) (equation 2.7, for more details look at section 2.4) where
µeff is the slope of ln(ρ2I(ρ)) versus ρ [2].
The field autocorrelation Green’s function for semi-infinite bound-
ary conditions DCS measures the temporal speckle fluctuations of
the scattered light, that is sensitive to the motions of scatterers such as
red blood cells which in turn could be used to estimate microvascular
blood flow [24, 25, 29, 166–168]. The motional dynamics of the medium
can be determined by measurement of intensity autocorrelation from
which the electric field autocorrelation function (G1) can be derived.
The Green’s function solution of the correlation diffusion equation for
semi-infinite boundary conditions G1(ρ, τ) can be found in section 7.2.
For DCS analysis we converted measured normalized autocorrela-
tion (AC) g2 to normalized field autocorrelation using Siegert relation
(equation 7.2).
g1(τ) =
√
g2(τ)− 1
β
(7.2)
β is a constant determined primarily by the collection optics of the
experiment. In our experiments we use single mode fibers to collect the
scattered light. This setup makes β ≈ 0.5. In order to obtain BFI, in
a conventional DCS measurement, µa and µs′ should be known through
an NIRS measurement (hybrid devices), or typical values of measured
tissue. Any error in assumed µa and µs′ would be compensated by
underestimation or overestimation of blood flow index.
Figure 7.4 demonstrates the non-uniqueness of autocorrelation curves.
It shows media with different optical properties and BFI whose auto-
correlation curves are similar. It suggest that error in assumption of µa
and µs′ introduces error in fitted BFI [170].
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Fig. 7.4 Possibility of similar AC curves in different media. Left: The
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Different behavior of small and large source-detector separa-
tions Figure 7.5 shows how the separation-dependency of flow error
has different behavior in small and large separations. The BFI in simu-
lated medium is 1×10−8( cm2
sec
) with µs′ = 10 (cm−1) and µa = 0.1 (cm−1).
We have fitted for BFI with wrong µs′ assumption. As expected due
to error in µs′ assumption the fitted value of BFI has an error and the
error depends on the separation from the source. In Figure 7.5 the error
has direct relation to optode distances up to a certain distance and after
that separation the error gets smaller by increasing the optode distance.
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Fig. 7.5 The separation-dependency of flow error has different behav-
ior in small and large separations. The BFI in simulated medium is
1 × 10−8( cm2
sec
) with µs′ = 10 (cm−1) and µa = 0.1 (cm−1). Left: The
assumed µs′ is overestimated (µs′ = 20 cm−1). The fitted BFI is lower
than simulated value. The error in the fitted flow has direct relation
to optode distances up to a certain distance and after that separation
the error gets smaller by increasing the optode distance. Right: The
assumed µs′ is underestimated (µs′ = 5 cm−1). The fitted BFI is higher
than simulated value. The error in the fitted flow has direct relation to
optode distances up to a certain distance and after that separation the
error gets smaller by increasing the optode distance.
In figure 7.5 it is shown that in small source-detector separation the
separation dependency of BFI error due to wrong assumption of µa or
µs
′ is more pronounced. Since MD-DCS fitting is based on separation
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dependency of BFI, it suggests that MD-DCS to have more challenge in
larges source-detector separations.
7.3 Materials and methods
The multi-distance DCS fitting (MD-DCS) As it has been dis-
cussed in section 7.2, gathering all information from different separations
enables us to decouple the contribution of static (µa and µs′) and dy-
namic (BFI) properties of the medium. For this purpose, we fit for all
desired variables (µa, µs′, BFI) in a single fitting algorithm. Assuming
typical values for initial guess of µa,µs′ and BFI the theoretical g1 is
fitted to measured/simulated g1 over all source-detector separations. In
this fitting the function to be minimized (χ2) is defined as:
χ2 =
Nρ∑
i=1
Nτ∑
j=1
(gtheory1 (ρi, τj, Db, µs′, µa)− gmeasured1 (ρi, τj, Db, µs′, µa))
2
,
(7.3)
where ρi is the ith source-detector separation and Nρ is the number
of source-detector separations. τj is the the jth delay time and Nτ
is the number of delay times. The iterative minimization process has
been performed in Matlab by resorting to “fminsearch” function that
uses Nelder-Mead method at its core, which is a derivative-free simplex
method.
As described in section 7.2, multi-distance DCS measurements pro-
vide us with information on µeff of the medium. We can readily use this
information in our fitting to make it more robust and efficient. Knowing
µeff , we can evaluate the µa as
µa =
µeff
2
3µs′
, (7.4)
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and simplify equation 7.3 to:
χ2 =
Nρ∑
i=1
Nτ∑
j=1
(gtheory1 (ρi, τj, Db, µs′)− gmeasured1 (ρi, τj, Db, µs′))
2
. (7.5)
Numerical data generation In this study we have simulated 125
media with different 5 different µa (from 0.04 to 0.16 with steps of 0.03
cm−1), 5 µs′ (from 4 to 16 with steps of 3 cm−1) and 5 Db (from 4×10−9
to 16× 10−9 with steps of 3× 10−9 cm2
sec
). In order to increase signal to
noise ratio in DCS measurements, it is common to put multiple fibers
for each separation to increase the signal to noise level ratio [157, 313].
In this study we have assumed there are 16 acquisitions in each optode
distance. We have used three sets of optode separations:
1. Small separations: the same optode distances as our murine probe
(chapter 3) is used for small separations [134]. In this probe there
are 8 non-uniformly separations from 2.5 to 5 mm (2.5, 2.9, 3.2,
3.6, 3.9, 4.3, 4.6, 5.0 mm).
2. intermediate separations: 6 optode distances from 10 mm to 20
mm with intervals of 2 mm.
3. Large separations: 8 optode distances from 20 mm to 34 mm with
intervals of 2 mm.
The averaging time of one minute was kept constant for all measure-
ments. The maximum photon count rate (1000 kHz) is assigned to small-
est source-detector separations. This is the upper limit of avalanche
photodiodes (APDs) which are used in experiment setup.The photon
count rate decreases exponentially. The photon count rate for each op-
tode is calculated from green function solution for photon fluence rate
in semi-infinite boundary conditions [2]. In the simulated data, the min-
imum count rate is ≈ 15kHz. We have simulated DCS measurements
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using forward model (section 7.2). After producing the theoretical auto-
correlation curve for each media and each experimental setup, we have
added noise to the simulated autocorrelation curve using DCS noise
model which is described in section 2.6.
Comparison to other methods: We have compared the results of
MD-DCS fitting to other possible DCS analysis to show how MD-DCS
will modify the quality of BFI measurements, while it is providing us
with optical properties information (µa and µs′) without any hybrid
NIRS device. MD-DCS is compared with other methods.
1. Exact µa and µs′ value: it was assumed that the exact value for
absorption and scattering coefficients are known.
2. Exact µa and 30% error in µs′: it was assumed that the exact value
for absorption coefficient is known and scattering is over/under -
estimated by 30%.
3. Exact µa and 2 (cm−1) error in µs′: it was assumed that the exact
value for absorption coefficient is known and there is 2 (cm−1)
over/under -estimation of µs′.
4. Deploying MD-DCS fitting assuming µeff of the medium (MD-
DCS given µeff ).
5. Deploying MD-DCS fitting without any information about optical
properties of medium (MD-DCS without µeff )
Error of fitted BFI for different absorption and scattering co-
efficients: To compare the error in fitted BFI by MD-DCS to other
methods we need to define the error. For each of the simulated BFI
there are 5 µs′ and 5 µa. For each BFI, the error is root mean square of
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the relative difference between fitted and expected values of BFI,
εBFI =
√√√√√ 1
N
∑
µs′
∑
µa
(
BFIfitted −BFIexpected
BFIexpected
)2
(7.6)
where N is the total number of different sets of µa µs′ for a given
BFI (in this case: 5× 5 = 25).
Phantom measurements: We have performed the DCS measure-
ments on 7 liquid phantoms which consist of water and Lipofundin MCT
20%. The probe used in these tests is the same probe as we use for mouse
tumor studies [134]. In this probe there are 8 non-uniformly separations
from 2.5 to 5 mm (0.25, 0.29, 0.32, 0.36, 0.39, 0.43, 0.46, 0.5 mm). I
started with 160 ml of water and for each step 5 ml of lipofundinMCT
20% was added, except the last step which was 10 ml. The DCS device
and probe are described in chapter 3.
In-vivo measurements: We have monitored the blood flow changes
of the mouse tumors induced by antiangiogenic therapy. The details of
mouse strain, tumor line and therapy is explained in section 4.2.2. The
device employed in this study is described in chapter 3. In summary, we
have combined broadband NIRS and DCS in a single probe. Both NIRS
and DCS have 6 source-detector separations (from 2.5 to 5 mm). The
mouse was measured just before the start of therapy (day-zero). The
mouse received the therapy twice per week and before each drug injec-
tion we have performed optical measurements on the tumor. In every
measurement, in order to have better statics of the optical properties
of tumor we have re-positioned the probe 10 times and each relocating
include 11 acquisitions.
In our conventional analysis, DCS takes the measured µa and µs′
values from broadband NIRS device as known optical properties. Here
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we have re-analyzed the DCS data by MD-DCS fitting to compare the
results (µa, µs′ and BFI) with the results of hybrid device (NIRS and
DCS). The measured µeff values by NIRS is given to the MD-DCS fit-
ting in each location. We averaged the intensity autocorrelation curves
of all acquisitions, then for each location MD-DCS fitting provide us
with µa, µs′, and BFI of the location. We have averaged the fitted µa
and µs′ from MD-DCS method to have an average value for tumor opti-
cal properties. Afterwards given the estimated optical properties of the
medium we calculate the BFI of each location. We have investigated the
equality of fitted BFI of MD-DCS and traditional DCS (taking fitted µa
and µs′ as the input of DCS fitting) by student t-test. The “p-values”
less than 0.05 were considered statically significant to reject the null
hypothesis.
7.4 Results and discussions
7.4.1 Numerical simulations
In this section, the results of MD-DCS fitting on simulated data, phan-
tom, and in-vivo measurements is reported.
Noise-free simulations: In the simulated data, regardless of source-
detector separation, degree of absorption, scattering, or BFI, The MD-
DCS fitting always works accurately and the fitted µa, µs′ and BFI
are exact. In the figure 7.6 the error in fitted BFI by MD-DCS and
other methods is presented. The error is calculated using equation 7.6.
The source-detector separation is large (2-3.4 cm) where MD-DCS fit
is challenging. It can be seen that error in fitted BFI in both condi-
tions, without and with µeff (red triangles), is 0%. This accuracy is
possible only when we know the exact values of µa and µs′ (black tri-
angles). Overestimation in µs′ induces more than 30% error in fitted
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BFI, while µs′ underestimation causes more dramatic BFI error. This
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Fig. 7.6 The error in fitted BFI by MD-DCS comparing to other methods
in noise-free data. The source-detector separation is large (2-3.4 cm).
It can be seen that error in fitted BFI in both conditions, with and
without µeff (red triangles), is 0%. This accuracy is possible only when
the exact values of µa and µs′ are known.
results demonstrates MD-DCS fitting in principle can decouple µa, µs′
and BFI in noise-free data. To evaluate its efficiency in more realistic
conditions we have added noise to the data and in each separation type
the feasibility of MD-DCS fitting in the following sections is studied.
Noise-added simulations of small optode distances: To evalu-
ate the efficiency of MD-DCS fitting the noise model is added to the
simulated data (described in section 2.6). Figure 7.7 shows the values
of fitted µs′, µa, and BFI by MD-DCS versus the expected (simulated)
values in small source-detector separations (2.5-5 mm). Each color rep-
resents one µs′ (red: µs′ = 4, green: µs′ = 7, blue: µs′ = 10, cyan: µs′ =
13, black: µs′ = 16) and each µa is represents by a marker (star: µa =
0.04, circle: µa = 0.07, square: µa = 0.10, cross: µa = 0.13, triangle: µa
= 0.16). We have used dodging (moving the points slightly across the
x-axis) for better representation of BFI values (BFI increases from left
to right). In figure 7.7-left the fitted µs′ by MD-DCS is presented. We
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can see for all µas and BFIs the fitted µs′ is in good agreement with ex-
pected values. In figure 7.7-middle the fitted µa by MD-DCS is present.
For all µs′s and BFIs, fitted µa is in good agreement with expected val-
ues. The right side of figure 7.7 demonstrates that the fitted BFI is in
agreement compared with the expected values.
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Fig. 7.7 The values of fitted µs′, µa, and BFI by MD-DCS versus the
expected (simulated) values in small source-detector separations (2.5-5
mm). The linear fitting equation of fitted values versus expected ones
for each parameter is displayed. The fitted line for all parameters have
slope of one and zero intercept which indicate the complete agreement of
fitted and expected values. Each color represents one µs′ (red: µs′ = 4,
green: µs′ = 7, blue: µs′ = 10, cyan: µs′ = 13, black: µs′ = 16) and each µa
is represents by a marker (star: µa = 0.04, circle: µa = 0.07, square: µa =
0.10, cross: µa = 0.13, triangle: µa = 0.16). Dodging is used (moving the
points slightly across the x-axis) for better representation of BFI values
(For each µs′ or µa, BFI increases from left to right). [Left] The fitted
µs
′ by MD-DCS is present. For all µas and BFIs the fitted µs′ is in good
agreement with expected values. [Middle] The fitted µa by MD-DCS
for all µs′s and BFIs is in good agreement with expected values. [Right]
The fitted BFI is in agreement compared with the expected values.
In the figure 7.8 the error in fitted BFI by MD-DCS comparing to
the other methods in noise-added simulated data is presented. The
error is calculated using equation 7.6. The source-detector separation
is small (2.5-5 mm). The error in fitted BFI in both conditions, with
and without µeff (red triangles), is 0%. This accuracy is possible only
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when the exact values of µa and µs′ are known. Overestimation in µs′
induces ∼30% error in the fitted BFI, while µs′ underestimation causes
more dramatic BFI error.
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Fig. 7.8 The error in fitted BFI by MD-DCS comparing to the other
methods in noise-added simulated data. The source-detector separation
is small (2.5-5 mm). The error in fitted BFI in both conditions, with
and without µeff (red triangles) is 0%. Overestimation in µs′ induces
∼30% error in the fitted BFI, while µs′ underestimation causes more
dramatic BFI error.
Noise-added simulations of intermediate optode distances: As
figure 7.5 suggests the MD-DCS fitting may be more challenging in
larger source-detector separations. To test the efficiency of method
in larger optode distances (in noise-added data), we have applied the
method on intermediate separations (10-20 mm). The results are pre-
sented in figure 7.9. As in previous plots, each color represents one µs′
(red: µs′ = 4, green: µs′ = 7, blue: µs′ = 10, cyan: µs′ = 13, black: µs′
= 16) and each µa is represents by a marker (star: µa = 0.04, circle:
µa = 0.07, square: µa = 0.10, cross: µa = 0.13, triangle: µa = 0.16).
We have used dodging (moving the points slightly across the x-axis) for
better representation of BFI values (BFI increases from left to right).
In figure 7.9-left the fitted µs′ by MD-DCS is presented. We can see
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for all µas and BFIs the fitted µs′ is in good agreement with expected
values. In figure 7.9-middle the fitted µa by MD-DCS is present. For all
µs
′s and BFIs, fitted µa is in good agreement with expected values. The
right side of figure 7.9 demonstrates that the fitted BFI is in agreement
compared with the expected values.
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Fig. 7.9 The values of fitted µs′, µa, and BFI by MD-DCS versus the
expected (simulated) values in intermediate source-detector separations
(10-20 mm). The linear fitting equation of fitted values versus expected
ones for each parameter is displayed. Each color represents one µs′
(red: µs′ = 4, green: µs′ = 7, blue: µs′ = 10, cyan: µs′ = 13, black: µs′ =
16) and each µa is represents by a marker (star: µa = 0.04, circle: µa =
0.07, square: µa = 0.10, cross: µa = 0.13, triangle: µa = 0.16). Dodging
is used (moving the points slightly across the x-axis) for better repre-
sentation of BFI values (For each µs′ or µa, BFI increases from left to
right). [Left] The fitted µs′ by MD-DCS is present. The fitted line
of fitted µs′ versus expected values have slope of one and intercept of
-0.1 which indicate the a fair agreement between fitted and expected
µs
′. [Middle]. The fitted line of fitted µa versus expected values have
slope of one and zero intercept which indicate the complete agreement
of fitted and expected absorption coefficient. [Right] The fitted BFI is
in agreement compared with the expected values (slope = 1, intercept
= 0).
In the figure 7.10 the error in fitted BFI by MD-DCS comparing
to the other methods in noise-added simulated data is presented. The
error is calculated using equation 7.6. The source-detector separation is
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small (2.5-5 mm). The error in fitted BFI in both conditions, with and
without µeff (red triangles), is less than 5%. This accuracy is possible
only when the exact values of µa and µs′ are known. Overestimation
in µs′ induces ∼30% error in the fitted BFI, while µs′ underestimation
causes more dramatic BFI error. The results of MD-DCS fitting in
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Fig. 7.10 The error in fitted BFI by MD-DCS comparing to the other
methods in noise-added simulated data. The source-detector separation
is intermediate (10-20 mm). The error in fitted BFI in both conditions,
with and without µeff (red triangles) is less than 5%. Overestimation
in µs′ induces more than 30% error in the fitted BFI, while µs′ under-
estimation causes more dramatic BFI error.
intermediate source-detector separations suggest that the fitting is rigid
enough in this regime.
Noise-added simulations of large optode distances: In order to
evaluate the limits of MD-DCS fitting we have enlarged the simulated
optode distances to 20-34 mm. This is where the fitting loses its ac-
curacy specially in large µa, µs′, or BFI. Figure 7.11 shows the values
of fitted µs′, µa, and BFI by MD-DCS versus the expected (simulated)
values in large source-detector separations. In Figure 7.11-left the fitted
µs
′ by MD-DCS is present. The fitted line of fitted µs′ versus expected
values have slope of 1.2 and intercept of -1.2 which indicates that in
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large optode distances the algorithm starts to fail specially in higher µs′
values. In the middle plot, the fitted line of fitted µa versus expected
values have slope of 0.8 and zero intercept and in the right plot we
can see the fitted BFI is not in a good agreement compared with the
expected values (slope = 0.9, intercept = 0).
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Fig. 7.11 The values of fitted µs′, µa, and BFI by MD-DCS versus the
expected (simulated) values in large source-detector separations (20-34
mm). The linear fitting equation of fitted values versus expected ones
for each parameter is displayed. Each color represents one µs′ (red: µs′
= 4, green: µs′ = 7, blue: µs′ = 10, cyan: µs′ = 13, black: µs′ = 16) and
each µa is represents by a marker (star: µa = 0.04, circle: µa = 0.07,
square: µa = 0.10, cross: µa = 0.13, triangle: µa = 0.16). Dodging is used
(moving the points slightly across the x-axis) for better representation
of BFI values (For each µs′ or µa, BFI increases from left to right). [Left]
The fitted µs′ by MD-DCS is present. The fitted line of fitted µs′ versus
expected values have slope of 1.2 and intercept of -1.2 which indicates
that in large optode distances the algorithm starts to fail specially in
higher µs′ values. [Middle]. The fitted line of fitted µa versus expected
values have slope of 0.8 and zero intercept which indicate that in large
optode distances the algorithm starts to fail specially in higher µa values.
[Right] The fitted BFI is in agreement compared with the expected
values (slope = 0.9, intercept = 0).
The error in fitted BFI for every µa and µs′ is determined by equa-
tion 7.6 and is presented in the figure 7.12 The error in fitted BFI in
both conditions, with and without µeff (red triangles) is hight (between
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20-45%) which is similar to induced error by 30% overestimated of µs′.
It shows the MD-DCS fitting starts to lose its accurately in large optode
distances specially in higher values of BFI.
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Fig. 7.12 The error in fitted BFI by MD-DCS comparing to the other
methods in noise-added simulated data. The source-detector separation
is large (20-34 mm). The error in fitted BFI in both conditions, with and
without µeff (red triangles) is hight (between 20-45%) which is similar
to induced error by 30% overestimated of µs′. It shows the MD-DCS
fitting fails to fit accurately in large optode distances specially in higher
values of BFI.
7.4.2 Results MD-DCS fitting on liquid phantom
measurements
Figure 7.13 shows the results of MD-DCS fitting on liquid phantom mea-
surements. As described in section 7.3 we have performed Lipofundin
titration. Figure 7.13-left shows the measured (fitted by MD-DCS fit-
ting) µs′ versus expected value and their increase in each step of titra-
tion. The measured values have good agreement with expected values.
The linear fitting equation of fitted values versus expected ones for each
parameterµs′ is presented (slope = 0.9, intercept = 0.4). By assuming
the absorption coefficient for Lipofundin and water the absorption of all
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phantoms are expected to be the same. Figure 7.13-middle shows as ex-
pected the fitted absorption coefficient of all phantoms are the same and
in the range of expected µa for water of (µ785 nma = 0.02 − 0.03 cm−1).
Since the changes in viscosity due to Lipofundin titration is negligible, it
is expected for BFI to not change by Lipofundin titration. Figure 7.13-
right shows the measured (fitted by MD-DCS fitting) BFI is constant
over all phantoms.
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Fig. 7.13 The measured µa, µs′, and BFI by MD-DCS versus expected
values in liquid phantom measurement. [Left] The measured (fitted
by MD-DCS fitting) µs′ versus expected value and their increase in
each step of titration. The linear fitting equation of fitted values versus
expected ones for each parameter µs′ is presented (slope = 0.9, intercept
= 0.4). [Middle] The measured (fitted by MD-DCS fitting) absorption
coefficient of all phantoms are the same and in the range of expected µa
for water of (µ785 nma = 0.02 − 0.03 cm−1). [Left] The measured (fitted
by MD-DCS fitting) BFI is constant over all phantoms.
7.4.3 Results of MD-DCS fitting on in-vivo studies
To validate the MD-DCS technique on more realistic scenarios where
we should deal with heterogeneity of the medium, we have applied the
method on a mouse tumor which is a highly heterogeneous tissue. To
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validate our values we have compared the fitted µa, µs′, and BFI from
MD-DCS to the fitted values from broadband NIRS device. The details
of measurements and fittings are described in section 7.3. The results
of fitting values with both methods (MD-DCS, NIRS) for all three pa-
rameters over 24 days are presented in figure 7.14. Although the fitted
µa and µs′ from NIRS and MD-DB deviates slightly, the fitted BFI
from both fitting agrees with each other. In each day the values of BFI
from MD-DCS and traditional DCS are compared and the days that the
equality of mean values are statistically significant are marked by blue
stars. In all days except day 8,20 and 24 the measured BFI from both
methods are equal.
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Fig. 7.14 The fitted values from both methods (MD-DCS, NIRS) for
µs
′, µa, and BFI over 24 days in a mouse tumor. [Left] The fitted µs′
from NIRS and MD-DCS. [Middle] The fitted µa from NIRS and MD-
DCS. [Right] The fitted BFI from both fitting agrees with each other.
In each day the values of BFI from MD-DCS and traditional DCS are
compared and the days that the equality of mean values are statistically
significant are marked by blue stars. In all days except day 8,20 and 24
the measured BFI from both methods are equal.
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7.5 Conclusion
For the first time we have investigated the possibility of simultaneous
extracting of absorption coefficient (µa), scattering coefficient (µs′), and
blood flow index (BFI) of the tissue using multi-distance diffuse correla-
tion spectroscopy (MD-DCS). We have validated MD-DCS by numerical
simulations with realistic noise model. It is demonstrated that the fit-
ting is more robust in smaller source-detector separations (from 2 mm
to 20 mm). In larger source-detector separations the error in fitted
parameters increases. In addition to the numerical simulations, MD-
DCS is validated through measurement of tissue simulating phantoms.
To validate the MD-DCS fitting in more realistic scenarios where the
medium is heterogeneous, we have applied the method on a mouse tu-
mor which is a highly heterogeneous tissue. The results suggest that
multi-distance DCS can be an alternative to traditional hybrid devices
(NIRS + DCS) specially in small source-detector separations where ob-
taining optical properties of the medium with common NIRS techniques
are challenging.
Chapter 8
Conclusion
In this work, I have described the development of hybrid diffuse optical
devices for noninvasive hemodynamics monitoring to be used in human
and animal studies at hospitals and animal facilities.
The hybrid device is a combination of near infrared spectroscopy
(NIRS) for oxygenation and diffuse correlation spectroscopy for blood
flow measurements. Depending on the application and the limitations
of measurement different types of NIRS technique have been deployed.
The applied NIRS technique in this work are continuous wave (CW),
frequency domain (FD), and time resolved spectroscopy (TRS). The
advantages and limitations of each technique is described in chapter 2.
Continuous wave which is the simplest NIRS technique was deployed
for measurement of murine tumors in conjunction with diffuse correla-
tion spectroscopy in a hand-held, self-calibrated probe. The device is de-
signed for hybrid, broadband, multi-spectral, multi-distance NIRS/DCS
measurement and is validated by phantom and in-vivo studies. The de-
vice specification, probe design and validation results are presented in
chapter 3.
The designed, constructed, and validated device has been moved to
animal facility for hemodynamics monitoring in murine tumors during
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antiangiogenic therapy. In this study early hemodynamics changes cor-
relate with the outcome of therapy. These results suggest that diffuse
optics have potential to play an important role to understand the mech-
anism of tumor defense against the antiangiogenic therapies. continuing
the study with larger number of tumors may lead us to develop optical
parameters to predict the success of therapy which results in personal-
ized treatment procedure for each subject. The mice models, therapy
procedure, measurement, and the measured parameters are explained
in chapter 4.
In this work I have introduced diffuse optics as an potential tool to
study hematological malignancies in human. The hybrid device used
in this study is a combination of TRS and DCS. Since hematological
malignancies affect the red bone marrow, we have characterized the
manubrium as a site rich of red bone marrow in the adults. For the
first time, we have characterized the optical and hemodynamics prop-
erties of the manubrium in thirty-two healthy subjects. This study is
the first step in the path of applying optics for the studies on bone mar-
row cancer. The distribution of optical and physiological parameters in
the healthy bone marrow is demonstrated in chapter 5. Measuring the
same parameters in the patients with hematological malignancies will
illustrate the difference between distribution of measured parameters on
the healthy and malignant marrow. It can be applied for screening pur-
poses to detect subjects with high risk of hematological malignancies.
We can also monitor to changes in optical and physiological parameters
induced by antiangiogenic therapies to predict the effect of treatment
and personalize the therapy.
My interest in hematological malignancies and bone marrow led me
to learn more about the physiology of compact bone. Lack of optical
studies on bone motivated me to investigate the feasibility of optics to
answer bone physiological questions. We have demonstrated that FD-
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NIRS is a promising technique to study the pulsations and the physio-
logical properties of bones and normal tissue. In the future, therefore, it
may be applied to study vascular and skeletal diseases. In chapter 6, the
optical and the physiological properties of the patella were characterized,
and it has been shown that the absorption and scattering coefficients in
the bone are not constant during a cardiac cycle. They have “pulsatile
changes”. The wavelength dependency of the absorption coefficient was
translated to changes in the oxygenated and deoxygenated hemoglobin
which leads to pulsation in the total hemoglobin concentration and the
oxygen saturation. We have also studied the patella bone response to
cuff occlusion and a lower metabolism of the bone compared to the
skeletal muscle was observed.
Several years of experiments using hybrid devices raised a question
in my mind: Can we obtained absolute value of absorption and scatter-
ing coefficients from autocorrelation curves of DCS device? To answer
this question for the first time we have investigated the possibility of
simultaneous extracting of absorption coefficient, scattering coefficient,
and blood flow index of the tissue using multi-distance diffuse correla-
tion spectroscopy (MD-DCS). We have validated MD-DCS by numerical
simulations with realistic noise model. It is demonstrated that the fit-
ting is more robust in smaller source-detector separations (from 2 mm
to 20 mm). In larger source-detector separations the error in fitted
parameters increases. In addition to the numerical simulations, MD-
DCS is validated through measurement of tissue simulating phantoms.
To validate the MD-DCS fitting in more realistic scenarios where the
medium is heterogeneous, we have applied the method on a mouse tu-
mor which is a highly heterogeneous tissue. The results suggest that
multi-distance DCS can be an alternative to traditional hybrid devices
(NIRS + DCS) specially in small source-detector separations where ob-
taining optical properties of the medium with common NIRS techniques
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are challenging.
A major contribution of this manuscript was applying diffuse op-
tics to answer new biological questions in experimental biology. I have
introduced diffuse optics to hematological malignancies studies which
also demonstrated the feasibility of applying optics in bone and bone
marrow. Finally, I have demonstrated the possibility of measurement
of tissue static (absolute value of blood volume and oxygenation) and
dynamic (blood flow) using DCS autocorrelation curves. This can be
an alternative to hybrid DCS-NIRS devices.
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Appendix A
Design of DOS-DCS probe
and spectrometer bundle
In the following pages the design of hand-held self calibrated optical
probe and fiber bundle for spectrometer entrance (look at chapter 3) is
presented. In the probe design M1 and M4 are main and calibration
source and M5-M13 are detector fibers in DOS setup. A2 and A3 are
source fibers and S1-S7 are detector fibers for DCS. DCS detector fibers
(S1-S7) are single mode fibers with core diameter of 5.6 µm. The rest
of fibers are multimode with core diameter of 200 µm.
The bundle drawing shows the specification of an 8 leg fiber bundle
with 200 µm fiber per leg.



Appendix B
Measured optical and
physiological parameters on
murine tumors
In this appendix, the measured optical (absorption and reduced scat-
tering coefficient) and physiological parameters (total hemoglobin con-
centration and oxygen saturation) are presented. The control mice are
indicated by dashed lines and treated mice with solid lines. The number
of measurement days for each mouse is different because they have been
sacrificed in different days after start of the study.
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Fig. B.1 Absorption coefficient (µa) of both treated (solid orange lines)
and control mice (dashed green lines) are presented over all days of
measurement. Treated animal
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Fig. B.2 Reduced scattering coefficient (µs′) of both treated (solid orange
lines) and control mice (dashed green lines) are presented over all days
of measurement. Treated animal
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Fig. B.3 Total hemoglobin concentration of both treated (solid orange
lines) and control mice (dashed green lines) are presented over all days
of measurement. Treated animal
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Fig. B.4 Oxygen saturation of both treated (solid orange lines) and
control mice (dashed green lines) are presented over all days of mea-
surement. Treated animal

Appendix C
Optical and physiological
properties of manubrium.
In this appendix the measured optical (µa and µs′) and physiological
parameters (blood flow index, blood volume, and oxygen saturation) of
the manubrium for all subjects are presented.
Table C.1 Absorption coefficient (cm−1) of the manubrium.
Subject λ = 690 nm λ = 785 nm λ = 830 nm
01 0.10 ± 0.00 0.11 ± 0.00 0.12 ± 0.00
02 0.15 ± 0.01 0.15 ± 0.01 0.16 ± 0.01
03 0.10 ± 0.00 0.10 ± 0.01 0.10 ± 0.01
04 0.08 ± 0.01 0.09 ± 0.01 0.10 ± 0.01
05 0.17 ± 0.00 0.16 ± 0.01 0.17 ± 0.01
06 0.14 ± 0.01 0.15 ± 0.01 0.16 ± 0.01
07 0.12 ± 0.01 0.12 ± 0.01 0.12 ± 0.01
08 0.09 ± 0.01 0.09 ± 0.01 0.10 ± 0.01
09 0.13 ± 0.00 0.13 ± 0.00 0.14 ± 0.00
10 0.15 ± 0.00 0.16 ± 0.00 0.17 ± 0.00
204 Characterization of manubrium
(Continued.)
Subject λ = 690 nm λ = 785 nm λ = 830 nm
11 0.12 ± 0.01 0.14 ± 0.01 0.15 ± 0.01
12 0.14 ± 0.02 0.15 ± 0.02 0.16 ± 0.02
13 0.10 ± 0.01 0.11 ± 0.01 0.12 ± 0.01
14 0.16 ± 0.02 0.17 ± 0.02 0.17 ± 0.02
15 0.19 ± 0.02 0.19 ± 0.02 0.19 ± 0.02
16 0.13 ± 0.01 0.15 ± 0.01 0.16 ± 0.01
17 0.21 ± 0.03 0.20 ± 0.02 0.21 ± 0.02
18 0.18 ± 0.01 0.18 ± 0.01 0.20 ± 0.01
19 0.17 ± 0.01 0.17 ± 0.01 0.18 ± 0.01
20 0.17 ± 0.00 0.19 ± 0.00 0.20 ± 0.00
21 0.11 ± 0.00 0.12 ± 0.00 0.13 ± 0.00
22 0.22 ± 0.02 0.22 ± 0.01 0.24 ± 0.02
23 0.05 ± 0.01 0.06 ± 0.01 0.06 ± 0.01
24 0.14 ± 0.01 0.15 ± 0.01 0.16 ± 0.01
25 0.15 ± 0.02 0.16 ± 0.02 0.18 ± 0.02
26 0.12 ± 0.02 0.12 ± 0.02 0.14 ± 0.02
27 0.20 ± 0.01 0.19 ± 0.01 0.21 ± 0.02
28 0.13 ± 0.01 0.14 ± 0.01 0.15 ± 0.01
29 0.17 ± 0.01 0.17 ± 0.01 0.18 ± 0.01
30 0.11 ± 0.00 0.12 ± 0.00 0.13 ± 0.00
31 0.16 ± 0.02 0.17 ± 0.03 0.18 ± 0.03
32 0.12 ± 0.00 0.14 ± 0.00 0.15 ± 0.00
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Table C.2 Reduced scattering coefficient (cm−1) of the manubrium.
Subject λ = 690 nm λ = 785 nm λ = 830 nm
01 10.1 ± 0.4 09.5 ± 0.3 08.9 ± 0.4
02 11.4 ± 0.3 10.4 ± 0.2 09.3 ± 0.2
03 10.4 ± 0.7 09.9 ± 0.7 09.2 ± 0.6
04 09.6 ± 0.9 09.3 ± 0.9 08.6 ± 0.9
05 10.8 ± 1.0 10.2 ± 0.8 09.3 ± 0.7
06 10.1 ± 1.1 09.7 ± 1.0 08.8 ± 0.9
07 11.0 ± 1.2 10.6 ± 1.1 09.9 ± 1.0
08∗ 09.3 ± 0.3 08.9 ± 0.2 08.2 ± 0.2
09 09.8 ± 0.3 09.0 ± 0.3 08.3 ± 0.3
10 10.0 ± 0.8 09.3 ± 0.7 08.5 ± 0.7
11 09.7 ± 0.6 09.0 ± 0.5 08.3 ± 0.5
12 10.4 ± 0.7 09.6 ± 0.7 08.6 ± 0.6
13 09.9 ± 0.1 09.2 ± 0.2 08.5 ± 0.2
14 13.2 ± 0.4 12.6 ± 0.3 11.2 ± 0.3
15∗ 12.1 ± 0.4 11.5 ± 0.3 10.1 ± 0.3
16 09.7 ± 0.3 08.9 ± 0.3 08.3 ± 0.3
17 11.0 ± 0.3 10.1 ± 0.2 09.2 ± 0.3
18∗ 11.1 ± 0.4 10.2 ± 0.6 09.0 ± 0.5
19 12.1 ± 0.4 11.5 ± 0.4 10.2 ± 0.4
20 10.7 ± 0.2 10.3 ± 0.2 09.5 ± 0.2
21 10.3 ± 0.2 09.6 ± 0.2 08.9 ± 0.2
22 10.2 ± 0.5 09.2 ± 0.7 08.4 ± 0.5
23 09.5 ± 0.2 08.7 ± 0.2 08.1 ± 0.2
24 09.4 ± 0.5 08.9 ± 0.5 08.1 ± 0.4
25 11.3 ± 0.9 10.3 ± 0.8 09.4 ± 0.7
26 11.1 ± 0.4 10.1 ± 0.4 09.6 ± 0.3
27 09.8 ± 1.6 09.0 ± 0.6 08.4 ± 0.6
28 09.0 ± 0.5 08.3 ± 0.5 07.9 ± 0.5
29 10.2 ± 0.6 09.1 ± 0.5 08.3 ± 0.4
30 09.5 ± 0.2 08.8 ± 0.1 08.2 ± 0.1
31 10.8 ± 0.6 10.2 ± 0.5 09.0 ± 0.6
32 09.7 ± 0.3 09.4 ± 0.3 08.3 ± 0.3
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Table C.3 Physiological parameters of the manubrium.
Subject Blood flow index Blood volume Oxygen saturation
(cm2/s) (µM) (%)
01 4.4×10−9 ± 1.6×10−9 56.0 ± 1.4 71.4 ± 2.1
02 4.0×10−9 ± 3.7×10−10 77.3 ± 5.8 69.8 ± 0.9
03 3.5×10−9 ± 6.2×10−10 50.0 ± 3.1 68.5 ± 1.8
04 7.4×10−9 ± 2.0×10−9 48.4 ± 5.6 73.6 ± 1.2
05 6.5×10−9 ± 2.6×10−9 82.1 ± 5.4 65.2 ± 3.3
06 5.6×10−9 ± 1.4×10−9 78.7 ± 3.3 71.0 ± 1.1
07 3.5×10−9 ± 1.0×10−9 60.6 ± 3.9 69.4 ± 1.4
08∗ 2.7×10−9 ± 6.3×10−10 46.7 ± 4.8 68.5 ± 1.8
09 3.7×10−9 ± 1.2×10−9 70.1 ± 1.8 70.5 ± 1.0
10 6.5×10−9 ± 2.9×10−9 83.6 ± 2.1 71.7 ± 0.7
11 4.5×10−9 ± 1.1×10−9 73.2 ± 6.6 75.0 ± 0.5
12 7.3×10−9 ± 3.0×10−9 79.8 ± 10.5 71.8 ± 1.2
13 5.1×10−9 ± 1.0×10−9 55.5 ± 5.7 71.9 ± 1.1
14 7.5×10−9 ± 2.4×10−9 85.8 ± 9.3 70.6 ± 0.6
15∗ 2.9×10−9 ± 5.3×10−10 95.3 ± 11.4 67.8 ± 0.8
16 8.7×10−9 ± 2.6×10−9 77.2 ± 5.3 73.3 ± 0.6
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(Continued.)
Subject Blood flow index Blood volume Oxygen saturation
(cm2/s) (µM) (%)
17 4.8×10−9 ± 1.1×10−9 103.7 ± 12.1 65.9 ± 1.7
18∗ 1.0×10−8 ± 5.3×10−9 95.9 ± 4.0 70.1 ± 2.1
19 4.3×10−9 ± 6.9×10−10 88.8 ± 4.8 68.8 ± 1.1
20 8.2×10−9 ± 2.2×10−9 98.1 ± 1.8 72.6 ± 0.8
21 4.7×10−9 ± 1.0×10−9 61.1 ± 1.0 73.4 ± 0.9
22 5.2×10−9 ± 1.5×10−9 115.4 ± 6.3 70.1 ± 2.7
23 9.7×10−9 ± 3.1×10−9 29.6 ± 3.0 76.9 ± 1.3
24 5.8×10−9 ± 1.9×10−9 77.3 ± 6.1 72.1 ± 1.3
25 9.2×10−9 ± 1.7×10−9 86.5 ± 9.2 74.1 ± 1.0
26 3.8×10−9 ± 1.1×10−9 66.0 ± 9.2 71.8 ± 1.1
27 8.4×10−9 ± 1.7×10−9 101.0 ± 6.7 68.4 ± 2.3
28 4.9×10−9 ± 2.0×10−9 71.4 ± 4.3 70.8 ± 0.5
29 6.0×10−9 ± 1.5×10−9 90.0 ± 5.9 69.5 ± 1.0
30 4.1×10−9 ± 1.4×10−9 63.4 ± 2.4 71.9 ± 0.6
31 4.8×10−9 ± 1.2×10−9 88.4 ± 14.6 71.2 ± 1.4
32 4.6×10−9 ± 1.6×10−9 70.6 ± 1.9 73.2 ± 1.4
∗ Smoker subjects.

Appendix D
Optical and physiological
properties of patella.
In this appendix the measured optical (µa and µs′) and physiological
parameters (blood flow index, blood volume, and oxygen saturation) of
the patella for all subjects are presented.
Table D.1 µa values of the patella in three wavelengths during rest.
µa (cm−1)
λ = 690 nm λ = 785 nm λ = 830 nm
Subject 1 0.044 ± 0.007 0.034 ± 0.004 0.045 ± 0.004
Subject 2 0.041 ± 0.004 0.037 ± 0.002 0.042 ± 0.003
Subject 3 0.053 ± 0.009 0.055 ± 0.004 0.071 ± 0.006
Subject 4 0.024 ± 0.006 0.026 ± 0.003 0.038 ± 0.003
Subject 5 0.029 ± 0.004 0.027 ± 0.002 0.033 ± 0.003
Subject 6 0.046 ± 0.006 0.037 ± 0.004 0.041 ± 0.004
Subject 7 0.043 ± 0.004 0.040 ± 0.003 0.044 ± 0.003
Subject 8 0.028 ± 0.009 0.032 ± 0.002 0.048 ± 0.003
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Table D.2 µs′ values of the patella in three wavelengths during rest.
µs
′ (cm−1)
λ = 690 nm λ = 785 nm λ = 830 nm
Subject 1 6.1 ± 0.2 4.3 ± 0.3 3.5 ± 0.2
Subject 2 8.7 ± 0.2 6.5 ± 0.3 5.2 ± 0.2
Subject 3 6.3 ± 0.2 4.5 ± 0.2 3.7 ± 0.2
Subject 4 6.0 ± 0.2 4.3 ± 0.2 3.7 ± 0.2
Subject 5 7.1 ± 0.2 5.3 ± 0.2 4.3 ± 0.2
Subject 6 9.2 ± 0.3 6.5 ± 0.5 5.2 ± 0.3
Subject 7 8.6 ± 0.2 6.6 ± 0.3 5.4 ± 0.2
Subject 8 7.2 ± 0.2 4.9 ± 0.2 3.8 ± 0.2
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Table D.3 Total hemoglobin concentration and oxygen saturation during
rest.
Total hemoglobin concentration (µM) Oxygen saturation(%)
Subject 1 20 ± 2 63 ± 8
Subject 2 20 ± 1 66 ± 4
Subject 3 32 ± 3 76 ± 4
Subject 4 16 ± 2 81 ± 6
Subject 5 15 ± 1 70 ± 6
Subject 6 20 ± 2 60 ± 7
Subject 7 21 ± 1 66 ± 5
Subject 8 20 ± 3 83 ± 5
Table D.4 µa values in three wavelengths at the end of cuff occlusion.
µa (cm−1)
λ = 690 nm λ = 785 nm λ = 830 nm
Subject 1 0.069 ± 0.007 0.057 ± 0.007 0.062 ± 0.012
Subject 3 0.103 ± 0.008 0.076 ± 0.007 0.086 ± 0.008
Subject 5 0.058 ± 0.005 0.050 ± 0.006 0.054 ± 0.007
Subject 6 0.088 ± 0.015 0.077 ± 0.015 0.085 ± 0.031
Subject 7 0.092 ± 0.009 0.088 ± 0.012 0.093 ± 0.016
Subject 8 0.062 ± 0.006 0.069 ± 0.012 0.118 ± 0.032
Average 0.079 ± 0.016 0.069 ± 0.013 0.083 ± 0.021
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Table D.5 µs′ values in three wavelengths at the end of cuff occlusion.
µs
′ (cm−1)
λ = 690 nm λ = 785 nm λ = 830 nm
Subject 1 8.6 ± 0.5 5.5 ± 0.3 4.3 ± 0.3
Subject 3 6.5 ± 0.3 4.5 ± 0.2 3.8 ± 0.2
Subject 5 7.3 ± 0.3 5.5 ± 0.3 4.6 ± 0.2
Subject 6 10.7 ± 0.9 7.3 ± 0.8 5.7 ± 0.9
Subject 7 11.0 ± 0.5 9.1 ± 1.0 7.8 ± 0.9
Subject 8 5.7 ± 0.3 3.9 ± 0.2 2.8 ± 0.3
Average 8.3 ± 2.2 6.0 ± 1.9 4.8 ± 1.7
